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Abstract 
 
The unique situation where there is persistent clinical suspicion of prostate cancer (PCa) 
despite repeated benign histology from conventional prostate biopsy is a diagnostic 
dilemma for clinicians and patients. Transperineal template guided saturation biopsy (TTSB) 
has a high cancer yield in this group, but is associated with unacceptably high morbidity 
particularly high rates of acute urinary retention (AUR). As localised PCa rarely involves 
periurethral area at the base, we hypothesised that urethral trauma from extensive 
sampling of this area is a major trigger factor for AUR. This thesis presents data from 
modified periurethral sparing TTSB technique to determine whether the risk of AUR is 
reduced compared with rates reported in the literature, without compromising cancer yield 
and investigates biochemical predictors of pathological outcome and role of pre-biopsy 
MRI in this group. 
 
 
Three hundred and three men with persistent clinical suspicion of PCa despite a median of 
2 (range 1-6) sets of negative biopsies were investigated. Patients prospectively completed 
a questionnaire evaluating bleeding, pain (visual analogue scale, range 0-10) and analgesic 
requirements which were assessed at 1 hour post biopsy and on days 1, 3 and 7. Serum 
PSA, PSAD and %fPSA were documented and evaluated for their ability to predict PCa 
diagnosis, Gleason score and cancer volume. Furthermore, a pre-biopsy magnetic 
resonance imaging (MRI) was performed and abnormalities in 4 anatomical quadrants were 
compared with TTSB to assess whether pre-biopsy MRI could defer need for TTSB or allow 
a more targeted biopsy regime.  
 
 
Median age was 64 years (range 43-85). PCa was diagnosed in 167 of 303 men (55.1%) 
from median of 29 cores [range 16-43, Gleason 6 (29.9%), 7 (45.5%) and 8-10 (24.6%)] and 
140 (83.8%) were clinically significant with 77.2% of cancers involving the anterior region. 
AUR occurred in 23 men (7.6%). On multivariate analysis, only prostate volume predicted 
AUR (P=0.004). Pain was minimal (peak on day 1, mean 0.8 out of 10), requiring simple 
analgesia in 27% on day 1, mostly for mild perineal discomfort. Haematuria (75%) and 
rectal bleeding (20%) significantly decreased over one week, with 33% still experiencing 
haematospermia at this stage. PSAD (AUC 0.76) was more predictive of cancer diagnosis 
compared to 0.71 for %fPSA and pre-TTSB PSA respectively. The overall sensitivity and 
specificity of MRI for cancer diagnosis were 65% and 77% respectively with multiparametric 
MRI showing more accuracy with sensitivity and specificity of 83% and 95% respectively 
compared to other MRI sequences. Of the 24 false negative MRI cases, 16 (67%) were 
clinically significant. So complete prostate mapping should continue at present. 
 
 
In conclusion, this thesis demonstrates that clinical suspicion of PCa despite negative 
histology from conventional TRUS Biopsy should not be disregarded, as a significant 
proportion harbour aggressive disease. Modified TTSB is well tolerated with low risk of 
AUR. Presentations of aspects of this thesis at key regional, national and international 
urology meetings have generated interest and helped set up dedicated units in the region 
for PCa diagnosis in this group. Questions raised in this study provide backbone for future 
research in this field.  
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Chapter 1 Introduction 
 
1.1  Overview of Cancer 
 
The origin of the term ‘cancer’ frequently used to describe all malignant tumours is 
unclear. However, it has been used in the ancient Egyptian medical book, Papyrus 
Ebers, dating back to 1500 BC. Nevertheless, investigators attribute the first use of 
the term ‘cancer’ and ‘carcinoma’ to Hippocrates (460 – 370 BC) who used these 
terms in his writings to describe benign and malignant growths respectively 
(Garrison, 1926). Although human beings are noted to be affected by cancer since 
record began, it still remains a disease with huge public health concern till date and 
a leading cause of death in both economically developed and developing countries 
(World Health Organization, 2008). In fact, there are very few diseases with such 
profound psychological, emotional and life changing effects on an individual when 
it is diagnosed.  
Histologically, carcinoma is used to describe malignant tumours arising from 
epithelial cells hence can affect any organ or system in the body. Carcinomas are 
further classified into adenocarcinoma when they posses glandular growth pattern 
microscopically and squamous cell carcinoma where they produce recognisable 
squamous cells in any epithelium of the body. Nevertheless, unlike benign 
conditions, malignant tumours have the ability to transform affected cells, invade 
surrounding tissues and metastasise to a distant area of the body. When normal 
body cells are transformed, they show considerable difference compared to 
unaffected cells. The degree to which malignant cells differ from normal is referred 
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to as differentiation. Therefore, malignant tumours range from the well 
differentiated category with close resemblance to a normal cell hence making it 
difficult to distinguish microscopically, to the poorly differentiated or anaplastic 
types which exhibit considerable morphological and functional variation to the 
normal cell.  
 
1.2  Epidemiology of Cancer 
 
Interest in the study of cancer has never been greater, partly due to the huge public 
health concern that it presents and the need to plan and manage limited healthcare 
resources. Hence, the study of patterns of cancer occurrence in populations is vital 
as it provides useful knowledge of the extent of disease burden and possible 
associations. 
Over the last 30 years, the number of new cases of cancer has increased. In 2002, 
there were 10.9 million new cancer cases, 6.7 million deaths, and 24.6 million 
persons living with cancer within 5 years of diagnosis worldwide, excluding non-
melanoma skin cancer (Parkin et al, 2005). According to 2004 estimate, cancer is 
responsible for 25.2 percent of deaths making it the third leading cause of death 
globally (World Health Organization, 2008). Unfortunately, the number of new 
cancer cases continues to rise. According to recent report by the International 
Agency for Research on Cancer, there were more new cancer cases diagnosed in 
2008, with an estimated 12.7 million new cases worldwide, resulting in 7.6 million 
deaths (Jemal et al, 2011). In Europe, the incidence of cancer rose by 300,000 in 2 
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years from 2004 to 2006 with  an estimated 3.2 million new cases, resulting in 1.7 
million deaths (Ferlay et al, 2007). 
In the United Kingdom (UK) a similar trend is observed. The number of new cancer 
cases excluding non-melanoma skin cancer in the last 30 years (1978 – 2007) has 
increased by 14% and 32% in males and females respectively (Cancer Research UK, 
2008). In 2008 alone, 156,723 cancer deaths were recorded in the UK (Cancer 
Research UK, 2009). It is suggested from Thames Cancer Registry and Macmillan 
cancer support that over 2 million people in the UK are living with or beyond cancer 
diagnosed at any time with annual increase of 3.2%  (Maddams J et al, 2008).  
The risk of developing cancer increases with age. Amongst women aged 40 to 79 
years and among men aged 60 to 79 years in the Unites States, cancer is the leading 
cause of death (Jemal et al, 2009). Similar data is reported for the United Kingdom. 
Office of National Statistics’ report showed that rates of cancer were higher in 
males than females from the 60–64 age group onwards, with an increasing 
difference in rates between the sexes with age up to 85 years in 2008 (Office for 
National Statistics, 2010).  
The rise in incidence of cancer with age could be attributed to increasing longevity 
(Thun et al, 2010), use of cancer screening programmes (Nishizawa et al, 2009) or 
rising  world population (World Health Organization, 2008). It is estimated that the 
world population will increase from 6.1 billion in 2000 to 8.9 billion by 2050, but the 
most important changes would occur in the elderly population; the number of 
those aged more than 65 years worldwide is expected to rise from 6.9% in year 
2000 to 16.4% by 2050 (Bray & Moller, 2006). Therefore it is expected that the total 
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number of people living with cancer is likely to rise in parallel to this change in 
global demographics.  
As expected, this is likely to further add pressure to existing healthcare resources.  
This increasing economic burden of cancer has been observed in the past twenty 
years. Tangka and his colleagues (Tangka et al, 2010), in their medical expenditures 
survey, observed that the total medical cost of cancer in the United States of 
America has nearly doubled from $24.7 billion dollars in 1987 to $48.1 billion in 
2005. Consequently, in order to combat this growing economic burden, strategies 
to improve early cancer detection and prevention have been advocated (Kim et al, 
2009).  
 
1.3  Prostate Cancer 
 
The prostate is a gland that lies just beneath the bladder and encircles the urethra, 
a tube that carries urine from the bladder and also semen from the testes and 
prostate to the tip of the penis. In the normal adult male, the prostate is about the 
size of a walnut, with an average weight of 11 grams, ranging from 7 to 16 grams 
(Leissner & Tisell, 1979).  
The term prostate originated from the Greek word ‘prostates’ which literally means 
‘to stand before someone or something’; but the English anatomist, William 
Cheselden is credited with the first suggestion of prostate being a single organ  
rather that two glands in 1792 (Josef Marx & Karenberg, 2009). Prostate cancer is 
most commonly adenocarcinoma, however, other rare subtypes including sarcomas 
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in 0.1 – 0.2% and primary urothelial prostate cancers accounting for 1 to 4% of all 
prostate cancers (Epstein, 2012). 
 
1.4  Epidemiology of Prostate cancer 
 
Prostate adenocarcinoma (PCa) is the most common male cancer and a leading 
cause of death. In 2008, PCa was the second most frequently diagnosed male 
cancer worldwide, accounting for 14% (903,500) of the total new cancer cases and 
6% (258,400) of the total male cancer deaths worldwide (Jemal et al, 2011). The 
incidence is 25-fold more in developed countries of Oceania, Europe, and North 
America largely due to wide use of routine Prostate Specific Antigen (PSA) testing. 
Thus, in Europe, PCa is the commonest cancer diagnosed in men, comprising 22.2% 
(382,000) of cases and resulting in 89,319 deaths in 2008 (Ferlay et al, 2010). In the 
UK, it is estimated that there is a 1 in 9 lifetime risk of being diagnosed with PCa 
and 37,051 new cases of PCa were diagnosed in 2008, making it the commonest 
male cancer, accounting for 10,168 deaths (Cancer Research UK, 2011). One study 
suggests that the increased mortality in PCa for successive birth cohorts is real and 
cannot be explained by increased detection from widespread use of PSA screening 
(Post et al, 1999).  
 
The cause of PCa is unclear, but several studies have looked into possible risk 
factors for developing the disease. The three most established risk factors for PCa 
are age, ethnic origin and family history. Other less established risk factors include 
physical activity and diet. 
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1.4.1 Age and Prostate Cancer 
 
The risk of developing PCa with advancing age is well reported in literature. Franks 
(Franks, 1973) observed that PCa is rare before 50 years, after which the incidence 
rises rapidly in a linear fashion until 80 years of age. However, despite the 
contemporary widespread use of PSA testing in many European countries, the 
number of deaths from PCa increased by 16% from 1995 to 2006 mainly due to the 
rapid increase in the number of men reaching older ages (Ferlay et al, 2007). In the 
UK, the risk of developing PCa is low in men less than 50 years but rises significantly 
from above 50 years of age (Cancer Research UK, 2011). It is therefore a bigger 
health concern in western countries with increased elderly populations. For 
example, the age standardized Incidence of PCa in North America is 120 per 
100,000 compared to 4.4 per 100,000 in South Central Asia (Parkin et al, 2005). 
Regional variations exist amongst western countries and are thought to be 
influenced by their demographic differences. Thus, in Sweden with increasing life 
expectancy, PCa is the commonest male cancer accounting for 36.8% of all new 
cases in 2004 (The National Board of Health Welfare Centre for Epidemiology, 
2006). In a recent study, it was reported that PSA concentration ≤1 ng/mL at 60 
years predicts lifetime risk of metastasis and death from PCa (Vickers et al, 2010). 
Of the 1167 men aged 60 years who were followed up for 25 years, Vickers and 
colleagues observed only 0.5% and 0.2% risk of metastasis and death respectively if 
the initial PSA was ≤1 ng/mL  prompting the authors to propose targeted screening 
at 60 years.  
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1.4.2  Ethnicity and Prostate Cancer 
 
Several studies have demonstrated wide variations in the incidence and mortality of 
PCa amongst racial groups; in particular, African-Americans (AA) who are the 2nd 
largest ethnic minority group in America. The incidence of PCa in AA men is 35 to 58 
percent higher than in white men (Ghafoor et al, 2002; Parker et al, 1998; Wingo et 
al, 1996). Furthermore, AA are twice more likely to die from PCa than their white 
counterparts (Parker et al, 1998; Wingo et al, 1996). In a study of 369 consecutive 
men (120 AA and 249 white) who had radical prostatectomies at a single institution, 
Powell and colleagues found that AA men had more  locally advanced PCa than the 
white American men [69% among blacks compared with 57% among whites] with 
higher rate of positive surgical margin [P = 0.002] (Powell et al, 1997). However, the 
high mortality and incidence rate of PCa seen in African-Americans is not observed 
in blacks from nations in Africa where incidence remains low (Walker et al, 1993). 
Several migrant studies suggest that the incidence of clinical PCa varies widely 
across geographical regions alluding that environmental factors may play a 
dominant role in development of PCa. For example, when Japanese men migrated 
to Los Angeles County, their incidence of PCa rose compared to their native 
homeland populations (Shimizu et al, 1991). Similar observation was found 
amongst the same group who migrated to Sao Paulo, Brazil (Iwasaki et al, 2008) and 
in Asian American migrants (Cook et al, 1999). In another study, it was observed 
that Korean immigrants to the US had a 3.5 times higher incidence of PCa compared 
to their native counterparts (Lee et al, 2007).  
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1.4.3  Hereditary Prostate Cancer 
 
There have been recent interests from investigators looking at familial and 
hereditary associations for PCa. In a metanalysis of familial PCa risk, Johns and 
Houlston found a 2.5 fold increased risk in first degree relatives. When the relatives 
of cases were diagnosed before 60 years; the relative risk dramatically increased 4.3 
fold and  3.5 fold where 2 first degree relatives are affected (Johns & Houlston, 
2003). Hereditary prostate cancer is reported to occur in 9% of PCa cases. This is 
defined as nuclear families with 3 cases of prostate cancer, families with prostate 
cancer in each of 3 generations and families with 2 men diagnosed before age 55 
years (Carter et al, 1992a).  Using segregation analysis, autosomal dominant 
inheritance of rare high-risk alleles which predisposes 88 - 97% of all carriers to 
become affected by 85 years of age compared with 5 - 10% of non-carriers has 
been suggested (Carter et al, 1992a; Verhage et al, 2001). A recent report by Lange 
and co-workers (Lange et al, 2012) suggested that early onset PCa cases had a 
significantly greater average number and frequency of risk alleles than in the 
control group. An inheritance of one defective copy of either of the two breast-
cancer susceptibility genes (BRCA1 and BRCA2) has been implicated in familial PCa 
amongst other cancers. BRCA1 and BRCA2 are tumour suppressor genes which 
encode large proteins that function in multiple cellular pathways (Venkitaraman, 
2001). Carriers of BRCA1 and BRCA2 mutations have a 1.8 to 3.75 and 7.3 to 8.6 fold 
increased risk of PCa by the age of 65 years (Consortium, 1999; Kote-Jarai et al, 
2011; Leongamornlert et al, 2012; Thompson et al, 2002). Increasingly, evidence 
from published reports suggests that carriers of these mutations are more likely to 
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present with aggressive form of PCa compared to non-carriers (Castro et al, 2013; 
Edwards et al, 2010). It has been suggested that targeted screening may be 
beneficial in this group as the age of onset is 6 -7 years earlier for hereditary PCa 
and as a consequence, a greater proportion would die of their disease compared to 
sporadic cases (Bancroft et al, 2014; Bratt, 2002). However, hereditary PCa does 
appear not differ in any other way from sporadic forms (Bratt, 2002; Siddiqui et al, 
2006).  
 
1.4.4  Lifestyle factors 
 
It is believed that exogenous factors play a key role in the progression from latent  
to clinical PCa. Modifiable lifestyle factors like physical activity, diet and obesity 
have been suggested as possible risk factors. In a recent metanalysis of 88,294 
cases from 19 studies, it was demonstrated that increasing total physical activity 
was significantly associated with a decreased risk of PCa with a relative risk 
reduction of 10% (Liu et al, 2011).  
Dietary and nutritional factors that may influence disease development include 
total energy intake (as reflected by body mass index), dietary fat, cooked meat, 
micronutrients and vitamins (carotenoids, retinoids, vitamins C, D, and E), fruit and 
vegetable intake, minerals (calcium, selenium), and phyto-oestrogens 
(isoflavonoids, flavonoids, lignans) (Heidenreich et al, 2011). Therefore, Western 
diet, with its high content of processed animal products containing saturated fat 
may be of importance. For example, compared to Far East Asian countries like 
China and Japan where traditional food is rich in fresh vegetables, the incidence of 
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PCa is low. The influence of diet in the development of PCa and definition of an 
ideal prostate diet were the subject of a recent review (Hori et al, 2011). Other 
factors such as occupational exposure to cadmium common to farmers by 
inhalation (Elghany et al, 1990; Nakamura et al, 2002) and  vasectomy (Dennis et al, 
2002) have been discussed as being of aetiological importance.  
 
1.5 Diagnosis of Prostate Cancer 
 
A diagnosis of PCa is made based on a combination of different modalities including 
prostate specific antigen (PSA), digital rectal examination (DRE), transrectal 
ultrasound (TRUS) and magnetic resonance imaging (MRI). However, transrectal 
ultrasound and biopsy (TRUSB) is required to provide the ultimate tissue sample for 
definitive diagnosis and grading of the disease by histological analysis of the TRUSB 
specimen. 
 
1.6 Prostate Specific Antigen (PSA) 
 
PSA is a 34 kD glycoprotein made up of a single polypeptide chain of 240 amino 
acids, manufactured almost exclusively by the epithelium of the prostate gland 
(Watt et al, 1986). It is a serine protease belonging to the human kallikrein (hK) 
gene family located on chromosome 19q 13.3 to 13.4 (Lilja, 2003). PSA is produced 
as an inactive form which is later converted to the active serine proteinase 
(Lundwall & Lilja, 1987; Watt et al, 1986). The physiological function of PSA is 
unclear, but the hypothesis proposed by Lilja (Lilja, 1988) has been widely accepted. 
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According to Lilja, within the seminal fluid, the proteolytic action of PSA liquefies 
the gel-forming proteins from the seminal vesicles, initiating liquefaction of the 
ejaculate, thereby increasing the motility of sperm cells and aiding fertilization.    
Antigens with structure similar to PSA had been reported by several workers in the 
1970s, however, Wang and his co workers are credited with the purification of a 
human PSA in 1979 and considering its use as a useful marker for assessing 
treatment responses and follow-up among patients with PCa  (Wang et al, 1979). 
However, Stamey and colleagues were first to show its clinical use as a marker for 
monitoring responses and recurrence after radical prostatectomy by demonstrating 
that PSA fell to undetectable level after prostatectomy (Stamey et al, 1987) with a 
serum half life of 2 to 3 days after prostatectomy (Oesterling et al, 1988; Stamey et 
al, 1987).  
The use of PSA as a biomarker for early PCa detection is limited by its lack of cancer 
specificity. Consequently, elevated serum level has been reported in benign 
prostatic hypertrophy [BPH] and prostate massage (Clements et al, 1992; Kane et 
al, 1992; Stamey et al, 1987), prostatitis (Morote Robles et al, 1988), acute urinary 
retention (McNeill & Hargreave, 2000), after coronary stent implantation (Ozcan et 
al, 2009) and other non-cancerous conditions (Glenski et al, 1992).   
Furthermore, there is no universally accepted optimal PSA cut off limit despite 
availability of numerous commercial test kits.  In a study of 2950 men with normal 
PSA less than 4ng/ml, PCa was identified in 15% (Thompson et al, 2004). The 
difficulty in finding a PSA cut-off value that would result in a sufficiently high 
specificity concurrently with a reasonably high sensitivity (i.e. above 50%) was 
highlighted by Holmstrom and colleagues. In their study, they observed that PSA 
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failed to attain likelihood ratios (i.e. the likelihood that a given test result would be 
expected in a person with a disease compared with the likelihood that the same 
result would be expected in a person without the disease) required for a screening 
test irrespective of cut-off value even though PCa occurred in only 3.9% of the 439 
men with initial PSA of 1ng/mL or less (Holmstrom et al, 2009).  
In contrast, a PSA screening study including 5855 men with a mean age of 58 years 
followed up for a median of 7.6 years showed that no man with initial PSA level less 
than 0.5ng/mL was diagnosed with PCa. Of the 1,992 men with PSA ranging from 
0.55 – 0.99ng/mL, PCa detection rate was only 0.9% (Aus et al, 2005). The authors 
proposed introduction of strategies aimed at individualised screening programmes 
based on initial PSA levels. 
 
Several studies have reported the potential use of PSA as a screening tool to 
identify men who are likely to be harbouring PCa, resulting to its widespread use in 
clinical practice for the diagnosis and management of PCa but the benefit for PCa 
screening remains controversial. Results from two randomised studies to determine 
if PCa screening using PSA decreased PCa mortality have been published recently. In 
the European Randomized Study of Screening for Prostate Cancer [ERSPC] trial of 
182,000 men, PSA based screening was associated with a 20% reduction in PCa 
mortality at a median follow-up of 9 years. However, a total of 1410 men needed to 
be screened and 48 men with PCa treated to save 1 death (Schroder et al, 2009). 
Compared with the US Prostate, Lung, Colorectal and Ovarian cancer [PLCO] 
screening trial of 76,693 men, screening was associated with a relative increase of 
22% in the rate of PCa diagnosis compared with control group but did not provide 
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reduction in death rates at 7 years  (Andriole et al, 2009). There was no indication 
of a benefit appearing with 67% of the subjects having completed 10 years of 
follow-up. It is suggested that the high rates of contamination (52%) in the control 
group compared to 20% in the ERSPC study could account for this disparity.  
In another randomised population-based trial (Hugosson et al, 2010) of Twenty 
thousand men with 14 years of follow-up, the number who needed to be invited to 
screening (corresponding to NNS) to prevent one prostate cancer death was 293, 
and the number who needed to be diagnosed (corresponding to NNT) was 12, with 
a relative risk of 0.56. Importantly, the difference between the cumulative risks of 
death in the screening and control groups was not apparent before 10 years 
(Hugosson et al, 2010; Schroder et al, 2009). 
One concern against the use of PSA screening is the fact that PCa has a long lead 
time and natural course resulting to an increase in the rate of over diagnosis (i.e. 
the diagnosis in men who would not have clinical symptoms during their lifetime) 
depending on the age at commencement of screening programme. This is 
estimated to range from 27 – 50% (Draisma et al, 2003; Etzioni et al, 2002). 
McGregor and co-workers (McGregor et al, 1998) estimate that only 16% of men 
with screen detected PCa could have their lives extended by invasive therapy, since 
PCa rarely causes death before the age of 85 years. Furthermore, a recent Cochran 
review concluded that screening did not significantly decrease all-cause or PCa-
specific mortality and recommending that any benefits from PCa screening may 
take more than 10 years to accrue; therefore, men who have a life expectancy of 
less than 10 to 15 years should be warmed against undergoing  screening for PCa 
(Ilic et al, 2011).   
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Despite these concerns, PSA remains widely used in clinical practise as a screening 
tool for early detection of PCa with the aim of reducing mortality from the disease. 
Currently, there is no long term data to support its use or an optimum PSA 
threshold to diagnose non-palpable but clinically significant PCa.   
These inconsistencies prompted investigators to search for alternative PSA 
modifications in order to improve its specificity for early detection of PCa. The PSA 
modifications have been proposed include:- age specific PSA ranges, free to total 
PSA, PSA density, PSA velocity (PSAV) and PSA doubling time (PSADT). 
 
1.6.1 Age-specific PSA reference range 
 
In order to enhance PSA as a predictor of PCa and improve its ability to distinguish 
cancer from BPH, the concept of age specific reference range was proposed. In a 
population-based study of healthy 471 white Caucasian men aged 40 to 79 years 
divided into four 10 year age groups, Oesterling and colleagues (Oesterling et al, 
1993) found that PSA correlated with patients’ age, increasing at the rate of 
0.04ng/ml per year. Using regression analysis, their proposed reference range for 
serum PSA (95th percentile) for men aged 40 to 49 years is 0.0 to 2.5 ng/ml; for 50 
to 59 years, 0.0 to 3.5 ng/ml; 60 to 69 years, 0.0 to 4.5 ng/ml; and 70 to 79 years, 
0.0 to 6.5 ng/ml. The expectation is that age-specific PSA range would increase PSA 
sensitivity in younger men who are more likely to benefit from invasive therapy 
whilst increasing specificity in the older age group. In one study, el-Galley and 
colleagues showed that the use of age-specific PSA reference range increased PSA 
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sensitivity in men younger than 60 years whilst avoiding 22% of TRUS biopsies in 
those 70 years and over (el-Galley et al, 1995).  
Age-specific PSA shows considerable variation amongst racial groups. In Asians, the 
observed value is lower and may be accounted for by their smaller prostate size 
compared to whites (Ku et al, 2002; Lee et al, 2000; Oesterling et al, 1995). In 
contrast, PSA value is slightly higher in healthy AA men compared to whites 
(Cooney et al, 2001). A potential source of bias is the high participation by younger 
men with prostatic symptoms and positive family history of PCa in whom higher 
PSA values are usually observed (Heeringa et al, 2001). Nevertheless, the use of 
race-specific PSA reference range remains controversial (Morgan et al, 1996a; 
Whittemore et al, 1995) so further study is required to ascertain the clinical 
relevance of the minor variations seen in black men compared to Caucasians. 
 
1.6.2 Free and Total PSA 
 
The lack of PCa specificity is a drawback in the ability of PSA to reliably discriminate 
PCa from other non-cancerous conditions involving the prostate which can result in 
an elevated serum PSA level. The dilemma is in correctly identifying men with BPH 
with borderline raised PSA in the intermediate range of 4 to 10ng/ml [diagnostic 
‘gray zone’], who are unlikely to be harbouring cancer. If correctly identified, 
unnecessary biopsy which is invasive and costly could be avoided in this group.  
Although benign conditions can cause a raised PSA, studies have also shown that 22 
to 32% of men diagnosed with PCa have PSA within the normal range (Kellokumpu-
Lehtinen et al, 1989; Van Cangh et al, 1996). This means that if PSA is used as the 
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sole diagnostic tool for early PCa detection, a significant number of PCa would have 
been missed. Furthermore, 78% men who underwent prostate biopsy purely for a 
raised PSA in the range of 4.0 to 9.9ng/ml had a negative biopsy (Catalona et al, 
1991).  
The discovery that PSA exists in various forms in the serum coupled with 
development of commercial assays that accurately measure these forms helped to 
increase knowledge of their possible utility as an adjunct to further increase the 
ability of PSA to discriminate benign prostatic disease from cancer. Using 
monoclonal antibodies produced against PSA from serum of 64 patients, Lilja and 
co-workers (Lilja et al, 1991) demonstrated the existence of PSA predominantly in 
an 80 to 90 kDa complex to α1-antichymotrypsin with an immunoreactive 25 to 40 
kDa free (non-complexed) form. Subsequent report by Christensson and colleagues  
characterised PSA in 3 different forms and highlighted differences in their serum 
concentrations in men with BPH compared to those with PCa (Christensson et al, 
1993).  
In a prospective multicentre study of 773 men, it was demonstrated that 
percentage of free PSA [%fPSA] is more predictive of cancer than total PSA [tPSA] 
level with an area under the receiver operating characteristic curve [AUC] of 0.72 
compared to 0.53 for total PSA. Furthermore, at a cut off of 25%, %fPSA yielded a 
sensitivity of 95% whilst avoiding unnecessary biopsy in 20% of those patients with 
BPH (Catalona et al, 1998). In another large, well controlled population based trial 
of 11,644 men with PSA level between 4 to 10ng/ml, %fPSA was significantly more 
predictive of PCa than tPSA with an AUC of 0.72 compared to 0.60. furthermore, at 
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a cut off of 20%, 95% of cancers were detected and whilst avoiding 15% of 
unnecessary biopsy (Luboldt et al, 2001).  
To determine predictive value of %fPSA in the group of men whose PSA 
concentration remained in intermediate range after an initial negative TRUS biopsy, 
Djavan performed a repeat extended biopsy showing a sensitivity of 90% and at a 
cut-off of 30%, unnecessary biopsy was avoided in 50% of the patients (Djavan et al, 
2000). In another study of men with negative initial histology who underwent 
repeat biopsy for a persistently elevated PSA, not only was %fPSA significantly 
lower in the cancer detected group compared to the no-cancer group (8% vs 14%, p 
<0.01), it was the single most important predictor for the detection of PCa at repeat 
biopsies (Uemura et al, 2004).      
However, limitations of %fPSA include the variability of assay characteristics, 
dilutional effect of enlarged prostate (Moon et al, 2000; Stephan et al, 1997), 
instability of free PSA at room temperature and its unreliability at higher PSA 
concentration (above 10ng/ml). Furthermore, %fPSA is not clinically useful for the 
follow-up of patients with prostate cancer.   
 
1.6.3 PSA Density (PSAD) 
 
PSAD is the quotient of serum PSA and prostate volume (PSA ng/ml/prostate 
volume cc). It was developed by Benson and colleagues aimed at increasing the 
specificity of PSA in the intermediate range of 4 to 10ng/ml without influencing 
sensitivity with biopsy based on a PSAD of 0.15 or more (Benson et al, 1992a; 
Benson et al, 1992b).  
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According to Benson and colleagues, the concept of PSAD is based on the logic that 
by accounting for PSA elevations resulting from BPH, it would be possible to 
differentiate BPH from those due to PCa.  The normal prostatic stromal/epithelial 
relationship which is maintained in BPH is disrupted in PCa. Benign tumours are 
known to grow by expansion, unlike malignant tumours which grow by a 
combination of both expansion and infiltration; resulting to an increase in prostatic 
epithelial cell number (hence PSA) but only minimal effect on gland volume (Benson 
& Olsson, 1994). Several studies have investigated the value of PSAD in 
discriminating BPH from PCa in men with serum PSA concentration within this 
diagnostic gray zone (Benson et al, 1993; Schmid et al, 1996). Of 142 healthy men 
with intermediate range PSA and normal DRE and TRUS, a PSAD cut-off of 0.15 
provided a sensitivity of 91% and reduced the number needed to biopsy to detect 
one cancer from six to three (Bazinet et al, 1994). In contrast, some conflicting 
reports suggest that PSAD cut-off of 0.15 is an unreliable predictor of PCa in this 
cohort (Brawer et al, 1993; Cookson et al, 1995). PSAD is highly dependent on 
accurate volume determination and this is believed to explain the mixed 
observations by various reports in literature (Benson & Olsson, 1994). Furthermore, 
the cost of having to perform a TRUS scan and the operator variability of TRUS 
prostate volume measurement are limitations to its routine use in clinical practice.  
 
1.6.4 PSA and Kinetics 
 
There are two methods of measuring changes in serum PSA value over time (PSA 
Kinetics), including PSA Velocity (PSAV) and PSA Doubling Time (PSADT). 
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PSAV is based on the observation by Carter and co-workers (Carter et al, 1992b) in a 
small cohort of men, that the most significant factor affecting PSA levels with age is 
the development of PCa and the use of PSA rate of change of 0.75 µg/L/yr not only 
maintained sensitivity, but was more significantly associated with PCa with 
specificity rising to 90% compared to PSA alone which had a specificity of 60%. One 
study found that PSAV of 0.35 ng/ml/yr determined ten to fifteen years before 
diagnosis can identify men with life-threatening PCa at a period when their serum 
PSA levels are associated with curable disease (Carter et al, 2006). Similar 
observation was reported more recently, using a PSAV threshold of 0.4ng/ml/yr and 
showing PSAV to be useful for PCa risk stratification several years prior to actual 
diagnosis of PCa when most men would usually have low PSA levels (Loeb et al, 
2011b). In the time period prior to diagnosis, longitudinal PSA changes in men with 
and without PCa are so significantly different that annual testing of men with initial 
PSA of ≤ 1.0ng/ml/yr may not be necessary (Berger et al, 2005).  
Furthermore, PSAV ≥ 2.0ng/ml/yr during the year prior to diagnosis has been 
associated with a ten to twelve fold increase in the rate of PCa specific mortality 
following radical prostatectomy or radiation therapy (D'Amico et al, 2004; D'Amico 
et al, 2005). The suggestion is that PSAV is more useful than PSA doubling time in 
the prediction of high risk PCa (Loeb et al, 2008). 
The concept of PSADT was described by Schmid and co-workers (Schmid et al, 1993) 
who observed that serial PSA determinations in untreated PCa conform to an 
exponential model suggesting that PCa  has a log linear growth pattern. In their 
study, 43 men aged 51 to 83 years with untreated PCa were observed for a mean of 
30 months and found to have a significantly longer PSADT (>24 months) when PCa 
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is locally advanced (93% vs. 53%) than with higher histological grade. In another 
study, D’Amico and Hanks (D'Amico & Hanks, 1993) used regression analysis to 
show that PSADT of recurrent PCa after radiation therapy is a constant [r > 0.98], 
indicating that PSA rises exponentially and correlates linearly with the interval to 
clinical manifestation after PSA failure. The slope of the correlation curve is the 
number of PSADT determinations (4.5, 95% CI 3 – 6) needed before disease is 
clinically manifested after PSA failure and can be useful for grouping this group into 
those with aggressive [PSADT ≤  3.8] and less aggressive tumour biology [PSADT ≥ 
3.8]. Recent report suggest that PSADT is useful for predicting disease progression 
in men with non-metastatic biochemical relapse after radical prostatectomy or 
radiation therapy who are treated with intermittent androgen hormone therapy 
(Keizman et al, 2011). Nonetheless, the diagnostic use of both PSA kinetics is limited 
by the dilution effect of BPH, racial differences (Tang et al, 2011), circadian 
fluctuation of PSA values (Mermall et al, 1995), variations in interval of PSA 
determinations, acceleration/deceleration of PSAV and PSADT over time. 
Furthermore, a prospective study failed to show any clear evidence that PSAV or 
PSADT substantially enhances the predictive accuracy compared to a single pre-
treatment PSA alone (O'Brien et al, 2009) and is not useful for monitoring of men 
on active surveillance (Ross et al, 2010). 
 
1.7 Digital Rectal Examination (DRE) 
 
DRE was the principal method for detection of PCa prior to introduction of PSA in 
the 1980s. Using DRE, PCa volume of 0.2ml or greater can be detected because 
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majority are located in the peripheral zone of the prostate. A suspect DRE is an 
absolute indication for prostate biopsy. The use of suspect DRE alone for screening 
will correctly detect PCa in up to 18% of patients  (Crawford, 1996; Schroder et al, 
1998). In a screening programme of healthy volunteers aged 50 years and over, the 
positive predictive value of suspect DRE at a serum PSA value 1.0 ngm/ml or greater 
ranged from 14 – 30% (Carvalhal et al, 1999). A metanalysis of published report 
showed that when a patient has abnormal PSA levels or DRE findings, the chance of 
having cancer is 20 – 25% (Mistry, 2003). The combined use of PSA and DRE for 
screening is more effective than either test alone for early detection of localised 
PCa (Carvalhal et al, 1999; Crawford, 1996). However, its low reproducibility and 
inter-examiner variability (Smith, 1995); and the need for an examination room and 
trained examiners are limitations. Furthermore, it is hypothesised that negative 
perception of DRE may deter some men from screening programmes (Underwood, 
1991).   
 
1.8 Transrectal Ultrasonography (TRUS) 
 
Since its description by Watanabe and colleagues, TRUS has become widely 
accepted for clinical use (Watanabe et al, 1971). Prior to this, DRE was the primary 
modality for assessing the local extent of PCa. Technical advances have resulted in 
better transducers allowing clearer delineation of internal architecture of the 
prostate. Earlier investigators explored the possible role of TRUS as a tool for early 
detection of PCa. Lee and co-workers (Lee et al, 1985) described visualisation of 
hypoechoic lesion on ultrasound as the criterion for diagnosis of PCa on TRUS. 
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Using this criterion, Kenny and Hutchinson found 81.1% correlation between TRUS 
and biopsy findings with a false positive rate of 15.1% (Kenny & Hutchinson, 1988). 
In another prospective study of 784 men to compare the usefulness of TRUS for 
screening over DRE, it was demonstrated that TRUS correctly detected twice more 
PCa than DRE and interestingly, 59% of tumours measuring less than 1.5cm were 
not palpable (Lee et al, 1988). Overall, the probability that a hypoechoic area is 
malignant ranges from 36 to 37% (Andriole et al, 1988; Chodak et al, 1986). On the 
other hand, 31.8% of PCa are isoechoic  whilst 7.6% are found to be hyperechoic 
(Spajic, 2007).  
To improve differentiation of benign from malignant hypoechoic lesions, several 
investigators have modified TRUS technique. Sperandeo and colleagues described 
the use of compression of suspicious lesions with the ultrasound probe to 
determine if they are deformable or non-deformable. In their report, 92.6% of non-
deformable hypoechoic lesions were shown to have PCa (Sperandeo et al, 2003). 
Using contrast enhanced ultrasound, Tang and co-workers reported a statistically 
significant difference between malignant and benign hypoechoic nodules by 
demonstrating that malignant nodules are more likely to enhance (Tang et al, 
2008).  
Despite these advances, the specificity of TRUS alone for predicting PCa remains 
disappointing. In one study that evaluated 256 hypoechoic lesions, the PPV of TRUS 
when used alone was 41% which fell to 24% when DRE is normal (Lee et al, 1989). 
In contrast, when PSA, DRE and TRUS are used together, the number of biopsy 
cores needed to diagnose one cancer decreased from 26.5 for TRUS alone to 1.3 
(Bangma et al, 1995). 
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Furthermore, focal non-malignant lesions like benign prostatic hyperplasia, 
prostatitis, prostatic atrophy and infarction produce sonographic appearances 
diifficult to distinguish from PCa (Brawer & Lange, 1989).  
Therefore, in clinical setting, the established role of TRUS in early detection of PCa 
is for accurate measurement of prostate volume and to facilitate biopsy by 
providing guidance for needles through the channel in the probe. 
 
1.9 Prostate Biopsy 
1.9.1 Anatomy of the Prostate, Biopsy and Cancer Location 
 
Improvements in TRUS technology from the first description by Watanabe have 
expanded its clinical use for PCa detection. It is essential to understand prostate 
anatomy seen at TRUS because although current improvements in ultrasound 
technology have vastly improved prostate image resolution; its accuracy depends 
on the concise demonstration and interpretation of the visualised internal 
architecture of the prostate. 
Lowsley was the first to publish a detailed description of lobar division of prostate. 
He divided the prostate into five lobes based on anatomical findings on human 
embryos at different stages of development. Lowsley’s five lobes include an 
anterior, posterior, 2 lateral, and 1 middle lobes with the anterior lobe regressing 
after birth (Lowsley, 1912). This observation was supported by Robert Moore in his 
report of 678 prostates from consecutive autopsies (Moore, 1936). In contrast, 
Lowsley’s lobar pattern could not be confirmed in the adult prostates investigated 
by Le Duc using ductile injection of india ink (Le Duc, 1939). Instead, he concluded 
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that the prostate has no posterior lobe but is rather comprised of two lateral and 
one middle lobe. In support of Le Duc’s observations, Franks concluded that 
Lowsley’s lobar anatomy did not exist in the adult prostate and proposed that the 
prostate is comprised of two functionally distinct outer and inner gland, with 
benign hyperplasia said to arise exclusively from the later (Franks, 1954a). 
This controversy existed until 1968 when McNeal, in a sequence of related 
investigations of the adult prostate reported for the first time, the existence of 
distinct functional and histologically separate zones within the prostate (McNeal, 
1968; McNeal, 1981; McNeal, 1988). These histological distinctions cause 
differences in the reflection of sound waves on ultrasound hence enabling 
identification of different zones within the prostate. McNeal proposed that 
although the prostate developed in relation to the urethra, its subsequent 
development and function are related to the Wolffian duct, so he examined the 
prostate by making his cuts in a plane along the course of the ejaculatory duct from 
the base of the seminal vesicles through to verumontanum, a plane at right angle to 
usual plane of section and described three zones and an anterior fibromuscular 
stroma.  
The peripheral zone (PZ) comprises 70% of the glandular prostate is the most 
susceptible to inflammation and some 70 – 80% of PCa. It has a simplified, rounder 
sacculations with less prominent intraluminal partitions and pale simple columnar 
epithelium.   
In contrast, the central zone (CZ) is a vertical wedge of glandular tissue lateral to 
each ejaculatory duct with its apex at the verumontanum. It comprises about 25% 
of the total mass of the glandular prostate with more elaborate acini and large 
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rectangular sacculations which are concentrated peripherally. It makes up almost 
the entire base of the prostate and is seldom involved with PCa. Lee and colleagues 
believe that the point of entry of the ejaculatory duct through the capsule of central 
zone at the base creates an invaginated extraprostatic space down to the apex of 
the prostate resulting in anatomical defect which creates a pathway for tumours of 
apical origin to invade the CZ (Lee, 1989). 
The transition zone (TZ) consists of two independent small lobes comprising 5-10% 
of glandular prostate. This region is believed to be the main site of BPH origin, but 
10 – 20% cancers are believed to originate from here. Because of their central 
location, this zone is not palpable. The final zone described by McNeal corresponds 
to the anterior fibromuscular stroma (AFMS). This is a non-glandular region at the 
anterior surface of the prostate. Because it is non-glandular, it is not thought to be 
a site of origin for prostate cancer 
 
The precise locations of cancer within the prostate has been shown in autopsy and 
radical prostatectomy whole mount specimens with the suggestion that the 
periurethral area at the base of the prostate is rarely the only site of tumour and 
when involved, is usually due to invasion from adjacent zones (Chen et al, 2000; 
McNeal, 1969). McNeal (McNeal, 1969) reported on 134 autopsy prostate glands of 
which 45 had PCa and demonstrated that the central area at the base surrounding 
the urethra and ejaculatory duct was consistently spared of PCa involvement. 
Cancer involvement of the periurethral area is a late progression event which 
strongly correlated with increasing tumour size. Of the 44 small tumours [<0.1cc], 
none originated solely from the central zone and more interestingly, this area was 
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consistently spared even in larger tumours [0.1 to >1cc]. McNeal thus postulated 
that this restricted pattern of PCa spread was likely due to increased density of the 
central zone and the propensity of tumours to spread along planes of least 
resistance (figure 1-1).   
 
Figure 1-1: Cancer distribution in the prostate at 5 serial planes [V-Z] and 3 ranges 
of tumour volumes [A-C]. Light gray = one tumour; dark gray = two tumours 
overlapping; black = three or more tumours overlapping. C = central zone; P = 
peripheral zone; S = central stromal core. Adapted from McNeal (McNeal, 1969). 
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In agreement with McNeal’s observation, Chen et al (Chen et al, 2000) reported on 
a computer generated cancer distribution plot obtained from step sectioned 180 
radical prostatectomy specimens and showed that the periurethral region at the 
central area of the base was rarely involved with small volume PCa [figure 1-2].  
 
 
 
 
Figure 1-2: Five sections of the computer plots showing distribution of all cancer 
foci [A] and distribution stratified according to tumour volume [B]. The sections 
nearest the base are represented by the first section to the left whilst the apical 
sections are represented on the right. Adapted from Chen et al (Chen et al, 2000) 
A 
B 
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1.9.2 TRUS Biopsy (TRUSB) 
 
In 1989, Hodge and colleagues described the random systematic sextant biopsy and 
demonstrated that systematic sextant biopsy technique was significantly better 
than lesion directed biopsy. Of 136 patients who underwent their six systematic, 
spatially separated paramedian biopsies, 83 were positive for PCa and 96% of these 
were correctly identified using the sextant technique (Hodge et al, 1989). In support 
of sextant biopsy technique, Stamey advocated its use in routine clinical practice, 
but suggested that rather than sampling the mid lobar plane, cores should be taken 
more laterally in order to adequately sample cancers located in the anterior horn of 
the peripheral zone (Stamey, 1995).  
As technology evolved, investigators began to use computer simulations to 
determine the optimum biopsy sites in order to improve cancer detection. Kawata 
et al  reconstructed  86 autopsy prostates and 40 radical prostatectomy specimens 
to demonstrate that a modified laterally directed sextant biopsy scheme detected 
significantly more life threatening PCa (tumour ≥0.25cc and or ≥Gleason 7) 
compared to routine sextant scheme (Kawata et al, 2003). In a similar study, Chen 
et al used a computer to simulate 10 biopsy schemes and demonstrated that an 11-
core multisite-directed biopsy scheme comprising a sextant, one posterior midline, 
two TZ and anterior horn biopsies had the highest detection rate for cancers 
greater than 0.5 cc (Chen et al, 1999). Using Chen’s 11-core scheme, Babaian et al 
detected 33% more cancers and demonstrated that the most commonly positive 
non sextant site is the anterior horn (Babaian et al, 2000). To minimise this rather 
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high false negative rate of sextant biopsy, investigators began to explore alternate 
site sampling or extended biopsy schemes. 
 
1.9.3 Extended TRUS Biopsy  
 
Sextant biopsy as described by Hodge was designed to sample the PZ which 
harbours most of the cancers and it quickly became the gold standard biopsy 
technique; until reports began to emerge suggesting that significant numbers of 
cancers ranging from 20 to 35% are missed by this regimen (Babaian et al, 2000; 
Eskew et al, 1997; Eskicorapci et al, 2004; Presti et al, 2000). These studies show 
that laterally directed biopsy scheme significantly improved the diagnostic yield 
compared to the sextant technique. Gore et al (Gore et al, 2001) performed 
laterally directed biopsies in addition to the standard sextant regimen in 396 
patients and observed that although 8 core strategy which included mid lobar and 
laterally directed basal and apical cores optimally detected PCa in smaller prostates 
with volume <50cc; overall, a 10 core regimen that combined laterally directed 
biopsy cores obtained from the base, mid gland and apex of the prostate with cores 
obtained from the paramedian areas at the base and apex achieved an optimal 
detection rate in all patient subgroups independent of prostate volume or PSA 
level.  
However, in a systematic review of 20,698 patients from 87 studies based on 
Eskew’s 5 anatomical region biopsy model (Eskew et al, 1997), modified sextant 
scheme involving 12 laterally directed cores identified 31% more cancers without 
additional side effect compared to the sextant scheme (Eichler et al, 2006). 
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Furthermore, increasing the number of biopsy cores above 12 did not significantly 
alter the cancer yield. 
Another advantage of extended biopsy is that it improves the accuracy of Gleason 
score after radical prostatectomy. In a prospective study comparing laterally 
directed sextant biopsy to extended 12 core biopsy scheme, the concordance 
between biopsy and prostatectomy specimen was significantly higher in the 
extended biopsy group compared to the group undergoing sextant biopsy [85.2% vs 
50% p = 0.026] (Elabbady & Khedr, 2006). Similar observations was reported in 
another study (Divrik et al, 2007). Mian et al demonstrated that extended biopsy 
scheme comprising 10 or more samples was significantly less likely to be upgraded 
compared to sextant biopsy [17% vs 41% p = 0.001] (Mian et al, 2006). 
Consequently, it is now recommended that sextant biopsy should no longer be 
performed but instead, at least 8 cores should be sampled in a prostate 30 – 40mls 
in size (Heidenreich et al, 2011). 
 
1.10 Repeat Biopsy: Indications 
 
In the presence of persistent clinical suspicion of PCa despite a negative initial 
biopsy, majority of men would undergo a repeat and sometimes multiple repeat 
biopsies. The indications for repeat prostate biopsy include a persistently elevated 
or rising PSA, suspicious DRE, atypical small acinar proliferation (ASAP) of prostate 
and multifocal high grade prostatic intraepithelial neoplasia (HGPIN)  (Heidenreich 
et al, 2011). The incidence of PCa at repeat biopsy in patients initially diagnosed 
with ASAP ranges from 39% - 40% and no usual preoperative parameters including 
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PSA, DRE results, TRUS findings, PSAD and prostate volume significantly predicted 
cancer diagnosis in this group (O’dowd et al, 2000; Scattoni et al, 2005). Because of 
this high risk of cancer diagnosis with ASAP and the lack of clinical or pathological 
factors to predict which men will have cancer on repeat biopsy, a systematic review 
by Epstein and Herawi recommended that all men diagnosed with ASAP should 
undergo repeat biopsy within 3 to 6 months (Epstein & Herawi, 2006).   
The cancer detection rate for HGPIN has fallen over the years probably due to shift 
from sextant biopsy to extended biopsy schemes. Nevertheless, the role of HGPIN 
as a risk factor for subsequent PCa detection at repeat biopsy remains 
controversial.  In one Canadian study of men diagnosed with HGPIN who 
underwent repeat biopsies, multifocal HGPIN was an independent risk factor for 
PCa diagnosis (Merrimen et al, 2009). Recent study of identical design by the same 
group limited to only a cohort who underwent 10 or more extended biopsy regimen 
at both initial and repeat biopsy performed at a mean of 0.98yr showed similar 
result (Merrimen, 2010). Therefore, an isolated HGPIN is no longer an indication for 
repeat biopsy and such patients should be followed up with PSA and DRE (Moore et 
al, 2005). The optimum time for repeat biopsy is unclear, but the longer the time 
interval between initial and repeat biopsy, the higher the PCa detected (Lefkowitz 
et al, 2002). 
 
1.11 Transrectal Saturation Biopsy (TRSB) 
 
Although several studies had shown that extended biopsy schemes significantly 
increased PCa detection rate with superior concordance of Gleason score between 
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needle biopsy and radical prostatectomy, there remain significant number of men 
who would require repeat prostate biopsies because of either persistently raised 
PSA, rising PSA, abnormal DRE or inconclusive initial histology (Djavan et al, 2000; 
Nam et al, 2004).  
Unfortunately, the cancer detection rates from repeat biopsies show a diminishing 
return. In one study, 34% of 1136 men who had initial biopsies for raised PSA and or 
abnormal DRE were diagnosed with PCa. Of the 427 men who subsequently had 
serial prostatic biopsies for persistent clinical suspicion of PCa, 19% had PCa at 2nd 
biopsy and this number decreased to 8% and 7% for subsequent repeat biopsies 3 
and 4 respectively (Keetch et al, 1994). In another study of 1051 men with total PSA 
between 4 and 10 ng/ml who had sextant plus two TZ biopsies, PCa detection rates 
of 22%, 10%, 5% and 4% for biopsies 1, 2, 3 and 4 respectively (Djavan et al, 2001). 
These studies were based largely on sextant biopsy schemes even though Djavan 
included two cores from the TZ. However, even with laterally directed extended 
biopsy schemes, significant false negative rates still persist (Kawakami et al, 2007). 
This prompted investigations to explore either increasing the number of samples or 
varying the distribution of biopsy sites in order to improve PCa detection rate.  
Several transrectal saturation biopsy techniques have been reported with varying 
cancer detection rates (table 1-1 overleaf).  
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Table 1-1: Transrectal saturation biopsy series and cancer detection rates 
Author 
 
Sample Size  
(N) 
Mean Age 
(yrs) 
 
Number 
of Cores 
PCa (%) 
Borboroglu et al 2000 57 61.4 22.5 30 
Stewart et al 2001 224 64.2 23 34 
Jones et al 2002 15 61 24 33 
Rabbets et al 2004 116 62 24 29 
Walz et al 2006 161 63.7 24 41 
Stav et al 2008 27 62.1 61.7 11.1 
Zaytoun et al 2011 663 64.5 20-24 32.7 
 
Borboroglu et al were the first to report an extensive TRUS guided prostate biopsies 
on men with persistent clinical suspicion of PCa after a mean of 2 previous negative 
sextant biopsies (Borboroglu et al, 2000). Of 57 men who underwent a mean of 
22.5 biopsy cores (range 15 – 31) from six sagittal zones, PCa was detected in 30%. 
Subsequently, Stewart et al reported a 34% cancer yield in 224 men undergoing 
repeat biopsy (Stewart et al, 2001). They described a ‘saturation’ biopsy comprising 
a mean of 23 cores (range 14 – 45) performed under general anaesthesia. Two 
studies from the same group reported 24 core TRSB as an office based procedure 
under local anaesthesia (LA) with a 33 - 41% cancer detection rate (Jones et al, 
2002; Rabets et al, 2004). They achieved periprostatic nerve block by injecting 
lignocaine lateral to a fat notch between the prostate and seminal vesicle which 
they named Mount Everest sign.  
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In another study, 41% of 161 patients who underwent an average of 24 cores TRSB 
were diagnosed with PCa. The authors proposed a model with 72% accuracy for 
prediction of PCa diagnosis (Walz et al, 2006). Similar to initial biopsy protocol, 
Patel et al demonstrated that more effort should be spent on laterally directed 
biopsies (Patel et al, 2004). Of the 25 cancers detected in their series, none were 
detected in the parasagittal biopsy cores alone. Only in one study (Stav et al, 2008) 
was the cancer detection rate of TRSB low (11.1%) after an average of 61.7 cores 
(range 41 – 76) using a technique aimed at extensive coverage of the peripheral 
zone. However, the mean prostate volume of the 27 patients in this series was 
89.6cc (range 35 – 210).  
The largest TRSB series reported in literature was by Zaytoun et al (Zaytoun et al, 
2011). In their study comparing cancer office based TRSB (n = 663) and extended 
transrectal biopsies (n = 393) after initial negative biopsy using a sampling scheme 
of 20 cores focused on the lateral and apical regions of the prostate. PCa was 
identified in 32.7% of the TRSB cohort which was 31.3% higher than detection rate 
in the extended biopsy group. 
The complication rates for TRSB is poorly reported in literature, but in two studies, 
this ranged from 2.5 to 12% (Borboroglu et al, 2000; Walz et al, 2006). However, 
haematuria described as self limiting was found in 100% of patients in one study 
(Stav et al, 2008), whilst routine use of urethral catheterisation for variable period 
of time was part of the procedure in other series (Fleshner & Klotz, 2002; Stewart et 
al, 2001). Nevertheless, the suggestion in literature is that complications of TRSB 
are self limiting and comparable to standard biopsy schemes (Rabets et al, 2004). 
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Despite this apparent improvement in PCa detection rate, there are physical and 
technical limitations with the use of transrectal approach resulting from the 
inability to adequately sample the anterior and apical regions of the prostate.  
TRSB lacks precision for localisation of cancer within the prostate. This was 
demonstrated in the study of Falzarano et al (Falzarano et al, 2010) in their series 
including 72 men diagnosed with prostate cancer from saturation needle biopsy 
who underwent radical prostatectomy. Their data showed that 90% of 39 men who 
were diagnosed with unilateral cancer by saturation biopsy had bilateral disease 
after radical prostatectomy. Saturation biopsy missed 12 potentially clinically 
significant cancers.  Furthermore, there is a potentially increased risk of sepsis and 
rectal bleeding arising from multiple needle sticks injuries to anterior rectal wall. 
Lastly, the transrectal approach relies heavily on operator dependent 3D visual 
recall for guidance when the procedure is performed. Coupled with the lack of 
fixation devise, it means that TRSB is devoid of precision which can lead to sampling 
inaccuracies. 
 
1.12 Transperineal Template Guided Saturation Biopsy (TTSB) 
 
In the current PSA era, prostate biopsy is a frequently performed procedure and 
remains an essential tool for prostate cancer diagnosis (Welch et al, 2007). It is 
estimated that more than 1 million prostate biopsies are performed annually in the 
United States of America and Europe (Loeb et al, 2011a; Wagenlehner et al, 2013). 
In the UK, Cross and McPhail from the National collaborating centre for cancer 
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analysed data from the hospital episode statistics (HES) showing a rising trend for 
prostate biopsies and an estimated 89,000 biopsies per annum in England and 
Wales (Cross & McPhail, 2008). With a recent update of a European randomised 
controlled trial after 11 years follow-up showing  that PSA based screening 
significantly reduced mortality from PCa by 21%, it is likely that the demand for 
prostate biopsies would increase (Schröder et al, 2012).  Furthermore, a significant 
proportion of men with negative first biopsy would proceed to have repeat 
biopsies. In one study, it was shown that the risk of subsequent repeat biopsy when 
initial procedure is negative was 11.6% after 1 year rising to 38% after 5 years 
(Welch et al, 2007). Further compounding this huge workload demand is the 
diminished accuracy of conventional TRUSB technique originally designed to sample 
the peripheral zone of the gland (Hodge et al, 1989). This led to increasing use of 
extended biopsy schemes including saturation biopsy in order to improve cancer 
detection rate. 
In 2001, by adapting the brachytherapy template grid into their technique to enable 
systematic sampling of all regions of the prostate, Igel and colleagues described a 
systematic transperineal ultrasound guided template biopsy of the prostate (TTSB) 
in patients at high risk of harbouring potentially life threatening PCa (PSA >10ng/ml, 
PSAV >0.75, previous ASAP or PIN on biopsy) despite at least one previous negative 
set of TRUS biopsies (Igel et al, 2001). Depending on the size of the prostate, 4 
cores were obtained anterior to posterior from 4 coronal planes similar to the 
technique used for interstitial radioactive seed insertion at brachytherapy. In order 
to ensure complete sampling of the prostate in patients with prostate volume 
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greater than 45cc, additional 2 cores were obtained from each of 2 distal coronal 
planes. Of 88 patients who were biopsied, PCa was detected in 38 (43%) from a 
mean of 17 cores. Subsequent report from the same group on 210 high risk patients 
who underwent TTSB showed similar result with 37% PCa detection rate from a 
mean of 21.2 cores (Pinkstaff et al, 2005). 
Several groups have since described various techniques for TTSB with high cancer 
detection rates (22.7 – 68%) which is comparable to that reported for transrectal 
approach in repeat biopsy population (Bittner et al, 2009; Bittner et al, 2013; 
Demura et al, 2005; Dimmen et al, 2012; Furuno et al, 2004; Gershman et al, 2012; 
Mabjeesh et al, 2012; Merrick et al, 2007; Pal et al, 2011; Satoh et al, 2005).  
Merrick et al divided the prostate into 24 predetermined regions corresponding to 
areas covering sextant, lateral PZ, TZ and apex (Merrick et al, 2007); and depending 
on prostate size; one to three cores were obtained from 24 regional locations. 
Other series have described an  equally distributed and systematic sampling of the 
entire prostate such that on transverse image, the biopsy spots had a diamond 
shape appearance in most cases (Demura et al, 2005; Furuno et al, 2004).  In 
contrast, Barzell and Whitmore described a TTSB technique in which the prostate 
was divided into eight regions using transverse, sagittal and coronal planes which 
were chosen arbitrarily (Barzell & Whitmore, 2003). Rather than a predetermined 
number of cores, 4 to 8 cores are obtained from each of the 8 prostate regions at 
5mm intervals depending on the size of the prostate to allow complete mapping of 
the whole gland. In another study, a technique aimed at ensuring maximum 
sampling and shortening of the procedure time was described (Bott et al, 2006). In 
this technique, the prostate was divided equally into right and left halves and 
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anterior, middle and posterior areas transversely in addition to inferior and 
superior longitudinal subdivisions using an indelible marker made on the ultrasound 
monitor. In order to sample the prostate, between 6 to 12 needles were inserted 
into each area divisions at the same time and biopsies obtained from each needle 
respectively. More recently, a standardised 36 core technique has been described 
(Pal et al, 2011). 
There are potential advantages of TTSB over transrectal saturation approach. 
Firstly, the use of fixation devise should allow precise sampling of all regions of the 
prostate, especially tumours located anteriorly within TZ, resulting to increased 
diagnostic accuracy. In a study of 210 high risk patients after at least one previous 
negative TRUS biopsies, TZ cancer was identified in 60 of the 78 patients [77%] who 
were diagnosed with PCa at TTSB (Pinkstaff et al, 2005). Furthermore, in 36 patients 
[46%], PCa was exclusively identified in the TZ. In another series, it was 
demonstrated that the cancer core rate [ratio of the number of cancer cores to the 
number of biopsy cores] was significantly higher in the anterior region compared to 
the posterior region in patients who underwent repeat biopsy using TTSB (Furuno 
et al, 2004).   
Secondly, prostate mapping with TTSB should result to an improved accuracy of 
staging in men with low volume disease who are considering active surveillance 
[AS]. In a recent study, 34% of 101 men who underwent TTSB re-biopsy as part of 
an AS programme for low risk disease diagnosed from extended TRUS biopsy were 
found to harbour higher risk disease (Ayres et al, 2012); furthermore, PCa was 
located predominantly in the anterior part of the gland in 44% of those men with 
worse disease on TTSB. More interestingly, PCa upgrading was identified in 38% of 
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the 34 men whose re-biopsy was done within 6 months of commencing AS. This 
suggests that these were most likely missed tumours from their initial TRUS 
biopsies rather than true progression of an indolent tumour in the time interval 
between biopsies.  
Lastly, mapping of the prostate with TTSB should provide detailed information to 
enable better assessment of patient’s suitability for focal therapeutic options.  In a 
study of 110 patients initially diagnosed with unilateral disease on TRUS biopsy who 
underwent a TTSB; bilateral disease was demonstrated in 55%; furthermore, 
Gleason score was increased in 23% of patients over the TRUS biopsy (Onik & 
Barzell, 2008). In another study to evaluate the usefulness of transperineal mapping 
biopsy [3-DPM] as a staging procedure in the appropriate selection of patients for 
treatment with focal cryoablation, 54% of the 80 patients who were re-biopsied 
were found to be unsuitable; furthermore, repeat TRUS biopsies had a false-
negative rate of 47% when compared with 3-DPM in assessing patient’s suitability 
for focal cryoablation (Barzell & Melamed, 2007). These findings are supported by 
reports from radical prostatectomy series which suggest that patients have far 
more advanced disease at their final pathological result than suggested from their 
seemingly low volume disease diagnosed at TRUS biopsies (Boccon-Gibod et al, 
2005; D'Amico, 2000; Wang et al, 1997). In two studies, significant disease was 
identified at radical prostatectomy in 57 to 70% of patients with insignificant PCa 
diagnosed at their preoperative TRUS biopsy (Boccon-Gibod et al, 2005; Wang et al, 
1997).   
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Prostate cancer is unique because of the discrepancy between reported frequencies 
of cancer occurrence at autopsy compared to lifetime clinically manifested cancer 
cases. Whilst autopsy series show a 30 to 38% rate of incidental cancer in men older 
than 50 years (Franks, 1954b), the prevalence of clinically significant cancer in a 
man’s life is 9.5% which is far less (Seidman et al, 1985). Consequently, there are 
concerns that increasing the number of cores as in TTSB would lead to a rise in 
detection of clinically insignificant cancer. According to Ploussard et al (Ploussard et 
al, 2011), insignificant cancers are PCa diagnosed in the absence of cancer related 
symptoms that would not have caused disease-specific morbidity or mortality 
during the patient’s life if left untreated. The first concept of insignificant cancer 
was proposed by Stamey et al (Stamey et al, 1993). The authors examined 139 
consecutive unselected cystoprostatectomies from patients with bladder cancer 
and identified PCa in 55 (40%). By applying previously determined 8% prevalence of 
prostate cancer within a man’s life to isolate clinically significant disease from the 
139 cystoprostatectomies; they concluded that tumours greater than 0.5cm3 which 
represented 8% of the total cohort is clinically significant cancer.  
By using Stamey’s classification of insignificant tumours and combining 
preoperative pathological and clinical criteria along with PSAD, Epstein et al 
(Epstein, 1994) demonstrated that fewer than  3 positive cores, no core with more 
than 50% involvement, no Gleason pattern 4 or 5 and PSAD less than 0.15 identified 
most significant and potential insignificant PCa. In another study by the same group 
to predict insignificant cancer rate at TTSB; an average of 44 cores were obtained 
on 103 radical prostatectomy specimens whose preoperative TRUS biopsies had 
suggested insignificant cancer. Their study showed that 29% of tumours were 
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misclassified as insignificant by conventional biopsy schemes; but when TTSB was 
used as the predictive tool, the false positive rate of insignificant cancer diagnosis 
was only 8 to 11.5% with specificity of 95.8 to 97.1% in the two TTSB schemes 
tested (Epstein et al, 2005).  In fact, the suggestion in literature is that increasing 
the number of cores at needle biopsy identifies more significant PCa at an earlier 
stage when it is potentially curable and may make the diagnosis of insignificant 
biopsy more accurate (Chan et al, 2001; Miyake et al, 2004).  
 
However, by far the greatest concern regarding the use of TTSB is the high rate of 
morbidity, particularly acute urinary retention [AUR] ranging from 11 to 39.4% 
reported in literature (Merrick et al, 2007; Merrick et al, 2008; Pinkstaff et al, 2005).  
In one study that evaluated the morbidity of TTSB, 39.4%, 7.1% and 1.6% of the 120 
patients who underwent TTSB for persistent clinical suspicion of PCa after a mean 
of 2 previous negative conventional TRUS biopsies were catheter dependent on the 
day of the procedure and at 3 and 6 days afterwards respectively (Merrick et al, 
2008). The overall catheter dependency rate in this study was 1 day even though 
that in virtually all patients, their international prostate symptom scores [IPSS] 
returned back to baseline within 30 days. The authors postulated that the AUR may 
have been instigated by TTSB. In a recently published large TTSB series including 
485 men, 27% developed AUR after a mean of 56 cores (Bittner et al, 2013).  
 
To prevent AUR, investigators have tried various manoeuvres including the use of 
tamsulosin - an α-adrenergic blocker known to cause relaxation of smooth muscles 
of the prostate and bladder neck resulting in an improvement in urinary symptoms 
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(Milicevic et al, 2012). The utility of tamsulosin administered prior to prostate 
biopsy in order to minimise biopsy induced urinary symptoms is not clear. In a 
randomised controlled trial of 66 patients to study voiding impairment after 
prostate biopsy, Bozlu and colleagues (Bozlu et al, 2003) treated 33 patients with 
tamsulosin commenced the day prior to a 12 core biopsy procedure for 30 days. 
They reported a significantly lower rate of voiding difficulty in the tamsulosin group 
compared to the control group (9 vs. 42%) with only one patient developing AUR in 
the tamsulosin group compared to three for the control group. Consequently, 
investigators have initiated tamsulosin from between 2 hours to 2 days prior to 
TTSB and continued this postoperatively for up to 2 weeks in some series (Bittner et 
al, 2013; Bott et al, 2006; Merrick et al, 2007). Nonetheless, despite prophylactic 
tamsulosin, 27 – 38% of patients developed AUR in two studies (Bittner et al, 2013; 
Merrick et al, 2007). 
Others have incorporated the use of prophylactic urethral catheterisation which 
was left insitu for several days in their TTSB technique (Ayres et al, 2012; Bott et al, 
2006; Demura et al, 2005; Furuno et al, 2004; Igel et al, 2001; Onik & Barzell, 2008; 
Pal et al, 2011; Pinkstaff et al, 2005). However, despite the use of prophylactic 
catheterisation, 9 of 110 patients who underwent mapping biopsies in Onik and 
Barzell series developed AUR and more noteworthy is that all AUR incidence 
occurred in 9 of the 58 (15%) patients who had bilateral mapping TTSB as in our 
study (Onik & Barzell, 2008). Thus when patients were not routinely catheterised, 
the rates of retention in vast majority of the studies were much higher as 
summarised in table 1-2 overleaf. 
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Table 1-2: Key TTSB publications indicating the incidence of prostate cancer (PCa) 
diagnosis and reported acute urinary retention (AUR) rates. 
‡ Denotes studies where prophylactic urethral catheter was left insitu as part of 
TTSB techniques for several days. X: Not reported 
 
Author 
 
Sample Size  
(N) 
Mean 
Age 
(yrs) 
 
Number 
of Cores 
PCa (%) AUR (%) 
Igel et al 2001 88 X 17 43 2‡ 
Buskirk et al 2004 157 69 22 X 11 
Furuno et al 2004 113 65 19 43 1‡ 
Demura et al 2004 371 67 20 36 2‡ 
Pinkstaff et al 2004 210 66 17 37 11 
Satoh et al 2005 128 67 22 23 2‡ 
Bott et al 2006 60 64 24 38 3‡ 
Merrick et al 2007 102 65 51 42 38 
Merrick et al 2008 129 65 54 46.5 39 
Bittner et al 2008 217 64 24 - 72 45.9 X 
Pal et al 2011 40 63 36 68 2.5‡ 
Mabjeesh et al 2012 92 64 30 26 X 
Gershman et al 2012 34 66 25 50 X 
Bittner et al 2013 485 65 56 46.6 27 
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1.13 Processing of Biopsy Specimen 
 
The quality of prostate biopsy specimen and its processing can influence the 
outcome of the histopathological analysis. It is recommended that biopsies taken 
from different regions of the prostate be sent to the pathology laboratory in 
separate pots with full clinical information (Heidenreich et al, 2014). In the 
laboratory, the cores are transferred into cassettes and prepared by fixation, 
dehydration and paraffin impregnation.  
The optimum embedding technique including number of cores embedded in one 
cassette remains subject of debate. It is believed that embedding multiple cores in 
a single block would result in less tissue being analysed because of the difficulty 
with alignment of all cores in one plane to allow optimal tissue representation. In a 
retrospective study, Gupta and colleagues (Gupta et al, 2004) observed that 
individual submission and processing of biopsy specimens significantly reduced the 
rates of equivocal diagnosis. The UK Prostate Cancer Risk Management Programme 
recommends that one core is embedded per cassette (PCRMP Guide, 2006). In one 
series using computer simulation of biopsy core, it was demonstrated that 
sectioning a biopsy core at a 0-degree angle provided optimal sectioning with 
maximum surface area for analysis and this was more likely when each core is 
embedded individually (Kao et al, 2002).  
Perhaps, the main drawback to widespread use of single embedding technique is 
that it is time consuming and costly especially with increasing number of cores with 
saturation biopsies. In order to allow embedding of multiple biopsy cores in one 
cassette, optimized techniques including flattening of cores between two nylon 
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meshes or enveloping them in a piece of paper is recommended. Furthermore, the 
cores should be pushed down with a tamper to keep the cores in the same plane 
during embedding in paraffin and allow sectioning at multiple levels through the 
entire length of the core (PCRMP Guide, 2006). It is recommended that blocks 
should be cut at three different levels each three to five sections (10 – 20 µm) apart 
in order to optimize detection of small lesions (Van der Kwast et al, 2013). 
 
1.14 Magnetic Resonance Imaging (MRI) and Prostate Biopsy 
 
The use of MRI as a non invasive modality for defining anatomical and pathological 
lesions in the prostate has evolved over the last 30 years. Conventional MRI (cMRI) 
reveals the morphological information of the prostate using a combination of T1 
(T1W-MRI) and T2 (T2W-MRI) weighted images with or without endorectal coil 
(Aigner et al, 2007). Initially used for staging of men diagnosed with PCa prior to 
radical therapy (Steyn & Smith, 1982), recent technological advancement has 
expanded its role to included screening prior to biopsy, risk stratification in patients 
with persistent clinical suspicion of PCa despite negative TRUSB, monitoring of 
patients on active surveillance and treatment follow-up (Türkbey et al, 2012).  
Furthermore, pre-biopsy MRI offer additional advantage with reduction of post-
biopsy artefact caused by haemorrhage which manifests as low signal on T2W-MRI 
similar to cancer and can lead to overestimation of cancer burden in 20% of cases 
(Ahmed et al, 2009). cMRI has a sensitivity and specificity of 70% and 76% 
respectively after previous negative TRUSB when additional targeted biopsies of 
suspicious areas on MRI are added to a sextant biopsy protocol in men with PSA 
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level ranging from 4 to 20ng/ml (Vilanova et al, 2001). Conventional MRI is limited 
in its diagnostic ability because not all low signal intensity in the peripheral zone is 
due to PCa. Benign conditions such as chronic prostatitis, hormonal treatment 
effects, atrophy and post-biopsy haemorrhagic artefact resulting in low signal on 
T2WI are difficult to distinguish from cancer (Ahmed et al, 2009). Furthermore, 
cancer in the central and transition zones are more difficult to discern on T2WI due 
to BPH (Hoeks et al, 2011). 
Recently, functional MRI techniques including diffusion weighted imaging (DWI), 
dynamic contrast enhanced MRI (DCE-MRI) and MR spectroscopy imaging (MRSI) 
have been introduced. Using differences in apparent diffusion coefficients, 
vascularity values and metabolic ratios between prostate tumour and non tumour 
tissues, these functional MRI sequences show improved tumour differentiation 
(Yoshizako et al, 2008). When combined with cMRI to provide both functional and 
anatomic information, it is called Multiparametric MRI (mp-MRI).  
Compared to cMRI, functional techniques may improve accuracy for PCa diagnosis. 
A review by Kirkham et al (Kirkham et al, 2006) to assess the ability of MRI to 
localise PCa within the prostate using whole mount histology as gold standard 
found that cancer detection rates are highly variable. The sensitivity of conventional 
T2W-MRI ranged from 37 to 96% whilst DCE-MRI had a narrower sensitivity range 
of 57 to 89%. When compared with whole mount prostatectomy, DCE-MRI has a 
sensitivity, specificity and negative predictive value of 86%, 94% and 95% 
respectively for detection of tumours greater that 0.5cc (Puech et al, 2009; Villers et 
al, 2006). Literature suggests that when both sequences are combined, the validity 
of MRI for cancer detection is likely to be improved (Amsellem-Ouazana et al, 2005; 
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Tanimoto et al, 2007).  Amsellem-Ouazana et al (Amsellem-Ouazana et al, 2005) 
combined MRSI and cMRI prior to TRUSB after 2 negative biopsies and reported a 
specificity of 96.3% and sensitivity of 73.3% when supplementary cores from 
suspicious areas on MRI were added to standard 10 core scheme in 42 men. 
Similarly, Tanimoto et al (Tanimoto et al, 2007) found a statistically significant 
difference in sensitivity, specificity and accuracy in favour of combined MRI 
sequence compared with either modality alone.  
In patients with persistent clinical suspicion of PCa, MRI may guide the area of 
biopsy and reduce the false negative rates of repeat conventional TRUSB. However, 
the critical question is whether the use of MRI would increase detection of clinically 
significant PCa to justify the operating time and high running cost of this 
technology. To achieve this, the use of MRI should allow targeted biopsy of 
suspicious areas to decrease number of cores and improve detection rate. Using 
MRI guided TRUS biopsies in 68 men with PSA greater than 4ng/ml and at least 2 
previous negative TRUSB, Hambrock et al (Hambrock et al, 2010) reported that a 
median of 4 MR image guided biopsy detected significantly more cancers compared 
to a matched standard biopsy protocol. A recent systematic review reported that 
MRI-targeted biopsy using 4 cores has equivalent cancer detection rates compared 
with standard 12 cores TRUSB (Moore et al, 2013). Furthermore, targeted biopsy 
resulted in a third fewer men being biopsied and avoided diagnosis of clinically 
insignificant cancer in 10% of patients. 
 In the current PSA era, with more men increasingly requiring extended repeat 
prostate biopsy especially with saturation scheme due to persistent clinical 
suspicion of PCa, it is surprising that despite the literature suggesting improved 
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diagnostic yield from pre-biopsy MRI information in transrectal biopsy series in this 
cohort of men, few studies have correlated pre-biopsy MRI and TTSB outcomes. 
Hadaschik et al (Hadaschik et al, 2011) developed software interfaces to 
superimpose suspicious areas of pre-biopsy MRI over peri-intervention ultrasound 
image at transperineal biopsy. Of the 106 patients, PCa was identified in 59.4% and 
highly suspicious image on MRI correlated with cancer diagnosis in 95.8%. 
Furthermore, lesion targeted cores had a significantly higher positivity rate 
compared to non-targeted cores. In another study using similar software interface 
(Miyagawa et al, 2010) , cancer was identified in 61% of 85 men undergoing 
combination of transrectal and transperineal biopsies after one negative sextant 
TRUSB. Targeted biopsy detected PCa uniquely in 35% of cancer positive cases with 
higher number of positive cores compared to non targeted scheme (32% vs 9%). In 
a recent study, Kasivisvanathan and colleagues (Kasivisvanathan et al, 2013) 
described a cognitive registration technique to determine clinically significant 
cancer diagnosis rate. Of the 182 men with suspicious lesions on mp-MRI who 
underwent transperineal MRI-targeted biopsies, no significant difference was 
observed with respect to clinically significant cancer (maximum core length 4 or 
greater and Gleason score 3+4 or greater) diagnosis (57% vs. 62%). However, 
targeted biopsy diagnosed fewer clinically insignificant cancers compared to non 
targeted biopsy and this was statistically significant (9.3% vs. 17%).  
Although emerging studies described thus far suggest a role for MRI-targeted lesion 
biopsy in the cohort of men studied in this field of science, there are inherent 
limitations to its use as a screening tool to determine whether or not to offer 
prostate biopsy in clinical practice. In one study, it was demonstrated that 52 of 92 
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patients on active surveillance had inapparent tumour on MRI. On multivariate 
analysis, there was no association between imaging findings and outcome 
prompting the authors to conclude that tumour apparency or inapparency in PCa 
patients on active surveillance is of no prognostic value (Cabrera et al, 2008). 
 
Herein, we compare pre-TTSB MRI and subsequent TTSB and assesses whether pre-
biopsy MRI would decrease the need for TTSB or allow a more targeted regime of 
repeat biopsy. 
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1.15 Hypothesis 
 
The composite studies comprising this thesis are based on a novel modified TTSB 
technique which avoids sampling of the periurethral area at the base of the 
prostate rarely involved with localised PCa based  on  the following hypothesis:-  
1. That urethral trauma from extensive sampling of the basal periurethral area  
is a major instigating factor for AUR in TTSB. 
2. That modifying TTSB technique so as to avoid sampling of this periurethral  
area at the base would reduce risk of AUR compared to the literature, 
without influencing cancer yield.  
 
1.16 Objectives 
 
1. To determine the detection rate of PCa using a modified TTSB.  
2. To determine the location, distribution and characteristics of cancer  
detected in men undergoing modified TTSB. 
3. To determine short term complications of modified TTSB and whether the  
risk of AUR would be reduced compared to rates reported in the literature. 
4. To evaluate the value of pre-biopsy PSA and its derivatives  for their ability  
to predict pathological outcomes of modified TTSB. 
5. To evaluate role of pre-biopsy MRI in predicting outcome of modified 
TTSB  
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Chapter 2 Patients and Methods 
 
2.1   Patients 
 
303 patients were recruited for this study from July 2007 to January 2013. Prior to 
the introduction of modified TTSB technique to the Wirral University Hospital trust, 
there were discussions between urologists, management and purchasers. As new 
technology committee had not been developed at the time, a thorough audit of this 
technique was mandated. Our initial information leaflet included details of the 
procedure as discussed in section 2.2.2 of this report, but with results from 
published reports of TTSB. Patients were given an information leaflet in advance 
and full informed consent obtained prior to procedure in the day unit.  Regular 
audit was undertaken and presented to the audit department on the Wirral in 
fulfilment of the Trust’s clinical governance policy.  
 
All patients underwent modified TTSB which was performed at the Wirral University 
Teaching Hospital, Merseyside. Patients were largely recruited from the Wirral but 
a significant proportion was referred by urologists from hospitals within and 
outside of the Mersey region (table 2-1 overleaf).  
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Table 2-1: Sources of patients referred for TTSB  
Hospital Number of Patients (%) 
Wirral University Hospital 132 (43.5) 
Warrington Hospital 71 (23.4) 
Countess of Chester Hospital 32 (10.6) 
Southport and Ormskirk Hospital 19 (6.3) 
University Hospital Aintree 15 (5) 
Royal Liverpool University Hospital 21 (6.9) 
Whiston Hospital 6 (2) 
Nobles Hospital 2 (0.7) 
Leighton Hospital  2 (0.7) 
Bangor Hospital Gwynedd 1 (0.3) 
Wrexham Maelor Hospital 1 (0.3) 
Coventry University Hospital 1 (0.3) 
 
 
 
Patients were referred for TTSB when there was a persistent clinical suspicion of 
PCa despite at least one negative conventional TRUSB; including PSA progression 
whilst on surveillance following negative TRUSB, raised PSA with family history of 
PCa, extensive high grade prostatic intraepithelial neoplasia (HGPIN) and atypical 
small acinar proliferation (ASAP, table 2-2 overleaf).  
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Table 2-2: Clinical Indications for repeat prostate biopsy in men referred for 
modified TTSB 
Indication  Number of Patients (%) 
Rising PSA  242 (79.9) 
Family History of Prostate Cancer 20 (6.6) 
Extensive HGPIN 23 (7.6) 
ASAP 18 (5.9) 
 
Within the study population are 66 men whose initial prostate volume was greater 
than 60cc.  During the early phase of the study it became apparent that technical 
difficulty is encountered as a result of pubic arch interference, which precludes 
adequate sampling of the peripheral zone of the gland, in those with very large 
prostates. Therefore, a protocol was adopted allowing for the use of dutasteride 
0.5mg daily for 3 to 6 months in order to downsize the prostate so as to minimise 
pubic arch interference in such patients. Subsequently, the prostate was scanned 
with TRUS for confirmation of size reduction to less than or equal to 60cc prior to 
TTSB. Dutasteride is a potent inhibitor of 5α-reductase types 1 and 2 isoenzymes 
which convert testosterone to dihydrotestosterone (DHT) leading to the reduction 
in androgenic drive of BPH development and hence a reduction in prostate volume 
(Andriole et al, 2004). Both 5α-reductase types 1 and 2 are normally expressed in 
prostate tissue but the type 2 is the predominant isoenzyme (Anderson et al, 2001). 
The level of expression of both 5α-reductase isoenzymes are significantly higher in 
BPH compared to  normal prostate (Iehle et al, 1999) and dutasteride 0.5mg daily 
for 3 months in men awaiting TURP for BPH reduced intraprostatic DHT by 
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approximately 94% (Wurzel et al, 2007). The use of 5α-reductase inhibitors 
consistently decreased prostate volume by 24% to 25.7% when compared with 
placebo in randomised trials (Roehrborn et al, 2002; Tsukamoto et al, 2009).  
As potent antiandrogens, 5α-reductase inhibitors have been explored as potential 
chemopreventive agents for PCa. The prostate cancer prevention trial (PCPT) 
randomised 18,882 aged 55 years or older to 5mg daily of finasteride or placebo. 
They reported a 25% risk reduction of PCa over a 7 year period but with 6.4% 
increased risk of high grade PCa (Thompson et al, 2003). A similar study with 
identical design found that dutasteride 0.5mg daily resulted in a relative risk 
reduction of 22.8% but with 12 more high grade tumours diagnosed (Andriole et al, 
2010). Studies examining the effects of 5α-reductase inhibitor therapy on prostate 
pathology have reported conflicting results (Bostwick et al, 2004; Yang et al, 1999). 
Bostwick et al reported that finasteride therapy results in significantly higher 
Gleason grade which can result in grading bias. Dutasteride induces an involution 
and atrophy of epithelium relative to the stroma in benign prostatic tissue 
(Iczkowski et al, 2005 ). On the contrary, Yang et al (Yang et al, 1999) did not find 
any significant histologic differences between benign and cancerous prostates in 
finasteride treated men compared to placebo. Others have questioned the validity 
of the increased high grade tumour reported in the PCPT trial in the 5α-reductase 
inhibitor treated arm suggesting that this may be a result of an increased biopsy 
sensitivity with finasteride therapy (Redman et al, 2008). Nevertheless, the 
pathologist should be made aware when a patient is on 5α-reductase inhibitor 
therapy in view of above controversies.  
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2.2   Modified TTSB procedure 
2.2.1 Equipment  
 
All modified TTSB procedures were carried out using biplanar transrectal ultrasound 
transducer (BK Medical, Herlev, Denmark) mounted on a brachytherapy stepping 
unit (DK Technologies®, Barum, Germany) as shown in figure 2-1 below. 
 
 
 
Figure 2-1: Flex focus 800 ultrasound machine with biplanar implant probe 
mounted on a brachytherapy stepping unit  
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The image of the prostate is obtained with the flex focus 800 ultrasound scanner 
(BK Medical, Denmark). A Magnum spring loaded biopsy gun (BARD, Covington, 
USA) was used to obtain the transperineal prostate biopsy samples. 
 
2.2.2 Modified TTSB Technique 
 
Modified TTSB was performed under general anaesthesia and as a day case 
procedure. Patients were admitted to a day ward one hour preoperatively and 
given a phosphate enema, which decreases the amount of faeces in the rectum, 
thus enhancing the acoustic image of prostate on TRUS (Trabulsi et al, 2012). Each 
received a single dose of intravenous gentamicin 0.24g on induction of anaesthesia, 
plus metronidazole 1g suppository at the end of the procedure according to local 
hospital protocol. No patient was catheterised prophylactically. 
Once anaesthetised and placed in extended lithotomy position, the scrotum is 
secured anteriorly with adhesive op-tape (Barrier®, Göteborg, Sweden); the perineal 
skin is shaved and prepared.  An endocavity balloon (CIVCO®, Iowa, USA) is placed 
over the implant probe. Water is injected and withdrawn from the balloon until all 
bubbles are removed, so as to avoid acoustic interference. The side viewing, 
biplanar implant probe attached to a brachytherapy stepping unit is then inserted 
into the rectum. Water is injected into the endocavity balloon so as to improve 
contact between the probe and the anterior rectal wall. An image of the prostate is 
obtained in the broadest transverse section and centred on the D line of the 
template grid. The stepper is set for 5mm slices. Prostate volume was measured 
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and calculated as an ellipsoid using the formula, height x width x length x 0.5236 as 
previously described (Terris, 1991).  
A Magnum biopsy gun set on 22mm pass is used to take biopsy cores in rows 
systematically from right to left using an 18G needle. The interval between biopsy 
cores on a row is 10mm, but with 5mm between rows (figure 2-2).  
 
Figure 2-2: Transverse view of prostate superimposed on the template grid showing 
sampled sites 
 
 
The number of biopsies within a row is dictated by the width of the prostate, but 
we always ensured that the most lateral cores are near the capsule to cover the 
peripheral zone.   
After inserting the biopsy needle through the aperture in the template and into the 
prostate, the image is switched to the longitudinal view. The needle is then 
withdrawn so that a 22mm core is taken from the apex inwards. Each biopsy site is 
recorded on a copy of the image of broadest transverse section and each biopsy 
individually potted in formalin. 
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Previous studies have estimated the average length of the prostate (Kälkner et al, 
2006; Terris, 1991). Kälkner et al compared prostate lengths assessed on 
computerised tomography (CT), step-sectioned TRUS and conventional TRUS on 31 
men diagnosed with localised PCa prior to combined external beam radiotherapy 
and high dose rate brachytherapy (Kälkner et al, 2006). The mean lengths of the 
prostate were 4.5 cm on CT compared to 3.6 cm for both step section and 
conventional TRUS respectively. In another study, Terris and Stamey (Terris, 1991) 
reported average sagittal cephalocaudal diameter of 3.4cm on TRUS volume 
estimation in 150 men prior to radical prostatectomy. Therefore, a 22mm 
peripheral biopsy cores taken anteriorly, posteriorly and laterally where prostate 
length is shortest should sample the full length of the prostate. However, as the 
cephalocaudal length of the gland increases when moving more centrally, the 
22mm length biopsies fall progressively short of the base, sparing this area (figure 
2-3). 
 
 
Figure 2-3: Schematic diagram showing sparing of the periurethral basal area with 
modified TTSB  
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Postoperatively, bladder emptying was not performed. Patients are discharged 
once they have successfully voided urine, with a 5 day course of ciprofloxacin 0.5g 
twice daily.  
All specimens were reported by a single pathologist. Tumour location at TTSB was 
marked as anterior, middle, posterior or either combination by dividing the 
prostate equally into anterior, middle and posterior regions on transverse image 
similar to the description by Bott et al (Bott et al, 2006) but without further division 
into right and left halves. This results in 7 possible tumour locations namely: - 
anterior, anterior + middle, middle, middle + posterior, posterior, anterior + 
posterior and anterior + middle + posterior areas (figure 2-4). 
 
Figure 2-4: Subdivisions of the prostate into anterior, middle and posterior regions 
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2.3 Processing of Biopsy Specimen 
 
Following TTSB, each individually potted specimen is sent to the histopathology 
laboratory where they are accessioned (ordered) with date, time and a unique lab 
number is assigned. The specimens are then manually placed and processed in a 
workstation prior to embedding. The total routine overnight tissue processing time 
is 15 hours. Three cores are embedded in a cassette (figure 2-5) and cut in three 
levels using a microtome as recommended by the pathology committee of the 
European Randomised Study of Screening for Prostate Cancer (ERSPC) guidelines on 
processing and reporting of prostate biopsies (Van der Kwast et al, 2013). The slides 
batch are stained with Haematoxylin and Eosin stain using an automated staining 
machine followed by automated cover-slipping. 
 
Figure 2-5: Three biopsy cores embedded in single cassette 
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2.4 Morbidity of Modified TTSB 
 
To further evaluate morbidity of modified TTSB, a questionnaire was designed and 
administered to all patients undergoing modified TTSB on the day of their 
procedure once they were admitted to the day ward. The survey questionnaire 
consisted of multiple questions in 3 domains seeking to explore patient’s 
experience of bleeding, pain and analgesic requirements after TTSB which were 
assessed from 1hour post biopsy and on days 1, 3 and 7 (see accompanying 
material). More specifically, the questions asked about severity of bleed using 
colour such as fresh, pale or dark and source or location including rectal and urine 
(haematuria) or semen (haematospermia, which was assessed from day 1 post 
biopsy). Pain was assessed and scored using visual analogue scale (range 0-10, with 
an increasing score indicating worsening pain). Furthermore, the location of pain 
was explored including perineal, rectal or pain elsewhere. Finally, the need for 
analgesic was documented and patients were required to document what analgesic 
agent they required for pain relief. 
Once completed, patients returned the questionnaire by post using a prepaid 
envelope. All questionnaires were independently collated by a urology nurse 
practitioner and blinded to patient’s name or hospital identification detail.  
 
2.5  Biomarkers of prostate cancer prior to modified TTSB 
 
Prior to modified TTSB, a venous blood sample was obtained for serum PSA and 
%fPSA determination. The obtained blood specimen was immediately sent to the 
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biochemistry laboratory and refrigerated on receipt at 4⁰C. The total PSA and %fPSA 
were subsequently analysed from the refrigerated serum using Roche Elecsys 
free PSA assay (Roche Diagnostics Corporation, Basel, Switzerland). PSA Density 
(PSAD) was calculated by dividing the preoperative PSA (ng/mL) by the calculated 
prostate volume (mL) at TTSB as previously described by Benson et al (Benson et al, 
1992b) and discussed in detail in chapter 1, subsection 1.6.3 of this report. 
The pre-biopsy PSA and its derivatives (PSAD and %fPSA) were then assessed for 
their ability to predict prostate cancer diagnosis and biopsy cancer volume including 
total number of cores positive with cancer (NPC), maximum tumour length (MTL), 
aggregate tumour length from all positive cores (ATLPC), maximum percent core 
involved (MPC) and percentage of positive cores (PPC). These prostate biopsy 
histological parameters have been shown to correlate with pathological tumour 
volume and recurrence after radical prostatectomy by several studies (Nelson et al, 
2002; Ochiai et al, 2005; San Francisco et al, 2004).  
In a study of 207 men who underwent radical prostatectomy for cancer detected 
after extended biopsy, the total number of positive cores correlated with total 
tumour volume (p<0.001) and the incidence of insignificant cancer was significantly 
higher amongst those with only 1 positive core (42.5%) compared to (16.4%) with 2 
positive cores and (5.5%) for 3 or more positive cores (Ochiai et al, 2005).  Nelson et 
al (Nelson et al, 2002) determined predictors of PSA-free survival from 588 radical 
prostatectomy specimens after 4 years follow-up. Of all the preoperative variables, 
greatest percentage of biopsy core involved with cancer, PSA and Gleason score 
significantly predicted PSA-free survival on multivariate analysis. Another study 
demonstrated that percentage of positive cores and biopsy Gleason score were the 
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only preoperative predictors of recurrence after radical prostatectomy (San 
Francisco et al, 2004).  
To describe significant cancer at TTSB, the full saturation biopsy classification 
scheme described by Epstein (Epstein et al, 2005) was utilised. After performing a 
44 core saturation biopsy on 103 radical prostatectomy specimens which were 
predicted to have insignificant PCa at their initial needle biopsy, Epstein and 
colleagues showed that using a classification scheme based on Gleason score ≥7, 
NPC ≥4, MTL ≥4.5mm and ATLPC ≥5.5mm predicted significant cancer with a 
sensitivity of 71.9%, specificity 95.8% and false negative rate of only 11.5% (Epstein 
et al, 2005). Consequently, using this classification, this study’s cohort were 
stratified into six groupings as follows:- NPC less than 4 and 4 or greater, MTL less 
than 4.5mm and 4.5mm or greater, ATLPC less than 5.5mm and 5.5mm or greater 
and maximum Gleason score (MGS) less than 7 and 7 or greater. Additionally, we 
also compared the group with MPC less than 50% and 50% or greater and PPC less 
than 15% and 15% or greater according to the median value. 
 
2.6  MRI prior to Modified TTSB  
 
Prior to TTSB, patients were imaged using a 1.5 Tesla (1.5 T Achieva Philips Medical 
Systems, Best, Netherlands) MRI scanner with a Synergy body coil.  
Firstly, a multiplanar reference images were acquired. This was followed by 
acquisition of T2 weighted images (T2WI) in the axial and coronal planes through 
the prostate, time to repetition (TR) 3300 ms, time to echo (TE) 125 ms, using a 
field of view (FOV) of 220 mm; image matrix 256 X 256; section thickness 3 mm 
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with 0.3 mm interval covering the prostate gland and seminal vesicles with 24 
sections and image acquisition time of 3 min 30 s. 
After acquiring the T2WI, diffusion image was then performed. Diffusion-weighted 
images (DWI-MRI) were obtained in a transaxial plane using a single-shot echo-
planar sequence; TReff/TEeff, 3,580/62; parallel imaging factor, 2; b factors, 0 and 
600 s/mm2; 80 x 71 matrix; 3-mm section thickness with a 1-mm intersection gap; 
18 sections obtained in 2 minutes 33 seconds. Spectral inversion recovery fat 
suppression was used to eliminate chemical shift artefacts. The isotropic motion-
probing gradient pulses were placed along three orthogonal oblique directions to 
achieve a shorter TE and an improved signal-to-noise ratio (Gradient Overplus, 
Philips Healthcare). The parameters derived from DWI include the b value (the 
amount of diffusion weighting) and Apparent Diffusion Coefficient (ADC, movement 
of water molecules within the interpulse time representing capillary and diffusion 
characteristics). As prostate cancer damages normal glandular structure resulting in 
higher cellular density, the ADC is restricted compared to healthy prostate tissue 
(Hoeks et al, 2011). 
Dynamic contrast-enhanced MR imaging (DCE-MRI) was performed with application 
of a fast three-dimensional T1-weighted fat saturated gradient-echo sequence 
(THRIVE) with a section thickness 7 mm with 3.5 mm overlap covering the prostate 
gland and seminal vesicles with 20 sections using a field of view (FOV) of 180 mm. 
Three-dimensional data sets were acquired once before contrast agent 
administration and then after contrast agent administration at the following time 
intervals; 25 seconds, 50 seconds, 1 minute 15 seconds, 1 minute 35 seconds, 2 
minutes, 2 minutes 45 seconds, 3 minutes 45 seconds, 4 minutes 45 seconds, 5 
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minutes 45 seconds, 6 minutes 45 seconds and 7 minutes 45 seconds. The MR 
contrast agent, Gadobutrol (Gadovist; Bayer Schering Pharma, Berlin, Germany), 
was injected as a bolus at 1mL per kilogram of body weight. For this purpose, a dual 
headed automated injection system (Spectris Solaris EP; Medrad, Pittsburgh, Pa) 
was used at a flow rate of 2.5mL/sec. Immediately afterwards, a 100mL saline flush 
was administered at a rate of 2.5 mL/sec.  
On DCE-MRI, prostate cancer would classically show an earlier or faster 
enhancement with mainly earlier washout of contrast agent compared to normal 
prostate tissue as shown in figure 2-5. 
 
Figure 2-6: DCE-MRI showing rapid increased enhancement of the right peripheral 
zone tumour compared to normal left peripheral zone with range of interest graph. 
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2.6.1 Prostate Anatomical Division 
In the axial plane, the largest sections of the prostate and central gland were 
selected and the maximum anterior-posterior dimension (APD) and maximum 
transverse dimension (TD) was taken. In the coronal plane the maximum superior-
inferior dimension (SID) was taken. The elliptical method was used to calculate the 
prostate and central gland volumes using the formula APD X TD X SID X π/6 as 
previously described (Al-Rimawi et al, 1994). 
The prostate was subdivided into 4 anatomical quadrants as shown in figure 2-6 
(right anterior (RA), left anterior (LA), right and left posterior (RP and LP) in the axial 
plane at the point of largest anterior-posterior dimension (APD).   
 
 
Figure 2-7: The four anatomical quadrants of the prostate 
 
Abnormality on MRI was reported in relation to the quadrants by an expert Uro-
radiologist who was blinded to the result of TTSB. Any area suspicious of tumour 
was localised to one or more quadrants and staged using the extent of primary 
tumour (T), regional lymph nodes (N) and presence of distant metastasis (M; TNM) 
classification (Sobin  et al, 2009) as shown on table 2.3. 
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Table 2-3: The new Union for International Cancer Control (UICC) recommended 
TNM Classification of Prostate Cancer (Sobin  et al, 2009). 
Primary Tumour (T) 
TX     Primary tumour cannot be assessed 
T0     No evidence of primary tumour 
T1     Clinically unapparent tumour not palpable or visible by imaging 
T1a   Tumour incidental histologic finding in 5% or less of tissue resected 
T1b   Tumour incidental histologic finding in more than 5% of tissue resected 
T1c   Tumour identified by needle biopsy (e.g. because of elevated PSA) 
T2     Tumour confined within the prostate 
T2a   Tumour involves one half of one lobe or less 
T2b   Tumour involves more than half of one lobe, but not both lobes 
T2c   Tumour involves both lobes 
T3     Tumour extends through the prostatic capsule 
T3a   Extracapsular extension (unilateral or bilateral) including microscopic bladder neck  
          involvement 
T3b   Tumour invades seminal vesicle(s) 
T4    Tumour is fixed or invades adjacent structures other than seminal vesicles: external   
         sphincter, rectum, levator muscles, and/or pelvic wall 
Regional Lymph Nodes (N) 
NX     Regional lymph nodes cannot be assessed 
N0     No regional lymph node metastasis 
N1     Regional lymph node metastasis 
Distant Metastasis (M) 
MX     Distant metastasis cannot be assessed 
M0     No distant metastasis 
M1     Distant metastasis 
M1a   Non-regional lymph node(s) 
M1b   Bone(s) 
M1c   Other site(s) 
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2.7 Grading of Prostate Cancer 
 
Donald Gleason described the grading system for PCa as a sum of the two most 
common architectural pattern of tumour growth identified, ranging from 1 to 5. In 
their report, Gleason and Melinger demonstrated that combination of the 
histological grade and clinical stage was a far better prognostic marker than clinical 
staging alone (Gleason & Melinger, 1974; Mellinger et al, 1967). The Gleason score 
as its now called ranges from 2 to 10, with 2 being the least score and 10 
representing the most aggressive cancer.  
More recently, in recognition of changing trends in PCa due to increasing use of PSA 
screening, TRUSB with thinner cores; increased number of radical prostatectomies 
and widespread use of immunohistochemical staining, the International Society of 
Urological Pathology (ISUP) consensus conference recommended some 
modifications to the original Gleason grading (Epstein, 2010). The worst grade is 
now assigned because any amount of high-grade tumour sampled on needle biopsy 
most likely indicates a more significant amount of high-grade tumour within the 
prostate because of the correlation of grade and volume coupled with the problems 
inherent with needle biopsy (Epstein, 2005). Summary of the 2005 modified 
Gleason grading system for prostate cancer is outlined table 2-4 overleaf. 
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Table 2-4: Summary of the 2005 ISUP Modified Gleason System  
Pattern 1:   Circumscribed nodule of closely packed but separate, uniform,     
                   rounded to oval, medium-sized acini (larger glands than pattern 3) 
Pattern 2:   Like pattern 1, fairly circumscribed, yet at the edge of the tumour  
                   nodule there may be minimal infiltration Glands are more loosely  
                   arranged and not quite as uniform as Gleason pattern 1 
Pattern 3:   Discrete glandular units  
                   Typically smaller glands than seen in Gleason pattern 1 or 2 
                   Infiltrates in and amongst non-neoplastic prostate acini  
                   Marked variation in size and shape  
                   Smoothly circumscribed small cribriform nodules of tumour 
Pattern 4:   Fused microacinar glands  
                   Ill-defined glands with poorly formed glandular lumina 
                   Large cribriform glands with an irregular border 
                   Hypernephromatoid  
Pattern 5:  Essentially no glandular differentiation, composed of solid sheets,    
                  cords, or single cells     
                  Comedocarcinoma with central necrosis surrounded by papillary,  
                  cribriform, or solid masses 
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2.8 Statistical Methods 
 
Continuous numeric data in this thesis are presented with mean, median and range. 
Statistical analysis was performed in four parts:- 
1. Majority of the pre and post-biopsy data are continuous variables. In this 
part of the analysis, Shapiro-Wilk test was first performed to determine normality 
of the sample data. This revealed that data is not normally distributed (W = 0.629, P 
= 0.0001). Consequently, Mann-Whitney U test was used to compare the difference 
between continuous and categorical variables with dichotomous outcomes (for 
example cancer and no cancer, retention and no retention) and Wilcoxon signed-
rank test to compare two related samples for statistical difference. Furthermore, 
Bivariate Spearman’s correlation coefficient (ρ) was used to determine correlation 
between two continuous variables and Chi square to assess relationship between 
two categorical variables, but where sample size is less than 5, Fisher’s exact test 
was utilised instead. 
2. To evaluate morbidity of TTSB including bleeding, pain and analgesic 
requirement, the questionnaire data was entered into an electronic spreadsheet 
and analysed using generalised linear model (GLM) for repeated measures since 
these variables were measured multiple times over a 7 day period following biopsy.  
3. Clinical and TTSB variables predictive of prostate cancer diagnosis, Gleason 
score and cancer volume were determined by binary logistic regression analysis. 
Firstly, univariate analysis was applied to identify variables with a significance of p ≤ 
0.05. Variables predictive of prostate cancer diagnosis, Gleason score and cancer 
volume on univariate analysis were then included into multivariate analysis by 
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forward stepwise method. Prior to multivariate analysis, bivariate Spearman’s 
correlation was performed to determine whether related variables are suitable for 
inclusion into the same multivariate model. When two related variables are highly 
correlated, they are not included into the same model as previously described 
(Mabjeesh et al, 2012). ‘Goodness of fit’ for the different models was assessed 
using -2 log likelihood difference and Nagelkerke’s R2. Odds ratio and 95% 
confidence interval were derived from regression analysis using Wald’s method. A 
receiver operating characteristics (ROC) curve was determined by plotting 
sensitivity (true positive) against 1-specificity (false positive). The area under the 
ROC curve (AUC) was used to assess PSA, PSAD and %fPSA for their accuracy to 
predict for cancer diagnosis. From the coordinates points of the ROC curve, cut-offs 
that would detect at least 90% of cancers including their corresponding specificity 
(i.e. number of unnecessary biopsies that would be avoided by using the cut-offs) 
was derived as described by Catalona et al (Catalona et al, 1998).   
4. Cross-tabulation was used to examine the relationship between outcome of 
MRI and TTSB. Using crosstab, sensitivity, specificity, positive predicted and 
negative predictive values were calculated.  
 
All statistics were 2-tailed with significant difference assumed where p < 0.05. 
Analysis was performed using the IBM SPSS statistics version 20 (IBM Corporation, 
Armonk, New York).     
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Chapter 3 Results 
 
3.1   Patient characteristics 
 
The preoperative clinical characteristics of the 303 men who underwent modified 
TTSB is summarised in table 3-1.  
 
Table 3-1: Clinical parameters of men undergoing modified TTSB 
 
  
Mean 
 
Median 
 
Range 
Age (yrs) 63.2 64 43 – 85 
Baseline PSA (ng/mL) 9.7 8.0 1.0 – 57 
Pre-TTSB PSA (ng/mL) 12.3 10 2.0 – 114 
%fPSA 11.9 10 1.0 – 35 
PSAD (ng/mL/cm3) 0.29 0.21 0.01 – 2.99 
Prostate Volume (mL) 46.7 46 17 – 106 
Prostate Length (mm) 48.5 48 30 – 90 
 
 
On average, patients had undergone median of 2 (range 1 – 6) sets of negative 
conventional TRUSB prior to referral for TTSB. There was a statistical significant 
difference between patients’ median baseline PSA level at their initial presentation 
compared to their pre-TTSB PSA levels (Wilcoxon signed-rank test, P = 0.0001).  Of 
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the 217 men in whom detail of number of conventional biopsy cores taken prior to 
referral for TTSB was available, analysis revealed that they had undergone a mean 
of 19 (range 6 – 58) transrectal biopsy cores prior to undergoing modified TTSB.  
  
3.2    TTSB parameters 
Parameters of the study population at saturation biopsy are summarised in table 3-
2.  
 
Table 3-2: TTSB Parameters of the study population   
 
  
Mean  
 
 
Median  
 
Range   
Number of cores at TTSB 
 
28 29 16 – 43 
Number of rows 
 
7 7 3 – 9 
Core/volume (core/cm3) 
 
0.6 0.6 0.3 – 1.3 
Peripheral cores 
 
13.7 14 6 – 18 
Central cores 
 
14.4 14 6 – 25 
 
The mean total number of central cores obtained at TTSB is comparable to the 
number of peripheral cores (14.4 vs. 13.7 cores). However, the sampling density 
(number of cores obtained at TTSB per unit prostate volume) is significantly higher 
in smaller prostates (Spearman coefficient ρ = -0.84, P = 0.0001, figure 3-1) 
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Figure 3-1: The relationship between sampling density of modified TTSB and 
prostate volume 
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3.3   Modified TTSB Outcome 
 
3.3.1 Incidence of prostate Cancer 
 
Prostate cancer was detected in 167 of 303 men who underwent TTSB (55.1%). Of 
the 66 patients who were on dutasteride, cancer was identified in 26 (39.4%) 
compared to 141 of 237 (59.5%) not on dutasteride. When compared with Mann-
Whitney U test, men on dutasteride had significantly older (P = 0.001) with higher 
baseline PSA (P = 0.014), pre-TTSB PSA (P = 0.004). However, PSAD (0.22 vs 0.31 
ng/ml/cc) and mean sampling density (0.6 vs. 0.7 core/cc) were significantly lower 
in patients having dutasteride than without (P = 0.0001 and P = 0.0001 
respectively). However, the number of prior TRUSB and number of cores at TRUSB 
were not statistically different between the 2 groups (P = 0.529 and 0.580 
respectively).  
The TTSB variables of the study population stratified according to cancer positive 
and cancer negative cohorts are compared in table 3-3 overleaf.  
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Table 3-3: Clinical parameters of cancer positive and cancer negative population. 
*Denotes statistically significant P value of Mann-Whitney U test. 
 
 Cancer Positive (N = 167) 
 
Cancer Negative (N = 136)  
 Mean  Median  
 
Range  Mean Median  Range  P* 
Age (yrs) 64.2 
 
64.4 43 – 85 61.9 61.7 47 - 78 0.003* 
No. of TRUSB 1.8 
 
2.0 1 – 5 1.9 2.0 1 - 6 0.511 
No. Cores 
TRUSB 
19.2 
 
16 6 – 58 18.5 14 6 – 55 0.586 
Prostate 
volume (cm3) 
43.1 41 17 – 94 51.2 50.4 21 – 106 0.0001* 
No. of Cores 
at  TTSB 
27.3 
 
27 17 – 41 29.6 30 16 – 43 0.0001* 
Core/Volume 
(core/cm3) 
0.7 
 
0.6 0.4-1.3  0.6 0.6 0.3 – 0.9 0.0001* 
 
 
The number of prior negative TRUSB and total number of cores taken at TRUSB 
prior to undergoing TTSB were comparable between men with and without PCa. 
However, men diagnosed with cancer were on average older (p = 0.003), with 
smaller prostate (P = 0.0001) requiring less number of cores but with higher 
sampling density at modified TTSB compared to the cancer negative cohort. 
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3.3.2 Cancer Grade and Volume 
 
The grade of tumour (maximum Gleason score) and volume of cancers identified is 
summarised in table 3-4. Cancer grade ranged from 6 to 10 with the vast majority 
having Gleason 7 cancer (44.3%). 
 
Table 3-4: Outline of Gleason score and cancer volume after modified TTSB 
 Count 
 
Percent (%) 
Maximum Gleason Score (MGS) 
6 
7 
8-10 
Total  
 
50 
76 
41 
167 
 
29.9 
45.5 
24.6 
100.0 
 
No. Positive Cores (NPC) 
1 
2-5 
>5 
Total  
 
35 
70 
62 
167 
 
21 
41.9 
37.1 
100.0 
Percentage Positive Cores (PPC, %) 
<10 
10-49 
≥50 
Total  
 
56 
105 
6 
167 
 
33.5 
62.9 
3.6 
100.0 
Maximum Percent Core (MPC, %) 
<10 
10-30 
>30 
Total  
 
21 
46 
100 
167 
 
12.6 
27.5 
59.9 
100.0 
Maximum Tumour Length (MTL, mm) 
<3 
3-6 
>7 
Total  
 
48 
63 
56 
167 
 
28.7 
37.7 
33.6 
100.0 
Aggregate Tumour Length (ATLPC, 
mm) 
<3 
3-10 
>10 
Total  
 
 
35 
43 
89 
167 
 
 
30 
25.7 
44.3 
100.0 
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The vast majority of patients were diagnosed with Gleason 7 to 10 cancers (70.1%). 
The distribution of positive cores identified was most heavily weighted towards 
patients with greater than 2 positive cores (79%), PPC greater than 10 (66.5%) and 
MPC greater than 10 (87.4%). Both the maximum tumour length in any single 
positive core (MTL) and the aggregate tumour length from all positive cores (ATLPC) 
were 3mm or greater in the majority of cases (71.3% & 70% respectively).  
 
3.3.3 Clinical significance of cancers identified 
 
To determine the rate of insignificant cancer diagnosis at TTSB, the full saturation 
biopsy scheme proposed by Epstein et al (Epstein et al, 2005) was utilised. 
According to Epstein’s criteria, all cancer grades 7 or greater are clinically 
significant. A clinically insignificant cancer was defined as having Gleason score 6 or 
less cancer, with 3 or less positive cores, maximum tumour length less than 4.5mm 
and total tumour length less than 5.5mm.  
Applying Epstein’s criteria to the 167 tumours detected, 117 were Gleason 7 or 
greater which is clinically significant. In addition, there were 50 Gleason 6 tumours 
of which 23 had adverse features making then clinically significant giving a total of 
140 (83.8%) clinically significant tumours overall. The remaining 27 Gleason 6 
tumours (16.2%) were clinically insignificant by Epstein’s criteria. 
When stratified according to the number of previous TRUSB, the proportion with 
clinically significant cancer was 56 of 73 (76.7%) patients with 1 negative TRUSB, 57 
of 65 (87.7%) after 2 negative TRUSB and 27 of 29 (93.1%) in patients after 3 or 
more prior negative biopsies. 
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3.3.4 Cancer Location 
 
Figure 3-2 shows the anatomical distribution of tumours within the prostate which 
were identified at TTSB. Tumours were confined solely to the anterior, middle and 
posterior regions in 34 (20.4%), 12 (7.2%) and 12 (7.2%) patients respectively. 
However, some involvement of the anterior region was observed in 129 cases 
(77.2%). Nevertheless, 52% of tumour involved the posterior third of the gland.  
 
Figure 3-2: Location of cancers detected by TTSB 
Ant+mid = anterior and middle, ant+post = anterior and posterior, ant+mid+post = 
anterior, middle and posterior, mid+post = middle and posterior 
 
 
 
Of the 12 posterior tumours, 10 (83.3%) were in patients who underwent TTSB after 
only 1 negative TRUSB. No patient with more than 2 previous negative TRUSB was 
diagnosed with cancer involving the posterior third. In addition, of the 34 anteriorly 
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located tumours, 23 (67.6%) were in patients who have had 2 or more negative 
TRUSB. 
Table 3-5 summarises clinical variables of the patients whose tumours were 
confined solely to the anterior, middle and posterior thirds of the prostate. 
Statistical analysis by Kruskal-Wallis test showed that baseline PSA (P = 0.021), 
number of prior TRUSB (P = 0.009), pre-TTSB PSA (P = 0.023) and PSAD (P = 0.032) 
significantly differed between the three anatomical regions. 
 
Table 3-5: Clinical characteristics of men with tumours confined to the anterior, 
middle and posterior regions.  
Data presented as median (range). ‡Denotes statistically significant P value.  
Unique cancer location (N = 58) 
 Anterior 
(N=34) 
Middle  
(N=12) 
Posterior 
(N=12) 
P 
Age (yrs) 65 (43-85) 60 (52-66) 59 (54-71) 0.107 
Baseline PSA 8 (1-57) 6.5 (5-22) 6 (4-12) 0.021‡ 
No. of TRUSB 2 (1-4) 1 (1-3) 1 (1-2) 0.009‡ 
Pre-TTSB PSA 10 (3-57) 8 (3-14) 7 (3-14) 0.023‡ 
Prostate volume 44 (18-94) 55 (33-65) 45 (28-56) 0.052 
PSAD 0.26 (0.07-1.5) 0.16 (0.04-0.33) 0.14 (0.1-0.46) 0.032‡ 
%fPSA 9 (2-24) 14 (6-21) 12 (4-27) 0.428 
 
There is a trend to smaller prostate volume in anterior tumours but this did not 
reach statistical significance (P = 0.052). However, the distribution of age (P = 
0.107), number of cores at TRUSB (P = 0.144), %fPSA (P = 0.428) and number of 
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cores at TTSB (P = 0.273) were not significantly different. Similarly, pathological 
findings including distribution of number of positive cores (P = 0.216), percent 
positive cores (P = 0.115), maximum percent core involvement (P = 0.487), 
aggregate of tumour lengths (P = 0.206), maximum tumour length (P = 0.313) and 
maximum Gleason score (P = 0.346) were not significantly different between the 
unique tumour locations. 
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3.4   Morbidity of TTSB 
3.4.1 Acute Urinary Retention (AUR) 
 
Following TTSB, 23 of 303 men developed AUR (7.6%). Table 3-6 compares the 
clinical parameters of patients with or without retention.   
 
Table 3-6: Comparison of TTSB variables for retention and no retention groups 
*Denotes significant difference by Mann-Whitney U test. 
 Retention  (n = 23) 
 
No Retention (n = 280)  
 Mean  
 
Median  Range  Mean  Median  Range  P* 
Age (yrs) 64.6 66 43 –78 63 63.9 43 – 85 0.89 
Baseline PSA 
(ng/ml) 
12.5 8.5 5 – 57 9.5 7 1 - 47 0.129 
No. of TRUSB 1.5 1 1–3 1.9 2 1 – 6 0.093 
No of Core TRUSB 15.7 12 12–28 19 16 6 – 58 0.444 
Pre-TTSB PSA 
(ng/ml) 
11.3 8.5 3 – 57 12.4 10 2 – 114 0.201 
PSAD 
(ng/mL/cm3) 
0.24 0.15 0.04–
1.5 
0.3 0.21 0.01 – 
2.99 
0.059 
Prostate volume 
(cc) 
56.3 57.9 31 – 90 45.9 45 17 – 106 0.002* 
Sampling density 
(core/cm3) 
0.6 0.5 0.4–0.8 0.7 0.6 0.3 – 
1.25 
0.001* 
 
See page 85 for definition of sampling density 
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There was no statistical significant difference between retention and no retention 
group for age, baseline PSA prior to their initial TRUSB, number of prior negative 
TRUSB, number of cores taken at previous TRUSB, pre-TTSB PSA or PSAD.  However, 
prostate volume and sampling density significantly differed between the 2 groups.  
Of the 66 patients on dutasteride, 9 (13.6%) developed AUR compared to 14 of 237 
(5.9%) in patients not on dutasteride and this was statistically significant (Chi-
Square, P = 0.036). Univariate and multivariate logistic regression analysis was 
performed to determine which clinical and TTSB variable predicted occurrence of 
AUR following TTSB (table 3-7). 
 
Table 3-7: Predictors of AUR by binary logistic regression analysis 
Parameters Univariate Multivariate  
Age  0.263  
Baseline PSA 0.070  
No. of TRUSB 0.076  
No. of cores at TRUSB 0.155  
Pre-TTSB PSA 0.684  
PSAD 0.456  
Prostate volume 0.001 0.004 
No. of cores at TTSB 0.079  
No. of Rows at TTSB 0.042 0.862 
Core/volume 0.005 0.459 
Operation time 0.905  
Dutasteride therapy 0.041 0.457 
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On multivariate analysis and controlling for the effect of dutasteride, larger 
prostate volume was the only predictor of AUR (P = 0.004). 
 
3.4.2 Bleeding, Pain and Analgesic requirement after modified TTSB  
168 of 303 patients responded to the questionnaire, a response rate of 55.4%.   
 
3.4.2.1   Bleeding  
The incidence of the three categories of post TTSB bleeding (rectal bleed, 
haematuria and haematospermia) evaluated are summarised in figures 3-3, 3-4 and 
3-5. Assessment of haematospermia was undertaken from day 1 post TTSB as 
obviously, no patient would have experienced this event in the hour following 
biopsy. 
Figure 3-3: Incidence of rectal bleed after TTSB 
 
 
 
Following TTSB, 19.6% experienced rectal bleed within the 1st hour whilst 13.7%, 
4.8% and 1.2% reported minor, self limiting rectal bleed on days 1, 3 and 7 after 
1 hour Day 1 Day 3 Day 7
No 135 145 160 166
Yes 33 23 8 2
0%
20%
40%
60%
80%
100%
Rectal bleed
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TTSB. Analysis of the within-subject contrasts by generalised linear model for 
repeated measure showed a statistically significant decrease in rectal bleed with 
time (P = 0.0001). 
 
Figure 3-4: Incidence of haematuria after TTSB 
 
            
 
Similarly and as expected, the vast majority of the patients (75%) experienced 
minor and self limiting haematuria following TTSB which significantly decreased to 
60.7%, 41.1% and 28% on days 1, 3 and 7 respectively (P = 0.0001).  
 
On the contrary, the incidence of haematospermia shown in figure 3-5 increased 
over time. Following TTSB, 12.5%, 17.9% and 33.3% reported haematospermia on 
days 1, 3 and 7 respectively which was statistically significant (P = 0.0001).  
 
 
1 hour Day 1 Day 3 Day 7
No 42 66 99 121
Yes 126 102 69 47
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Figure 3-5: Incidence of haematospermia after TTSB 
           
 
3.4.2.2   Pain  
 
The incidences of the two domains of pain examined (perineal and rectal) are 
shown in figures 3-6 and 3-7 whilst figure 3-9 shows the overall mean pain score of 
the study respondents.  
Figure 3-6: Incidence of perineal pain after modified TTSB 
 
 
Day 1 Day 3 Day 7
No 147 138 112
Yes 21 30 56
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Figure 3-7: Incidence of rectal pain after modified TTSB 
 
 
 
The commonest location of patient reported pain immediately following TTSB is 
perineal (48.8% at 1 hour) compared to 35.7% reporting rectal pain at the same 
period. On days 1, 3 and 7 following TTSB, 45.2%, 36.9% and 23.2% reported 
perineal pain compared to 31.5%, 20.8% and 15.5% for rectal pain over the same 
period. Analysis using General Linear Model (GLM) for repeated measures showed a 
statistically significant reduction in perineal and rectal pain over time (P = 0.0001 
and P = 0.0001 respectively).  
 
 
Figure 3-8 shows the overall pain scores reported by patients following TTSB. Pain 
following TTSB rose from 0.03 1hr post-biopsy and peaked on day 1 with a mean 
score of 0.8 out of 10 on the visual analogue scale. Subsequently, there was a 
significant reduction in pain experience to 0.6 and 0.3 on days 3 and 7 respectively 
(P=0.0001). 
1 hour Day 1 Day 3 Day 7
No 108 115 133 142
Yes 60 53 35 26
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Figure 3-8: Overall mean pain score after modified TTSB  
 
 
 
 
Analysis of the within-subject contrast using General Linear Model (GLM) for 
repeated measures showed a statistically significant increase in pain score between 
1 hour and day 1 post TTSB (P = 0001). However, after the peak of pain on day 1, 
there was statistically significant reduction in pain between days 1 and 3 (P = 0.003) 
and between days 3 and 7 (P = 0.002).  
 
3.4.2.3    Analgesic requirement 
 
The numbers of patients requiring analgesics are shown in figure 3-9. When 
required, pain relief was satisfactorily achieved with simple analgesics including 
paracetamol in 25 patients (14.9%), codeine and paracetamol in 11 (6.5%) and 
ibuprofen in 5 (3%). The vast majority did not require any analgesia after TTSB. One 
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patient required morphine for pain control 1 hour after TTSB but was discharged 
successfully on simple analgesia afterwards (figure 3-9).  
 
Figure 3-9: Analgesic requirements after modified TTSB 
 
 
 
 
Overall, analysis using General Linear Model (GLM) for repeated measures showed 
that analgesic requirement reduced significantly over time following TTSB (P = 
0.0001). 
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3.5   Evaluation of Biochemical Predictors of PCa Diagnosis and Adverse   
Pathological Outcome in patients Undergoing Modified TTSB 
 
3.5.1 Description of study population 
 
Of the 303 patients who underwent modified TTSB, 245 had complete information 
regarding %fPSA. Nevertheless, there was no statistical significant difference 
between the 58 patients without %fPSA and the 245 patients with complete data 
for age, baseline PSA, number of TRUSB, total number of TRUSB, prostate volume, 
number of cores at TTSB and sampling density between (table 3-8).  
 
Table 3-8: Comparison of clinical parameters of patients with and without %fPSA 
information. *Denotes Mann-Whitney U test 
 
 %fPSA Available %fPSA Not available  
 Mean Median Range Mean Median Range P* 
Age 62.9 63.1 43 – 85 64.3 65 43 – 78 0.055 
Baseline PSA 9.6 8.0 1 – 47 9.9 7.0 1 – 57 0.075 
No. of TRUSB 1.8 2 1 – 6 2 2 1 – 5 0.125 
No. of core 
TRUSB 
18.7 12.5 6 – 58 20 18 8 – 55 0.365 
Prostate 
Volume 
46.9 46 17 – 
106 
45.9 46 18 – 76 0.532 
No. of core 
TTSB 
28.6 29 16 – 43 27.2 27 17 – 38 0.086 
Core/Volume 0.6 0.6 0.3 – 
1.25 
0.6 0.6 0.3 – 
1.0 
0.934 
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Of the 245 men with complete %fPSA data, cancer was diagnosed in 133 (54.3%). 
Table 3-9 shows the pre-TTSB total PSA and its derivatives stratified according to 
cancer positive and cancer negative cohorts. 
 
Table 3-9: Total PSA, Percent free PSA (%fPSA) and PSA density (PSAD) of cancer 
positive and cancer negative groups. *Denotes Mann-Whitney U test 
 
 Total Patients (N = 245)  
 Cancer Positive (N = 133) 
 
Cancer Negative (N = 112)  
 Mean  Median  
 
Range  Mean Median  Range  P* 
Baseline PSA      
(ng/ml) 
10.4 8 1 - 39 8.7 7 2 - 47 0.011 
 
Pre-TTSB PSA    
(ng/ml) 
15 11 2 - 114 8.2 8 2 - 22 0.0001 
%fPSA 10.2 9 2 - 35 14 13 1 - 32 0.0001 
PSAD  
(ng/ml/cc) 
0.38 0.27 0.04 –  
2.99 
0.16 0.15 0.01 –  
0.38 
0.0001 
 
 
Both total serum PSA values (Baseline and pre-TTSB PSA) and their derivatives 
including %fPSA and PSAD showed statistically significant difference between 
cancer positive and cancer negative patients. Similar to findings from analysis of the 
overall cohort (table 3-3), there was statistical significant difference for age (P = 
0.002), prostate volume (P = 0.0001), number of cores at TTSB (P = 0.0001) and 
sampling density (P = 0.001) between cancer positive and cancer negative groups 
for the cohort of 245 men with complete %fPSA and PSAD information. The 
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distribution of number of TRUSB and number of cores taken at TRUSB was similar 
between the two groups (P = 0.338 and 0.656 respectively). 
 
3.5.2 Histopathological outcome of the cancer positive cases 
 
Detail of the grade and cancer volume parameters of the 133 positive cases are 
outlined in table 3-10. The vast majority of patients were diagnosed with Gleason 7 
to 10 (70.7%) with a mean NPC of 5, PPC 19, MPC 49.6, MTL 5.5mm and ATLPC 
21.2mm. 
 
Table 3-10:  Summary of cancer grade and volume 
 
 Cancer Positive (N = 133) 
 Mean Median Range 
Maximum Gleason Score 7 7 6 - 10 
NPC 5 4 1 – 17 
PPC (%) 19 15.6 2 – 67 
MPC (%) 49.6 50 1 – 100 
MTL (mm) 5.5 4.2 1 – 16 
ATLPC (mm) 21.2 12.3 1 - 145 
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3.5.3 Predictors of cancer diagnosis, grade and volume 
 
3.5.3.1  Predictors of cancer diagnosis  
 
3.5.3.1.1  Univariate Analysis 
 
Univariate analysis was first performed in order to identify variables which are 
predictive for cancer diagnosis at P <0.05 (table 3-11).  
 
Table 3-11: Univariate predictors of cancer diagnosis 
 
 
 
The vast majority of the pre-TTSB clinical parameters of the study population 
including age, baseline PSA, pre-TTSB PSA, %fPSA, PSAD, prostate volume, number 
 Univariate P 
Age 0.001 
Baseline PSA 0.046 
No. of TRUSB 0.279 
No. Of cores TRUSB 0.418 
Pre-TTSB PSA 0.0001 
%fPSA 0.0001 
PSAD 0.0001 
Prostate volume 0.0001 
No. of cores at TTSB 0.0001 
Core/volume 0.0001 
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of cores at TTSB and sampling density were statistically significant predictors of 
cancer diagnosis on univariate analysis except for number of previous TRUSB and 
number of prior TRUSB cores (P = 0.279 and 0.418 respectively) 
 
3.5.3.1.2  Multivariate analysis for prediction of cancer diagnosis 
 
Variables which were significant on univariate analysis were entered included in a 
multivariate binary logistic regression analysis by forward stepwise method.  
Bivariate Spearman’s correlation was performed to determine the suitability of 
related variables for inclusion into the same multivariate model. This identified that 
pre-TTSB PSA and PSAD were highly correlated (Spearman’s correlation coefficient 
ρ = 0.9, P = 0.0001). Consequently, two separate models were constructed in order 
to avoid inclusion of PSAD and pre-TTSB PSA into the same model (tables 3-12). The 
fitness of the two models thus constructed was assessed using -2 log likelihood 
difference and Nagelkerke’s R2. More importantly, the models were controlled for 
the effect of dutasteride.  
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Table 3-12: Two models predicting cancer diagnosis by multiple binary logistic 
regressions.  
Exp B: odd ratio, CI: confidence interval 
‡Denotes significant P value 
 
Model 1 (Including Pre-TTSB PSA) 
 
-2 Log likelihood   -  240.7 
Nagelkerke’s R2     -  0.353 
 Exp B 95%CI P‡ 
Age 1.06 1.01 – 1.12 0.032‡ 
Baseline PSA 0.99 0.92 – 1.05 0.638 
%fPSA 0.93 0.88 – 0.99 0.021‡ 
Prostate volume 0.96 0.94 – 0.98 0.001‡ 
No. of cores TTSB 0.91 0.85 – 0.98 0.107 
Core/volume 1.30 0.97 – 1.74 0.081 
Dutasteride 1.66 0.74 – 3.71 0.218 
Pre-TTSB PSA 1.12 1.04 – 1.20 0.002‡ 
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Model 2 (Including PSAD) 
 
-2 Log likelihood   -  239.8 
Nagelkerke’s R2     -  0.362 
 Exp B 95%CI P 
Age 1.05 1.00 – 1.11 0.046‡ 
Baseline PSA 0.98 0.92 – 1.04 0.514 
%fPSA 0.94 0.88 – 0.99 0.026‡ 
Prostate volume 1.06 0.97 – 1.17 0.198 
No. of cores 
TTSB 
0.87 0.73 – 1.03 0.111 
Core/volume 1.60 0.73 – 3.50 0.243 
Dutasteride 1.47 0.64 – 3.38 0.365 
PSAD 3.69 1.79 – 7.61 0.0001‡ 
 
Multivariate regression analysis revealed that age, %fPSA, smaller prostate volume 
and pre-TTSB PSA were significant predictors of cancer diagnosis at TTSB in model 1 
whilst age, %fPSA and PSAD were significantly predicted cancer diagnosis in model 
2. PSAD was more predictive of cancer diagnosis (OR, 3.7, 95% confidence interval 
[CI], 1.79-7.61) and contributed significantly more than %fPSA (OR, 0.9, 95% CI 0.88-
0.99), age (OR 1.1, 95% CI 1.00-1.11) and pre-TTSB PSA (OR 1.1, 95% CI 1.04-1.20).  
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3.5.3.2  Predictors of tumour grade and volume 
 
3.5.3.2.1 Univariate analysis 
 
Based on Epstein’s definition of significant cancer at saturation biopsy, biopsy 
cancer grade and volume parameters were divided into two categorical groups of 
variables including NPC less than 4 and 4 or greater, MTL less than 4.5mm and 
4.5mm or greater, ATLPC less than 5.5mm and 5.5mm or greater and maximum 
Gleason score (MGS) less than 7 and 7 or greater, MPC less than 50% and 50% or 
greater and PPC less than 15 and 15 or greater according to the median value.  
 
Using the categorical groups thus created as the dependent variables, univariate 
analysis was performed on clinical and biopsy parameters including age, baseline 
PSA, number of TRUSB, number of cores taken at TRUSB, pre-TTSB PSA, %fPSA, 
PSAD, prostate volume, number of TTSB cores and sampling density in order to 
determine predictors of significant cancer (MGS ≥7, NPC ≥4, MTL ≥4.5mm, ATLPC 
≥5.5mm, MPC ≥50% and PPC ≥15%) at TTSB (table 3-13 overleaf). 
 
Variables which were statistically significant at P<0.05 on univariate analysis for 
each of the categorical groups were then entered into the multivariate analysis.  
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Table 3-13: Univariate predictors of cancer grade and volume 
P <0.05 is statistically significant 
 Univariate Analysis 
Median  MGS NPC MTL (mm) ATLPC (mm)  MPC (%) PPC (%) 
 <7 ≥7 P <4 ≥4 P <4.5 ≥4.5 P <5.5 ≥5.5 P <50 ≥50 P <15 ≥15 P 
Age 63.2 65.0 0.012 63.8 65.1 0.007 63.0 66.4 0.0001 62.7 65.0 0.003 63.5 65.0 0.009 63.0 65.6 0.001 
Baseline PSA 7 9 0.001 7 9 0.002 7 9 0.0001 6 9 0.001 7.5 9.0 0.015 7 9 0.002 
No. of TRUSB 1 2 0.214 2 2 0.084 2 2 0.223 1 2 0.042 1 2 0.016 2 2 0.336 
No. of cores TRUSB 12 18 0.175 12 19 0.023 14 18 0.545 12 18 0.123 12 18 0.136 13 18 0.192 
Pre-TTSB PSA 9.0 13.0 0.001 9 14 0.0001 9 14 0.0001 9 12 0.0001 9.0 13.5 0.0001 9 13 0.0001 
%fPSA 12 8 0.010 11.5 7.5 0.001 11 7.5 0.005 13 8 0.0001 11 7 0.0001 11.0 7.5 0.004 
PSAD 0.19 0.33 0.0001 0.19 0.40 0.0001 0.19 0.37 0.0001 0.18 0.35 0.0001 0.19 0.39 0.0001 0.19 0.40 0.0001 
Prostate volume 46.7 39.8 0.041 45.8 38.1 0.007 44 39 0.076 49 38 0.0001 47.6 38.0 0.001 45.8 38.1 0.003 
No. of cores at TTSB 29 26 0.046 28 26 0.024 28 26 0.056 29 26 0.0001 29 26 0.003 28 26 0.002 
Core/volume 0.6 0.7 0.101 0.6 0.7 0.022 0.7 0.6 0.281 0.6 0.7 0.008 0.6 0.7 0.021 0.6 0.7 0.048 
3.5.3.2.2 Multivariate Analysis for prediction of tumour volume and grade 
 
Tables 3-14 to 3-19 summarises results of the two logistic regression models 
created. Multivariate binary logistic regression analysis by forward stepwise 
method was performed to determine predictors of Gleason score and biopsy 
tumour volume. As previously described, pre-TTSB PSA and PSAD were not included 
in the same model because they are highly correlated.  
 
Table 3-14: Multivariate analysis for prediction of Gleason score. 
‡Denotes significant P value 
 
Model 1 
 
-2 Log likelihood   -  129.4 
Nagelkerke’s R2        -  0.229 
 Exp B 95%CI P‡ 
Age 1.05 0.96 – 1.16 0.295 
Baseline PSA 1.05 0.90 – 1.23 0.549 
%fPSA 0.97 0.87 – 1.09 0.625 
Prostate volume 0.97 0.94 – 1.01 0.106 
No. of cores TTSB 0.96 0.77 – 1.20 0.734 
Dutasteride 1.64 0.36 – 7.38 0.522 
Pre-TTSB PSA 1.16 1.06 – 1.26 0.001‡ 
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Model 2 
 
-2 Log likelihood   -  130.4 
Nagelkerke’s R2         -  0.219 
 Exp B 95%CI P‡ 
Age 1.06 0.97 – 1.16 0.221 
Baseline PSA 1.07 0.92 – 1.25 0.395 
%fPSA 0.98 0.87 – 1.09 0.662 
Prostate volume 0.98 0.87 – 1.10 0.697 
No. of cores TTSB 1.01 0.80 – 1.27 0.927 
Dutasteride 1.94 0.45 – 8.31 0.370 
PSAD 2.69 1.55 – 4.67 0.0001‡ 
 
 
Controlling for the effect of dutasteride, the two models constructed were equally 
fitted to predict Gleason score ≥7 as demonstrated by their comparable -2 log 
likelihood difference and Nagelkerke’s R2 values. Multivariate analysis showed that 
pre-TTSB PSA and PSAD were the only significant predictors of Gleason score ≥7 in 
models 1 and 2 respectively (P = 0.001 and 0.0001). 
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Table 3-15: Multivariate analysis for prediction of number of positive cores (NPC) 
‡Denotes significant P value 
 
Model 1 
 
-2 Log likelihood   -  112.3 
Nagelkerke’s R2         -  0.270 
 Exp B 95%CI P‡ 
Age 1.04 0.95 – 1.13 0.392 
Baseline PSA 0.91 0.78 – 1.06 0.224 
No. of cores TRUSB 1.07 0.96 – 1.19 0.200 
%fPSA 0.92 0.83 – 1.02 0.124 
Prostate volume 1.02 0.89 – 1.16 0.829 
No. of cores TTSB 0.90 0.82 – 0.98 0.020‡ 
Core/volume 1.25 0.56 – 2.80 0.586 
Dutasteride 0.67 0.16 – 2.80 0.584 
Pre-TTSB PSA 1.10 1.04 – 1.17 0.001‡ 
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Model 2 
 
-2 Log likelihood   -  112.3 
Nagelkerke’s R2         -  0.270 
 Exp B 95%CI P‡ 
Age 1.06 0.96 – 1.14 0.304 
Baseline PSA 1.07 0.80 – 1.05 0.228 
No. of cores TRUSB 0.99 0.97 – 1.21 0.139 
%fPSA 0.98 0.84 – 1.04 0.189 
Prostate volume 0.98 0.87 – 1.14 0.974 
No. of cores TTSB 1.01 0.76 – 1.26 0.879 
Core/volume 0.97 0.42 – 2.23 0.945 
Dutasteride 1.94 0.17 – 2.74 0.587 
PSAD 2.44 1.54 – 3.85 0.0001‡ 
 
 
The two models constructed were equally fitted to predict NPC ≥4 positive cores as 
demonstrated by the equal values of their respective goodness of fit parameters (-2 
log likelihood difference and Nagelkerke’s R2). Multivariate analysis showed that 
pre-TTSB PSA and number of cores at TTSB significantly predicted NPC ≥4 in model 
1 (P = 0.020 and 0.001 respectively), whilst PSAD was the only significant predictor 
in model 2 (P = 0.0001). 
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Table 3-16: Multivariate analysis for prediction of Maximum tumour length (MTL) 
‡Denotes significant P value 
 
Model 1 
 
-2 Log likelihood   -  106.4 
Nagelkerke’s R2         -  0.345 
 Exp B 95%CI P‡ 
Age 1.09 1.01 – 1.18 0.028‡ 
Baseline PSA 1.01 0.87 – 1.16 0.930 
No. of cores 
TRUSB 
0.99 0.89 – 1.09 0.769 
%fPSA 1.00 0.89 – 1.11 0.928 
Dutasteride 1.20 0.28 – 5.08 0.806 
Pre-TTSB PSA 1.11 1.04 – 1.19 0.001‡ 
 
 
Model 2 
 
-2 Log likelihood   -  103.2 
Nagelkerke’s R2         -  0.376 
 Exp B 95%CI P‡ 
Age 1.10 1.02 – 1.19 0.012‡ 
Baseline PSA 1.01 0.89 – 1.15 0.892 
No. of cores TRUSB 0.99 0.90 – 1.10 0.892 
%fPSA 1.00 0.90 – 1.12 0.988 
Dutasteride 1.25 0.31 – 5.09 0.760 
PSAD 2.34 1.51 – 3.63 0.0001‡ 
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In the two equally fitted models constructed, age and pre-TTSB PSA significantly 
predicted MTL ≥4.5mm in model 1 (P = 0.028 and 0.001 respectively) whilst age and 
PSAD were significant predictors in model 2 (P = 0.013 and 0.0001 respectively). 
 
 
Table 3-17: Multivariate analysis for prediction of aggregate tumour lengths from 
positive cores (ATLPC) 
‡Denotes significant P value 
 
Model 1 
 
-2 Log likelihood   -  131.8 
Nagelkerke’s R2         -  0.265 
 Exp B 95%CI P‡ 
Age 1.01 1.00 – 1.14 0.047‡ 
Baseline PSA 0.99 0.86 – 1.14 0.877 
No. of TRUSB 0.92 0.22 – 3.90 0.906 
%fPSA 0.93 0.86 – 1.02 0.104 
Prostate volume 0.95 0.92 – 0.98 0.002‡ 
No. of cores TTSB 0.93 0.72 – 1.20 0.054 
Core/volume 1.11 0.54 – 2.32 0.773 
Dutasteride 0.65 0.14 – 3.02 0.583 
Pre-TTSB PSA 1.01 1.02 – 1.16 0.015‡ 
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Model 2 
 
-2 Log likelihood   -  135.3 
Nagelkerke’s R2         -  0.233 
 Exp B 95%CI P‡ 
Age 1.08 1.01 – 1.17 0.036‡ 
Baseline PSA 1.00 0.87 – 1.14 0.947 
No. of TRUSB 0.87 0.20 – 3.83 0.854 
%fPSA 0.94 0.86 – 1.02 0.142 
Prostate volume 0.97 0.93 – 1.00 0.062 
No. of cores TTSB 0.96 0.75 – 1.25 0.782 
Core/volume 1.02 0.48 – 2.19 0.956 
Dutasteride 0.69 0.15 – 3.08 0.626 
PSAD 2.00 1.16 – 3.33 0.012‡ 
 
 
On multivariate analysis controlling for effect of dutasteride therapy, age, prostate 
volume and pre-TTSB PSA were significant predictors of aggregate tumour lengths 
from positive cores (ATLPC) ≥5.5mm in model 1 (P = 0. 047, 0.002 and 0.015) whilst 
patients age and PSAD significantly predicted ATLPC ≥5.5mm in model 2 (P = 0.036 
and 0.012 respectively).  
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Table 3-18: Multivariate analysis for prediction of maximum percent core 
involvement (MPC) 
‡Denotes significant P value 
 
Model 1 
 
-2 Log likelihood   -  139.1 
Nagelkerke’s R2         -  0.297 
 Exp B 95%CI P‡ 
Age 1.04 0.95 – 1.13 0.03 
Baseline PSA 0.99 0.85 – 1.14 0.947 
No. of TRUSB 1.22 0.32 – 4.65 0.854 
%fPSA 0.96 0.86 – 1.07 0.023‡ 
Prostate volume 0.99 0.86 – 1.14 0.743 
No. of cores TTSB 0.89 0.81 – 0.97 0.008‡ 
Core/volume 1.30 0.63 – 2.69 0.754 
Dutasteride 1.36 0.31 – 5.91 0.626 
Pre-TTSB PSA 1.13 1.06 – 1.20 0.0001‡ 
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Model 2 
 
-2 Log likelihood   -  140.2 
Nagelkerke’s R2         -  0.288 
 Exp B 95%CI P‡ 
Age 1.05 0.96 – 1.14 0.293 
Baseline PSA 1.00 0.88 – 1.15 0.959 
No. of TRUSB 1.20 0.31 – 4.65 0.789 
%fPSA 0.97 0.87 – 1.08 0.557 
Prostate volume 0.98 0.86 – 1.13 0.817 
No. of cores TTSB 0.98 0.77 – 1.26 0.879 
Core/volume 1.06 0.51 – 2.20 0.880 
Dutasteride 1.43 0.34 – 6.02 0.624 
PSAD 2.70 1.71 – 4.27 0.0001‡ 
 
 
In the two equally fitted models constructed, number of cores obtained at TTSB, 
%fPSA, number of cores at TTSB  and pre-TTSB PSA significantly predicted maximum 
percent core involvement (MPC) ≥50% in model 1 (P = 0.023,  0.008 and 0.0001 
respectively). In model 2 however, PSAD was the only significant predictor of MPC 
≥50% (P = 0.0001). 
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Table 3-19: Multivariate analysis for prediction of percentage of positive cores 
(PPC).  
‡Denotes significant P value 
 
 
Model 1 
 
-2 Log likelihood   -  111.9 
Nagelkerke’s R2         -  0.274 
 Exp B 95%CI P‡ 
Age 1.06 0.99 – 1.14 0.109 
Baseline PSA 0.90 0.77 – 1.05 0.166 
%fPSA 0.92 0.86 – 0.99 0.278 
Prostate volume 1.02 0.89 – 1.17 0.771 
No. of cores TTSB 0.90 0.82 – 0.98 0.012‡ 
Core/volume 1.15 0.83 – 1.59 0.731 
Dutasteride 0.44 0.10 – 1.92 0.275 
Pre-TTSB PSA 1.10 1.04 – 1.17 0.001‡ 
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Model 2 
 
-2 Log likelihood   -  110.7 
Nagelkerke’s R2         -  0.288 
 Exp B 95%CI P‡ 
Age 1.07 1.00 – 1.15 0.055 
Baseline PSA 0.92 0.80 – 1.05 0.203 
%fPSA 0.92 0.86 – 0.99 0.260 
Prostate volume 1.00 0.87 – 1.14 0.959 
No. of cores TTSB 0.95 0.84 – 1.06 0.345 
Core/volume 0.84 0.55 – 1.29 0.424 
Dutasteride 0.48 0.12 – 1.97 0.307 
PSAD 2.10 1.37 – 3.24 0.001‡ 
 
 
The two multivariate regression models constructed were equally fitted to predict 
percentage of positive cores (PPC) ≥15% as shown by the equal values of their 
respective goodness of fit parameters (-2 log likelihood difference and Nagelkerke’s 
R2). Number of cores at TTSB and pre-TTSB PSA significantly predicted PPC ≥15% in 
models 1 whilst only PSAD was predictive in model 2. 
 
Figure 3-10 shows the ROC curve of PSA Density (PSAD), pre-TTSB PSA and 
percentage of free PSA (%fPSA) for prostate cancer diagnosis. The PSAD (AUC 0.76; 
95% CI, 0.70 – 0.82, P=0.0001) was more predictive of cancer than pre-TTSB PSA 
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(AUC 0.71; 95% CI, 0.65 – 0.77, P=0.0001) and %fPSA (AUC 0.71; 95% CI, 0.64 – 0.77, 
P=0.0001).  
 
Figure 3-10: Receive operating characteristics (ROC) curve for (A) PSA Density 
(PSAD) and pre-TTSB PSA; (B) percentage of free PSA (%fPSA) 
 
 
 
 
 
 
 
 
 
 
 
A 
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The cut-off values at which at least 90% of cancers would be detected (sensitivity) 
by the PSA parameters include ≥0.10ng/mL/cm3 for PSAD, ≥4.5ng/mL for pre-TTSB 
PSA and ≤17.5% for %fPSA. At these cut-offs, the number of unnecessary biopsies 
that would have been avoided (specificity) were 25% for PSAD, 16% for pre-TTSB 
PSA and 23% for %fPSA. 
 
Using these cut-offs, the number of significant cancer that would be predicted 
(sensitivity) and corresponding specificity (proportion of clinically insignificant 
cancer) according to Epstein’s criteria are shown in table 3-20 
B 
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Table 3-20: Sensitivity and specificity of PSAD, %fPSA and pre-TTSB PSA for 
predicting Gleason score and tumour volume 
 
  Sensitivity (%) Specificity (%) 
 
Gleason score ≥7 
PSAD ≥0.10 
%fPSA ≤17.5 
Pre-TTSB PSA ≥4.5 
95.7 
89.4 
93.6 
17.9 
17.9 
25.6 
 
NPC 
PSAD ≥0.10 
%fPSA ≤17.5 
Pre-TTSB PSA ≥4.5 
95.7 
91.4 
92.9 
12.9 
16.1 
17.7 
 
PPC (%) 
PSAD ≥0.10 
%fPSA ≤17.5 
Pre-TTSB PSA ≥4.5 
95.8 
88.9 
93.1 
13.1 
14.8 
18.0 
 
MPC (%) 
PSAD ≥0.10 
%fPSA ≤17.5 
Pre-TTSB PSA ≥4.5 
98.6 
85.9 
97.2 
16.1 
11.3 
22.6 
 
MTL (mm) 
PSAD ≥0.10 
%fPSA ≤17.5 
Pre-TTSB PSA ≥4.5 
97.0 
86.4 
97.0 
13.4 
11.9 
20.9 
 
ATLPC (mm) 
PSAD ≥0.10 
%fPSA ≤17.5 
Pre-TTSB PSA ≥4.5 
95.5 
88.6 
94.3 
15.6 
15.6 
24.4 
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3.6   Utility of MRI before TTSB 
 
Of the 303 men included in this study, 158 underwent an MRI scan prior to 
modified TTSB (52.1%). Table 3-21 shows a breakdown of the MRI sequences 
undertaken by the cohort. 
 
Table 3-21: Pre-TTSB MRI technique 
 N (%) 
Conventional MRI (T1/T2WI) 76 (48.1) 
Diffusion weighted imaging MRI + T2WI 49 (31.0) 
Full Multiparametric MRI                 
 (T2WI + dwi=MRI + DCE-MRI)                                  
33 (20.9) 
  
 
3.6.1 MRI stage  
 
Majority of cases were T1c. Table 3-22 presents the stage of cancers identified on 
MRI. 
 
Table 3-22: Cancer stage on MRI 
MRI Stage N (%) 
T1c 93 (58.9) 
T2a 61 (38.6) 
T3a 4 (2.5) 
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3.6.2 Comparison of pre-biopsy MRI to TTSB for cancer diagnosis 
 
Analysis of MRI data was performed to determine how well pre-saturation biopsy 
MRI scan result correlated with TTSB as the gold standard in order to determine 
whether MRI scan could decrease the need for TTSB. Firstly, a 2x2 crosstabulation 
table outlining MRI and TTSB outcomes was constructed (table 3-23). This enabled 
sensitivity, specificity to be determined.  
 
Table 3-23: MRI and TTSB results 
 
 TTSB positive TTSB negative Total  
MRI positive 44 21 65 
MRI negative 24 69 93 
Total  68 90 158 
  
 
MRI correctly detected cancer in 44 of 68 patients (64.7%) and was correctly 
negative when TTSB outcome is benign in 69 of 90 patients (76.7%). This 
observation was statistically significant by Chi-Square test (P = 0.0001).  However, 
MRI failed to identify 24 of 68 cancers (35.3%) detected by TTSB and of the 90 
negative cases on TTSB, MRI incorrectly found abnormality in 21 (23.3%). 
 
 127 
 
To further determine the contribution of the different MRI sequences to the 
observation above, we cross-tabulated the TTSB result with the three MRI 
sequences (table 3-24).  
 
Table 3-24: MRI sequence and TTSB result 
 TTSB 
positive 
TTSB  
negative 
Total  
cMRI                       positive 30 13 43 
cMRI                       negative 17 16 33 
                                Total  47 29 76 
    
dwi-MRI + T2WI   positive 4 7 11 
dwi-MRI +T2WI    negative 5 33 38 
                                 Total  9 40 49 
    
mp-MRI                   positive 10 1 11 
mp-MRI                   negative 2 20 22 
                                 Total 12 21 33 
 
The cross tabulation above shows that there is a huge difference between the three 
MRI sequences in their ability to detect abnormality. Multiparametric MRI (mp-
MRI) is significantly more accurate for identifying and excluding prostate 
abnormality compared to the other sequences (Fisher’s Exact test P = 0.0001). 
Conventional MRI (cMRI, Chi-Square test P = 0.104) and diffusion weighted imaging 
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MRI (DWI-MRI, Fisher’s Exact test P = 0.179) have no statistical significant 
relationship with TTSB for cancer detection.  
The sensitivity, specificity, positive and negative predictive values of MRI overall 
and for each of the three MRI sequences are shown in table 3-25  
 
Table 3-25: Diagnostic accuracy of MRI 
 
 Sensitivity 
(%) 
Specificity (%) PPV (%) NPV (%) 
Overall MRI 64.7 76.7 67.7 74.2 
cMRI (T1/T2WI) 63.8 55.2 69.8 48.5 
DWI-MRI + T2WI 44.4 82.5 36.4 86.8 
mp-MRI 83.3 95.2 90.9 91.0 
 
Multiparametric MRI (mp-MRI) outperformed the other MRI sequences in all 
parameters for detection of abnormality in the prostate with a sensitivity of 83.3% 
compared to 44.4% and 63.8% for diffusion weighted imaging and conventional 
MRI respectively. When mp-MRI identifies an abnormality, it is more likely to be 
positive at TTSB compared to other MRI sequences (PPV 90.9%). 
Importantly, analysis of the clinical characteristics of the patients in the three MRI 
sequences using Kruskal-Wallis test showed no difference for age (P = 0.524), pre-
TTSB PSA (P = 0.074), prostate volume ((P = 0.321), number of cores at TTSB (P = 
0.453) and sampling density (P = 0.282). Furthermore, the Gleason score (P = 0.089) 
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and tumour volume parameters including number of positive cores, percent of 
positive cores and maximum percentage core involvement (P = 0.296) were the 
same across the three groups of MRI sequence. 
 
3.6.3 Characteristics of tumours missed by MRI 
 
From the crosstabulation in table 3-22, it was shown that MRI missed 24 cancers 
which were identified by TTSB. Stratification of the tumours missed by MRI into the 
three sequences showed that majority of the missed tumours were by conventional 
MRI (17 of 24, 70.8%), DWI-MRI 5 (20.8%) and mp-MRI 2 (8.4%). Further analysis 
was performed on the 24 missed tumours (false negative) in order to determine 
their histological characteristics compared with the correctly identified (true 
positive) tumours (table 3-26). 
 
Table 3-26: Histological parameters of cancers detected by TTSB which were missed 
compared with those correctly identified by MRI. 
Data presented as median (range). 
 Histology 
MRI Gleason 
score 
NPC MTL 
(mm) 
ATLPC 
(mm) 
MPC (%) 
False negative             
(n = 24) 
7 (6-10) 2.5 (1-14) 2.5 (1-11) 5 (1-57) 25 (1-100) 
True positive              
(n = 44) 
7 (6-9) 5.0 (1-16) 5.3 (1-20) 17 (1-140) 60 (1-100) 
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There was no difference in tumour grade (Gleason score) between the missed 
cancers (false negative) and those that were accurately identified by MRI (Mann-
Whitney U Test, P = 0.179). Furthermore, a trend towards less median number of 
positive cores (NPC) in men diagnosed with cancer on TTSB which were missed by 
MRI was observed, but this did not reach statistical significance (Mann-Whitney U 
Test, P = 0.107). However, the median tumour volume parameters (MTL, ATLPC and 
MPC) of the MRI missed cancers were significantly smaller than those accurately 
identified on MRI (P = 0.002, 0.013 and 0.005 respectively). 
 
3.6.4 Characteristics of cancers missed by MRI according to Epstein’s criteria 
 
Analysis of the 24 missed tumours was performed to determine their clinical 
significance by Epstein’s criteria (Epstein et al, 2005). This criteria for classification 
of insignificant cancer at saturation biopsy described by Epstein et al has been 
discussed in detail in chapter 2, section 4.0 of this report.  
Using Epstein’s criteria, 16 of the 24 (66.7%) missed tumours on MRI could be 
classed as clinically significant (Gleason score ≥7, number of positive cores ≥4, 
maximum tumour length ≥4.5mm and aggregate tumour lengths from positive 
cores ≥5.5mm). 
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3.6.5 Correlation of cancer location between MRI and TTSB 
 
The location of abnormalities in any of the 4 anatomical quadrants on MRI scan was 
analysed and correlated with the ultimate location of tumour identified by TTSB in 
order to determine whether a limited TTSB might be feasible.  
Abnormalities were located in multiple quadrants in vast majority of the patients. 
Consequently, MRI scan demonstrated an abnormality in 89 quadrants compared to 
TTSB which detected cancer in 144 quadrants. Of the 89 abnormal MRI quadrants, 
82 (92%) were diagnosed with cancer by TTSB. 
 
Abnormality reported on MRI was concordant with result of TTSB in 113 of 158 
patients (71.5%) including 69 cases correctly reported as normal by MRI (true 
negative) and 44 cases with abnormality in at least one anatomical quadrant on 
MRI which was correctly diagnosed with cancer at TTSB (true positive).  
 
The characteristics of the tumours inaccurately localised to a quadrant (false 
negative) compared to correctly localised tumours (true positive) on MRI quadrants 
are summarised in table 3-27. 
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Table 3-27: Grade and volume of tumours correctly localised to anatomical 
quadrant on MRI compared to the missed cases. 
Data is presented as median (range) 
 Histology  
MRI Gleason 
score 
NPC MTL (mm) ATLPC (mm) MPC (%) 
False negative 
quadrant        
(N = 62) 
 
7 (6-10) 2.5 (1-14) 1 (1-11) 1.6 (1-83) 30.0 (1-100) 
True positive 
quadrant 
(N = 82) 
 
7 (6-9) 5.0 (1-16) 6.5 (1-20) 17.5 (1-140) 65.0 (1-100) 
 
MRI identified quadrants with higher tumour load as shown by the statistically 
significant difference between the number of positive cores (NPC), maximum 
tumour length (MTL), aggregate of tumour lengths of positive cores (ATLPC) and 
mean maximum percent core involved with cancer (MPC) for the quadrant 
concordant MRI detected tumours (true positive) compared to the false negative 
quadrants (Mann-Whitney U test, P = 0.027, 0.001, 0.006 and 0.006 respectively). 
However, Gleason score between the missed quadrant (false negative) and the 
accurately identified tumour quadrant by MRI was not significantly different (Mann-
Whitney U test, P = 0.123).   
Multiparametric MRI was better for identifying small tumours because of the 62 
quadrants from 24 patients which were falsely negative on MRI but diagnosed with 
cancer by TTSB, cMRI missed 40 (64.5%) quadrants, DWI-MRI 16 (25.8%) and only 6 
(9.7%) quadrants were missed by mp-MRI. 
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Chapter 4 Discussion 
4.1    Modified TTSB technique and prostate cancer diagnosis 
Modified TTSB identified PCa in 55.1% of men undergoing repeat prostate biopsy 
after a median of 2 previous negative TRUSB, from a median of 29 cores. The cancer 
detection rate is superior to the 11.1 to 41% incidence reported for transrectal 
saturation biopsy series listed in table 1-1 and comparable to 23 to 68% rates 
reported for other TTSB approaches which are summarised in table 1-2. This 
suggests that the periurethral sparing modified TTSB technique has no significant 
impact on cancer detection, a finding in keeping with previous studies showing that 
the basal periurethral area is hardly ever the sole site to be involved by localised 
prostate cancer. 
In a study of 88 men with persistent clinical suspicion of PCa despite having 
undergone a mean of 15.1 biopsy cores from their previous negative TRUSB, Igel et 
al (Igel et al, 2001) detected cancer in 43% at TTSB. In another study, Furuno et al 
(Furuno et al, 2004) performed TTSB on 113 men, 86 of which had no previous 
biopsies. Overall cancer detection rate was 43%. However, in the 27 patients with 
previous negative biopsy, cancer was detected in 7 (26%). The same group reported 
a cancer detection rate of 49% in 371 patients undergoing TTSB (first biopsy in 312 
and repeat biopsy in 59 patients). The cancer detection rate in the repeat group 
was only 26% (Demura et al, 2005). Pinkstaff et al reported a 37% detection rate in 
78 men from 21.2 cores after 2 or more negative TRUSB whilst Satoh and 
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colleagues performed TTSB on 128 high risk men after a median of one negative 
sextant tranrectal biopsy. They reported a PCa detection rate of 22.7%. Other TTSB 
series in patients with persistent clinical suspicion of PCa after negative TRUSB 
histology record cancer detection rates of 26 to 68% (Bittner et al, 2009; Bott et al, 
2006; Gershman et al, 2012; Mabjeesh et al, 2012; Merrick et al, 2007; Merrick et 
al, 2008; Pal et al, 2011). Bott et al (Bott et al, 2006) modified their technique 
aimed at reducing operating time by sampling the prostate from 6 to 12 needles 
placed simultaneously into the anterior, middle or posterior regions of the gland. Of 
the 67 men who underwent TTSB using their modified approach, cancer was 
detected in 38%. Merrick and colleagues (Merrick et al, 2007) reported a 42.2% 
cancer detection rate after 2 negative TRUSB from a mean of 22.4 cores using 
anatomic based TTSB technique in 102 patients. The same group reported a 45.9 to 
46.5% detection rates from two studies (Bittner et al, 2009; Merrick et al, 2008).  
Another study by Pal et al (Pal et al, 2011) in a relatively small cohort of 40 men 
undergoing TTSB due to high PSA of 22ng/ml and two negative sets of TRUSB 
detected PCa in 68% from a standardised 36 core  approach. Mabjeesh et al  
studied 92 patients and reported PCa incidence of 26% after TTSB whilst Gershman 
and colleagues (Gershman et al, 2012) reported 50% cancer detection in 34 
patients who had repeat TTSB. More recently, a large North American series 
involving 485 patients reported PCa detection rate of 46.6% from 56 cores at TTSB 
(Bittner et al, 2013).  
In addition to the advantages generic to TTSB which have been discussed in chapter 
1, section 9.0 of this report, this modified technique provided some unique 
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advantages. Firstly, the sampling density which is inversely proportional to the 
prostate volume (figure 3-1) means that contrary to previous reports where the 
number of TTSB cores rose with increasing prostate size resulting up to 50 to 76 
cores in some series (Merrick et al, 2007; Stav et al, 2008), modified TTSB results in 
far less number of cores (mean 28 cores) which in the current climate of tight 
hospital  resources, provides reasonable workload for the pathologist.  
Secondly, modified TTSB approach ensures an evenly spaced prostate sampling 
10mm apart horizontally and 5mm vertically between rows. This is similar to the 
description by Demura et al (Demura et al, 2005). In their study, they postulated 
based on their experience that if tumour focus is a sphere, then tumour foci 
>10mm in dimension would be equivalent to a tumour volume of 0.5cc and should 
be detected. Hence, biopsy spot with diagonal length measuring 10mm as in 
modified TTSB should detect tumour focus that is 0.5cc or greater which has been 
shown to be of clinically significant size by Epstein et al (Epstein et al, 2005). Using  
mathematical modelling to analyze evenly spaced transperineal biopsy pattern in 
order to determine the volume of a small spherical tumour that might be missed at 
TTSB, Kepner et al (Kepner & Kepner, 2010)  demonstrated that a 1cm core spacing 
at TTSB should detect 1cc tumour with 99% accuracy, although some tumours in 
the volume range 0.5-1cc may be cinically significant. This should not occur in our 
modified technique with 1cm horizontal, but 0.5cm vertical spacing. 
This study’s protocol allowed for the downsizing of prostate volume to less than 
60cm3 using dutasteride prior to biopsy which was aimed at ensuring adequate 
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sampling of the lateral peripheral zone of the gland. We found that the group of 
patients who received dutasteride were older, with higher PSA parameters 
compared to the patients not on dutasteride. This observation is not surprising as 
data from placebo arm of randomised controlled trials have demonstrated 
correlation between serum PSA, prostate volume and BPH progression.  Crawford 
et al (Crawford et al, 2006) analysed data from placebo arm of a randomised 
controlled trial including 737 men to determine clinical predictors of BPH 
progression. In their study, the risk of BPH progression was significantly greater in 
those with baseline prostate volume 31cm3 or greater and PSA 1.6ng/m or greater.  
In another randomised controlled trial of 3040 men with BPH comparing finasteride 
versus placebo to determine whether baseline PSA and prostate volume were 
associated with long-term changes in symptoms, Roehrborn et al (Roehrborn et al, 
1999) determined that baseline PSA 1.4ng/mL or greater, and enlarged prostate 
were best long-term response to finasteride predictors compared to placebo. In 
another placebo controlled randomised trial of 3047 men to compare the effects of 
placebo, doxazosin, finasteride and combination therapy on measures of the clinical 
progression of benign prostatic hyperplasia (BPH), it was shown that in men with 
PSA levels greater than 4ng/mL or a baseline prostate volume more than 40 cm3, 
the number needed to treat to prevent BPH progression was 4.7 and 4.9 
respectively compared to 8.4 for the entire cohort (McConnell et al, 2003). 
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4.2 Location and characteristics of tumours identified by modified TTSB 
We observed that tumours were confined to the anterior region of the gland in 
20.4% with some involvement of the anterior third in 77.2% of all identified 
cancers. This observation is consistent with published reports (Bott et al, 2006; 
Demura et al, 2005; Mabjeesh et al, 2012; Merrick et al, 2007). In a prospective 
study of 92 men who underwent TTSB to evaluate the cancer detection rate and 
location, Mabjeesh et al (Mabjeesh et al, 2012) demonstrated a high cancer 
detection rate of 83.3% in the anterior region of the prostate. These anteriorly 
located tumours had significantly higher number of positive cores compared to 
posterior tumours. In another study, Bott et al (Bott et al, 2006) reported anterior 
tumour location in 60% of the 23 cancers identified in their series. Dumura et al 
(Demura et al, 2005) obtained a total of 1224 biopsy cores at TTSB from 59 patients 
undergoing repeat biopsy using TTSB. Of the 57 cancer positive cores identified, 34 
(60%) were distributed in the anterior compared to posterior region of the gland. 
Similarly, Merrick and colleagues (Merrick et al, 2007) studied the distribution of 
PCa identified by TTSB. In their study, they found that although none of their 24 
arbitrary regions of the prostate was spared from cancer, 32 of 43 cancers they 
detected involved the anterior apex.  
Investigators now postulate that this anterior location make these tumours difficult 
to reach using conventional transrectal approach despite numerous repeat 
biopsies. This is supported by the observations of Demura et al (Demura et al, 
2005). In their series including 371 men who underwent TTSB of which 312 had 
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never had any previous biopsy whilst 59 were repeat biopsy. The cancer core rate 
(ratio of the number of cancer cores to the number of biopsy cores) in the anterior 
region was found not to be statistically different from that of the posterior region in 
the primary TTSB group. However, in the repeat biopsy group, the cancer core rate 
progressively increased anteriorly resulting in a statistically significant higher cancer 
core rate in the anterior region compared to posterior region. The difficulties 
associated with detecting anterior tumours were identified by Chen et al (Chen et 
al, 1997) using a stochastic computer simulation model of cancer foci. In their study 
of 607 tumour foci from 180 serially sectioned radical prostatectomy specimens, 
sextant biopsy identified cancer in 73% with tumour volume greater than 0.5cc 
compared to 18% less than 0.5cm3. The tumour distribution of the 40 cases with 
tumour volume greater than 0.5cm3 which were missed by sextant biopsy was 
mainly in the anterior region above and lateral to the urethra. When simulated 
biopsies were performed in this area, an additional 17% of cancers previously 
missed were identified. Bott el al (Bott et al, 2002) identified anterior prostate 
tumours in 21% of 547 radical prostatectomy specimens. Patients with anterior 
tumours required significantly more biopsy sessions to diagnose PCa with fewer 
numbers of positive cores and summated tumour lengths than those with posterior 
tumours. 
Our findings that men with anteriorly located tumours were older, with significantly 
higher baseline PSA, PSAD and number of previous TRUSB attempts is consistent 
with published reports and not surprising given that anterior location of these 
tumours make them less likely to be palpable and more likely to be under-sampled 
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with transrectal biopsy approach (Bott et al, 2002). Furthermore, anteriorly located 
tumours are difficult to detect by imaging, either with transrectal ultrasound (Terris 
et al, 1991) or MRI (Zakian et al, 2003). Differentiation of BPH from transition zone 
tumours using functional MRI scan is difficult because of the broad range of 
metabolic profile exhibited by transition zone cancer (Zakian et al, 2003). Hence 
majority of these patients as in ours are subjected to multiple repeat biopsies due 
to persistent clinical suspicion of PCa. Consequently, when diagnosed, they are 
older as our data suggests. However, contrary to the observation of Mabjeesh et al 
(Mabjeesh et al, 2012) who reported significantly higher number of positive cores in 
the anterior zone, we did not find a statistically significant difference in the 
distribution of all biopsy tumour volume surrogates including number of positive 
cores.  
Owing to the difficulty associated with detecting these awkwardly located anterior 
tumours, some authors have recommended the use of MRI prior to biopsy to aid 
their identification (Lawrentschuk et al, 2010). In a review of 31 patients diagnosed 
with anterior predominant tumours (14 on active surveillance and 17 with previous 
negative TRUSB) in order to determine the role of MRI in this cohort, Lawrentschuk 
et al found that MRI scan had a positive predictive value of 87%. Furthermore, 57% 
of cores from the anterior prostate had cancer and 10 of 13 patients who 
eventually underwent surgery were locally advanced (pT2 and above). Of the 8 
active surveillance patients with positive surgical margin, 5 were positive in the 
anterior region only and a third of the patients had biochemical recurrence at 1 
year follow-up. To highlight this potential aggressive nature, the authors coined the 
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name ‘prostate evasive anterior tumours’. Similarly, in a study comparing 
pathological characteristics of 259 patients with pure anterior tumours to 594 with 
posterior tumours,  Koppie et al (Koppie et al, 2006) reported that anteriorly 
located tumour cohort had more negative biopsy sessions before cancer diagnosis, 
but fewer number of positive biopsy cores and proportion of cancer positive cores 
which were significantly different. Patients with anterior tumours had higher 
tumour volume and positive margin rates.  
However, whether anterior tumours possess different biologic potential remains a 
subject of debate amongst investigators. Most of the earlier studies suggesting 
lower degree of biologic aggressiveness for anterior tumours are limited by the fact 
that they were based on inferences drawn from comparing transition and 
peripheral zone tumours (Greene et al, 1991; Grignon & Sakr, 1994; King et al, 
2009). However, McNeal’s anatomical descriptions utilising the prostatic urethra as 
the reference point showed that the anterior region of the prostate above the 
urethra is composed not only of transition zone, but also by anterior peripheral 
zone and the non-glandular anterior fibromuscular stroma (AFMS) (McNeal, 1981; 
McNeal, 1988).  In another study, Fine et al (Fine et al, 2007) reported topographic 
anatomy of 197 whole-mount radical prostatectomy specimens noting that the 
anterior prostatic anatomy exhibit considerable diversity at different levels of the 
gland. At the apex, all of the glandular tissue in the anterior region was composed 
of peripheral zones bilaterally prompting the authors to conclude that anterior 
anatomy of the prostate differed from apex, mid and base of the gland depending 
on the relationship of AFMS to the glandular zones suggesting that these diversities 
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be taken into account in order to accurately characterise the true nature of these 
tumours. Another study demonstrated that histological features of transition zone-
like tumours are non specific as they can be found in anteriorly located peripheral 
zone tumours (Garcia et al, 2008).  The authors cautioned against assigning zone of 
origin based on histological appearance especially in needle biopsy specimen.  
Contemporary studies are now beginning to emerge showing that zonal origin of 
tumours did not affect outcome after radical prostatectomy (Al-Ahmadie et al, 
2008; Chun et al, 2007). Al-Ahmadie et al (Al-Ahmadie et al, 2008) validated 
observations of Fine et al (described above) using detailed histopathological 
analysis of 197 prostatectomy specimens with predominant anterior tumours with 
emphasis on the variability in anterior prostate anatomy from apex to base in order 
to determine zonal origin and pathological staging. By utilising Fine’s approach, 
they observed that 97 of 197 anterior tumours (49.2%) were from anterior 
peripheral zone, 70 (35.5%) transition zone, 14 (7.1%) from both zones and 16 
(8.1%) were indeterminate. Anterior peripheral zone tumours were mostly localised 
within the apical third of the gland. Importantly, there was no statistical significant 
difference for Gleason score, incidence of extracapsular extension, overall surgical 
positivity rate or laterality.  The authors concluded that anterior tumours of 
peripheral zone origin are more prevalent than those from transition zone. Chun et 
al (Chun et al, 2007) assessed zonal origin of 1262 radical prostatectomy specimens 
using a modified computer assisted planimetric method. On multivariate cox model 
analysis, the zone of origin does not affect the rate of biochemical recurrence and 
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addition of zone of origin to the multivariate model did not improve its predictive 
accuracy.   
Another issue is whether extensive prostate sampling using TTSB will lead to over 
diagnosis of insignificant tumours. Modified TTSB identified insignificant cancer in 
16.2% of the 167 tumours detected in this series. This rate of insignificant cancer 
diagnosis is higher than the 11.5% incidence rate reported by Epstein et al (Epstein 
et al, 2005). Merrick et al (Merrick et al, 2007) reported an insignificant cancer 
detection rate of 7.1% from their TTSB series. However, they based their 
classification on criteria derived from conventional tranrectal biopsy series which is 
not an adequate assessment tool for saturation biopsies. This is the first study to 
utilise full saturation biopsy classification proposed by Epstein to analyse true 
incidence of potential over diagnosis of indolent cancer at TTSB.  
More interestingly and contrary to reports from tranrectal biopsy series suggesting 
a high risk of clinically insignificant cancer diagnosis after more than 2 negative 
TRUS biopsies (Djavan et al, 2001; Zaytoun et al, 2012), the rate of significant 
cancer diagnosis in this study correlated with increasing number of prior negative 
biopsy and was highest amongst those with more than 3 negative TRUSB (93.1%). 
Zaytoun and colleagues (Zaytoun et al, 2012) reported overall clinically insignificant 
cancer rate of 63% from 749 serial transrectal biopsies in men with persistent 
clinical suspicion of PCa after 2 negative biopsies. In their series, 74.6% of cancers 
detected by transrectal saturation biopsy were clinically insignificant prompting the 
authors to advise a high threshold for recommending repeat biopsy. In a 
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prospective European Prostate Cancer Detection study of 1051 men with raised PSA 
who underwent serial prostate biopsies; Djavan et al (Djavan et al, 2001) reported a 
significantly lower Gleason score, stage and tumour volume for cancers detected on 
biopsies 3 and 4. On the contrary, Tan et al (Tan et al, 2008) showed that although 
cancers diagnosed on repeat biopsy were smaller volume, there were significant 
number of higher grade tumours detected after second prostate biopsy. Of the 905 
cancers they investigated, the insignificant cancer diagnosis rate were 7.7%, 7% and 
8.2% on initial, first and two or greater numbers of prostate biopsy. Similar to 
findings in this study, Bittner et al recently reported a clinically significant cancer 
diagnosis rate of 86.7% after TTSB using Epstein’s criteria as in this study. There has 
been a consistent trend towards an upward Gleason score migration after prostate 
biopsy reported in the last 20 years. Two recent UK studies have reported an 
upward shift in Gleason score in men who underwent prostate biopsies over time 
(Oxley et al, 2014) and after radical prostatectomy (Laird et al, 2014).  From a 
randomised controlled study data in which 3282 cancer containing biopsies were 
analysed, Oxley and colleagues (Oxley et al, 2014) showed a shift to a higher 
Gleason score category for each of the 10 year duration of the study (Oxley et al, 
2014). The odds of been diagnosed with a higher Gleason score increased by 4.9% 
for each year of the study. Similarly, analysis of data from the UK radical 
prostatectomy database reported that intermediate or high risk disease increased 
from 82.5% preoperatively to 97.2% following radical prostatectomy (Laird et al, 
2014). This could be a direct result of the recent update to the original Gleason 
score system that has made lower Gleason grades to be less likely reported 
(Epstein, 2010).  
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Furthermore, in the subset of patients who have had more than 2 negative biopsies 
prior to undergoing TTSB, 83% were diagnosed with clinically significant cancer 
which is comparable to the 93% in this report.  This apparent discrepancy is likely 
due to the anterior location of tumours making them evade detection by 
conventional biopsy strategies. Our observation that 67.6% of the tumours confined 
to the anterior region were in patients who have had 2 or more negative TRUSB is 
definitely suggestive. Secondly, data from TTSB series show that conventional 
TRUSB underestimates extent of disease and Gleason score. Recently, Taira and 
colleagues (Taira et al, 2013) performed TTSB on 64 men who were initially 
diagnosed with insignificant cancer by TRUSB suitable for active surveillance. They 
identified clinically significant cancer in 71.9% and 44.6% had Gleason 7 or more. In 
another study, Ayres et al (Ayres et al, 2012) re-staged 101 men on active 
surveillance for PCa using TTSB. They found that 34% of patients had more 
significant cancer after TTSB compared to their previous TRUSB and 44% of these 
had disease predominantly in the anterior region of the gland.    
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4.3 Morbidity of modified TTSB 
The incidence of acute urinary retention (AUR) in this study is 7.6%. Routine 
catheterisation was not part of modified TTSB technique. Our rate of AUR is lower 
than the 11 to 39% rates reported by other series where prophylactic 
catheterisation was also not utilised (table 1-2).  
The mechanism for development of AUR in patients undergoing TTSB remains 
enigmatic. One theory suggests that needle trauma and subsequent prostate 
oedema are the likely cause of AUR after TTSB (Buskirk et al, 2004). In their study 
performed to determine the influence of needle trauma on AUR, the authors 
reviewed 157 men who underwent TTSB after at least one negative TRUSB. AUR 
was reported in 11.5%; and age, median prostate volume and number of cores 
being significantly higher in men with retention. On multivariate analysis, only 
number of cores predicted for AUR prompting the authors to suggest that needle 
trauma and subsequent prostate oedema are likely causes of urinary retention.  
On the contrary, our data showed that men with greater sampling density were less 
likely to develop AUR. In fact, on multivariate analysis, only prostate volume 
predicted AUR in this series. This observation suggests that rather than number of 
needle incursion, prostate volume appears to play a confounding role in the 
development of AUR after TTSB.  This is supported by prospective data investigating 
morbidity of TTSB reported by Merrick et al (Merrick et al, 2008) showing that 
median catheter dependency and urinary symptoms after TTSB worsened with 
increasing prostate volume. In their study, the median catheter dependency for 
prostate volumes <60, 60–90, 90–120 and >120mL were 0, 1, 2 and 3 days 
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respectively. Overall, there was a transient deterioration in the mean International 
Prostate Symptom Score (I-PSS) at 7 days post TTSB but 94% of patients had normal 
IPSS by 30 days with smallest (<40mL) and the largest (>120mL) prostate groups 
having the lowest rates of symptom resolution. Using the same symptom 
questionnaire, Zisman et al (Zisman et al, 2001) reported on post transrectal biopsy 
urinary symptom in 204 men. 52% reported new onset urinary symptoms at 7 days 
and 8% were severe. Of the patients reporting severe urinary symptoms, 5 
developed AUR and larger prostate transition zone volume was the only 
independent predictor of impaired voiding on logistic regression analysis.  
Another hypothesis is that temporary prostatic oedema from extensive prostate 
biopsy results in bladder outlet obstruction leading to AUR (Borboroglu et al, 2000). 
However, this proposal is contradictory to published reports from transrectal biopsy 
data which suggests no difference in morbidity with increasing number of biopsy 
cores (Berger et al, 2004; Ghani et al, 2004; Naughton et al, 2000; Paul et al, 2004).  
In a prospective randomised trial to study effect of increasing core number at 
TRUSB on morbidity, Paul and colleagues (Paul et al, 2004) investigated three 
different biopsy regimens with different core numbers and areas of sampling. There 
was no statistical difference between patient’s experience of pain and other biopsy 
side effects with increasing number of sapling cores. Berger et al performed TRUSB 
in 5957 men to assess complication rates of 6, 10 and 15 core strategies. Apart for 
haematospermia, there was no difference in haematuria, rectal bleeding, AUR and 
infective complications between the groups. In another questionnaire based study 
with 760 respondents, there was no difference in severity and duration of post 
biopsy bleeding between groups after 6, 8 and 12 core biopsy regimens. A similar 
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trend was reported in a randomised trial comparing 6 and 12 core biopsy schemes 
(Naughton et al, 2000). 
 
The incidence of bleeding, pain and analgesic need after TTSB has not been 
reported previously. This is surprising for an invasive procedure which has been 
established in the last 12 years. Analysis of our data showed comparable morbidity 
result to transrectal series with lower incidence of rectal bleeding. For example, 
immediately after TTSB, 75% and 13.7% of the patients experienced haematuria 
and rectal bleeding respectively which by day 7 had significantly reduced to only 
28% and 1.2% respectively by day 7. This is comparable to report from a 
randomised controlled trial investigating the morbidity of different transrectal 
biopsy regimens (Paul et al, 2004). Similar to our study, Paul and colleagues 
reported a 70% and 25.3% incidence of gross haematuria and rectal bleeding 
amongst cohort undergoing repeat biopsy. The higher incidence of rectal bleeding 
reported for transrectal approach is not surprising given that the technique involves 
repeated rectal wall punctures compared to transperineal technique’s needle 
trajectory which is parallel to the rectal wall. Furthermore we observed that the 
rate of haematospermia increased over time. This is similar to previous report 
suggesting high incidence of persistent haematospermia after prostate biopsy 
(Emiliozzi et al, 2001; Paul et al, 2004; Peyromaure et al, 2002). Emiliozzi and 
colleagues (Emiliozzi et al, 2001) reported haematospermia lasting up to 2 months 
in 66% of men after 12 core transperineal biopsy. Paul et al (Paul et al, 2004) 
reported a 71% incidence of haematospermia lasting between 10 to 12.8 days in 
men who underwent repeat transrectal biopsy. In another study, 78.3% of 
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respondents reported haematospermia after 1 month of biopsy (Peyromaure et al, 
2002). 
Perhaps the unexpected finding of this study is the low degree of pain experienced 
by patients after TTSB. Contrary to expectation for an extensive biopsy strategy, on 
the 1st day after TTSB when pain peaked, the mean pain score was only 0.8 out of 
10 on the visual analogue scale and 73% of patients did not require analgesics. This 
is significantly lower when compared to one previous transrectal series in which 
18.7% of patients reported moderate to severe pain one month after biopsy (Paul 
et al, 2004). Peyromaure and colleagues (Peyromaure et al, 2002) also evaluated 
pain after 10-core TRUSB from a visual analogue scale in 275 men and reported that 
36% of respondents still experienced perineal pain one month after biopsy. 
 
Our data show that overall rate of morbidity after modified TTSB is low. Although 
the 7.6% incidence of AUR is higher than reported for TRUSB series (Berger et al, 
2004; Zisman et al, 2001); it is nonetheless lower than reported in other TTSB series 
where routine catheterisation was not performed with the additional advantage of 
avoiding prophylactic urethral catheterisation which can add to patient morbidity 
(Hale et al, 2012). Although not studied in this series, transient erectile dysfunction 
has been reported after TTSB (Losa et al, 2013; Tsivian et al, 2013). However, using 
a validated questionnaire, Merrick et al (Merrick et al, 2008) reported that TTSB did 
not significantly influence erectile function in men who were potent prior to biopsy.   
The question is whether the additional gain of increased precision and cancer 
detection of TTSB outweighs the risk of increased morbidity or vice versa to the 
patient. Further study is required to answer this question. However, given the huge 
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psychological stress experienced by men following a negative biopsy especially in 
the setting of persistent clinical suspicion of cancer, it is probable that majority of 
men would accept to undergo repeat biopsy and a procedure with less morbidity 
would be more readily acceptable.   
 
4.4 Predictors of histopathological outcomes for TTSB 
Our data showed that PSAD, %fPSA and pre-TTSB PSA independently predicted 
cancer diagnosis after TTSB on multivariate analysis. When deciding to use at least 
90% sensitivity to set the cancer detection thresholds for PSAD, %fPSA and total 
PSA, we reasoned that physicians and patients were likely to be more concerned 
with ensuring a high detection rate of clinically significant cancer. Consequently, we 
observed that a cut-off of 0.10ng/mL/cm3 for PSAD and 4.5ng/mL for pre-TTSB PSA 
(i.e. perform TTSB at or above these cut-off levels) and 17.5% for %fPSA (i.e. 
perform TTSB at or below this cut-off) would identify at least 90% of cancer whilst 
sparing 16 to 25% from undergoing unnecessary biopsy. Given that 38% of men 
would undergo repeat biopsy within 5 years of their initial biopsy (Welch et al, 
2007); this represents a substantial proportion of men who would potentially avoid 
unwarranted repeat biopsy. Furthermore, when these cut-offs were applied to 
detect cancers with aggressive features relating to cancer volume and Gleason 
score, we found that 86 to 99% of clinically significant tumours would have been 
identified correctly whilst avoiding 12 to 26% of insignificant disease.  
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This study to our knowledge is the first study to explore the potential correlation 
between PSA and its derivatives pathological outcomes of TTSB. The vast majority 
of studies that evaluated predictive accuracy of PSAD, %fPSA and serum PSA for 
pathological outcomes have been performed in the setting of transrectal biopsies 
(see chapter 1, section 5.1). These studies report mixed observations. For example, 
in a recent large study performed to analyse the performance of PSAD as a 
predictor of Gleason upgrade after radical prostatectomy in 1516 men, Corcoran et 
al (Corcoran et al, 2012) reported that PSAD was the strongest predictor of 
subsequent tumour upgrade. Magheli et al (Magheli et al, 2008) determined the 
utility of PSA and PSAD for predicting pathological stage and biochemical 
recurrence in 13,434 men who underwent radical prostatectomy for clinically 
localized prostate cancer over a 22 year period. When stratified by Gleason score (≤ 
6, 7, and ≥ 8), PSAD was more predictive of extracapsular extension and 
biochemical recurrence than PSA in patients with biopsy Gleason ≤ 6 whilst PSA 
better predicted for seminal vesicle invasion, lymph node metastasis and 
biochemical recurrence in biopsy Gleason 7 group. For men with biopsy Gleason 
scores ≥ 8, there was no statistical difference between PSA and PSAD in prognostic 
value for pathological or clinical outcomes. Others have suggested that low %fPSA 
increased probability of cancer diagnosis and might be associated with more 
aggressive disease (Morgan et al, 1996b; Southwick et al, 1999; Uemura et al, 
2004). Southwick et al (Southwick et al, 1999) reported that higher %fPSA levels 
were associated with more favourable histopathological findings after radical 
prostatectomy, suggesting that a cut-off of 15% or greater provided the greatest 
discrimination in predicting favourable disease. On Multivariate logistic regression 
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analysis, %fPSA was the strongest predictor of adverse pathological outcome (odds 
ratio, OR 2.25), followed by biopsy Gleason sum (OR 2.06) and patient age (OR 
1.35). Morgan et al (Morgan et al, 1996b) reported that %fPSA can help avoid 
repeat biopsies as %fPSA was significantly lower in men diagnosed with cancer even 
after 2 previous negative conventional biopsies. They suggested that a %fPSA cut-
off of 10% has 91% sensitivity. Another study of similar design showed higher 
probability of cancer diagnosis using 11% as %fPSA cut-off level (Uemura et al, 
2004). 
Although there is paucity of literature correlating PSAD or %fPSA with saturation 
biopsy findings, outcome prediction using PSA velocity (PSAV) has been described. 
Bittner et al (Bittner et al, 2009) reported on the effect of PSA velocity (PSAV) on 
PCa diagnosis, Gleason score, tumour location and cancer volume in 217 men 
undergoing repeat biopsy using TTSB. In their study, they found that a greater PSAV 
did not correlate with PCa diagnosis or histological findings. On the contrary, 
Mabjeesh and colleagues (Mabjeesh et al, 2012) reported that only PSAV and PSA 
doubling time (PSADT) independently predicted cancer diagnosis amongst the 92 
men who underwent TTSB after 2 previous negative TRUSB. More recently, Ayres et 
al reported on 101 men on active surveillance for prostate cancer who underwent 
re-staging TTSB. Similar to the observation by Bittner et al, they found that PSA, 
PSAV and PSA doubling time (PSADT) did not correlate with TTSB outcomes (Ayres 
et al, 2012). Although not highlighted by the authors, a closer review of the data 
from both studies actually suggest a trend between increasing PSAD and TTSB 
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outcomes with one showing that PSAD was actually the strongest predictor of 
cancer diagnosis at multivariate logistic regression (Bittner et al, 2009).  
The AUC was higher for PSAD (0.76) than for pre-TTSB PSA (0.71) and %fPSA (0.71) 
indicating that PSAD is slightly more predictive of cancer diagnosis in patients 
undergoing modified TTSB in this series. Our data showed that across all 
pathological outcomes including cancer diagnosis, tumour volume and Gleason 
score, PSAD was consistently more predictive than either PSA or %fPSA. This finding 
is consistent with previous reports (Busch et al, 2012; Elliott et al, 2008; Oh et al, 
2012).  Similar to current study, a retrospective review of data from 1708 prostate 
biopsies from a single institution reported that PSAD had a statistically higher AUC 
than PSA for detecting all prostate cancers (0.737 vs. 0.633, P<0.001) as well as high 
grade (0.766 vs. 0.673, P<0.001) and high volume (0.843 vs. 0.755, P<0.001) disease 
respectively. Busch et al (Busch et al, 2012) reported from 1,334 radical 
prostatectomy data and showed that total PSA and PSAD significantly increased 
with increasing tumour aggressiveness as indicated by a rising Gleason score. PSAD 
but not %fPSA predicted biochemical free survival on multivariate Cox regression 
analysis. Another study compared the accuracies of PSA and PSAD for predicting 
Gleason score upgrading at radical prostatectomy in 505 men diagnosed with low 
grade by extended transrectal biopsies. The multivariate model incorporating PSAD 
was found to have significantly higher predictive accuracy for Gleason score 
upgrading compared to PSA model (Oh et al, 2012). Horiguchi et al (Horiguchi et al, 
2003) studied 114 men after radical prostatectomy to determine which 
preoperative variables including PSA based parameters and MRI predicted adverse 
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pathological stage. Similar to our observation, PSAD had the largest AUC (0.73) 
amongst the parameters tested and on multivariate analysis, PSAD, Gleason score 
and adverse MRI findings predicted extra-prostatic cancer.   
On the contrary, a few studies correlating PSAD and Gleason score have suggested 
diminished utility for PSAD as a predictive parameter. Corcoran et al (Corcoran et al, 
2012) reported from preoperative data of 1516 radical prostatectomies that the 
predictive ability of PSAD diminished with increasing tumour aggressiveness. They 
observed that for Gleason score 6 and 3 + 4, PSAD was the strongest predictor of 
subsequent tumour upgrade (OR 1.46 and 1.37 respectively. However, for tumours 
that were upgraded from Gleason 7 to greater than 7, PSAD was not predictive 
even on univariate analysis prompting the authors to postulate that this loss of 
predictive ability was due to less PSA production per unit volume in poorly 
differentiated tumours. Another study reported that PSAD provided only minimal 
and statistically insignificant improvement in predicting adverse pathological 
findings and biochemical recurrence compared to preoperative PSA (Freedland et 
al, 2003).  However, the suggestion in literature is that preoperative PSA and 
Gleason score have a linear relationship (Oh et al, 2012; Pierorazio et al, 2009); 
which would be contrary to Corcoran’s hypothesis (Corcoran et al, 2012). 
There are two possible explanations for the superior predictive accuracy of PSAD 
observed in this study compared to TRUSB based series. Firstly, conventional TRUSB 
technique fails to detect significant amount of tumours in this cohort of men 
undergoing repeat biopsy (refer to chapter 1, section 7.0). Even with extended 
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biopsy approach, a high false negative rate has been reported (Eskew et al, 1997). 
Compared to saturation biopsy, Merrick et al (Merrick et al, 2007) demonstrated 
that only 53.5% and 76.7% of the cancers diagnosed with TTSB would have been 
diagnosed by a sextant or standard 12-core biopsy respectively. Secondly, the use 
of fixation devise at TTSB removes operator dependent free hand probe 
manipulation of TRUSB and ensures a more accurate prostate volume 
measurement. As PSAD is highly dependent on accurate determination of prostate 
volume (Benson & Olsson, 1994), a correct volume estimation at TTSB should 
improve sensitivity of this parameter. This could explain the mixed reports from 
transrectal ultrasound based series regarding the utility of PSAD.  
In addition to the PSA based parameters, we found that other pre-saturation biopsy 
variables also independently predicted pathological outcome  in the cohort of men 
investigated in this study including age in both logistic models 1 and 2 for cancer 
diagnosis and prostate volume in model 1 (incorporating pre-TTSB PSA) whilst a 
lesser number of TTSB cores independently predicted tumour volume parameters 
including number of positive cores, maximum percent core involvement and 
percentage of positive cores in the logistic model incorporating pre-TTSB PSA.  
Our observation that age independently predicted cancer diagnosis is not surprising 
given that previous studies have demonstrated that prostate cancer is a disease of 
advancing age (chapter 1, section 4.1). In one study, only 2% of men below the age 
of 50 years had prostate cancer compared to 34% for 60 to 69 year olds (Jani et al, 
2008). Data from the United State’s Surveillance Epidemiology and End Result 
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(SEER) database show that the median age for prostate cancer diagnosis is 67 years 
with 61% of men diagnosed after 65 years of age (Altekruse et al, 2010). This is 
consistent with our data showing that older men were significantly more likely to 
be diagnosed with cancer on TTSB. Potter et al reported on data from 2054 men to 
determine the likelihood of finding prostate cancer on transrectal TRUSB. Similar to 
our finding, age, PSA and DRE result independently predicted probability of cancer 
diagnosis on prostate biopsy on multivariate analysis.  
Prostate volume has been reported in other series to be associated with 
pathological outcome both at biopsy and after radical prostatectomy with most 
studies reporting an inverse relationship between prostate volume and adverse 
pathology. Amongst 1995 men who underwent a 21-core extended prostate biopsy, 
prostate volume <50mL results in a 2 fold increase in risk of cancer diagnosis at 
repeat biopsy (Ploussard et al, 2013). Another study showed that prostate volume 
significantly predicted Gleason score upgrading after radical prostatectomy in 451 
men initially diagnosed with low grade disease (Kim et al, 2013). In one TTSB series, 
smaller prostate volume emerged as the only independent predictor of prostate 
cancer diagnosis on multivariate logistic regression analysis. Furthermore, patients 
with prostate volume ≤60mL had a substantially higher rate of prostate cancer 
diagnosis compared with patients with prostate volume ≥60mL (65.9% vs.29.8%) 
and no patient with prostate volume larger than 105mL was diagnosed with cancer 
(Merrick et al, 2007). Similar association between small prostate volume and 
prediction of cancer diagnosis on biopsy have also been reported (Al-Azab et al, 
2007; Campos-Fernandes et al, 2009; Leibovici et al, 2011).  The reason why smaller 
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prostates have more aggressive disease remains controversial. Some authors have 
proposed that cancer in smaller volume prostates are biologically different 
compared to larger glands (Freedland et al, 2005) whilst others postulate that lead 
time bias because of PSA-driven biopsies in larger glands (D’Amico et al, 1998; Kim 
et al, 2013).    
Interestingly, we found that number of cores obtained at TTSB independently 
predicted biopsy tumour volume parameters. This is likely due to our modified TTSB 
technique which ensures an even sampling distribution across the prostate such 
that the number of cores obtained is dictated by the size of the prostate. 
Consequently, smaller glands required less number of cores to diagnose cancer. 
This is demonstrated by the univariate analysis which showed that number of cores 
at TTSB was significantly less in patients with larger tumour volume including NPC 
≥4, MPC ≥50% and PPC ≥15 (table 3-13).  
This study is timely as deciding when and who to subject to TTSB in this very 
challenging cohort remains enigmatic. Accumulating evidence suggests that 
significant proportion of men with low risk prostate cancer will not progress to 
clinically life threatening disease in their lifetime, it is now increasingly common to 
offer these patients all options including active surveillance whereby invasive 
curative options are deferred until the tumour shows signs of progression (NICE, 
2008). Consequently, an ability to predict the likelihood of harbouring significant 
cancer prior to diagnosis has become even more important.  
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4.5 MRI and TTSB outcomes 
Data from this study confirm that an abnormality on MRI correctly identifies cancer 
in 64.7% of cases which is similar to cancer detection rates previously reported in 
literature and outlined in chapter 1 section 10.0 of this report. However, a crucial 
question in this cohort of men with persistent clinical suspicion of prostate cancer is 
whether a normal MRI is precise enough to permit limited prostate sampling or 
allow deference of the need for TTSB. In this study, MRI missed 24 tumours of 
which 16 (66.7%) where clinically significant cancers. Our findings compare with 
that of other series from biopsy naive men with ‘normal’ MRI scan who underwent 
prostate biopsy and where cancer was diagnosed in 11.7 to 35%  (Hadaschik et al, 
2011; Haffner et al, 2011; Kuru et al, 2013; Labanaris et al, 2011).  Haffner et al 
(Haffner et al, 2011) performed 10 to 12 core extended prostate biopsies on 555 
consecutive biopsy naive men after pre-biopsy dynamic contrast enhanced MRI. 
Abnormality on MRI was reported using a 24 region scheme with additional 2 cores 
taken from each of the suspicious areas on MRI. Overall cancer detection rate was 
54%. Of the 204 men with negative MRI report, cancer was detected in 50 (24.5%) 
on biopsy. MRI had a sensitivity and specificity of 83% and 61% respectively for 
cancer detection. In another study, Labanaris et al (Labanaris et al, 2011) 
determined whether a patient with clinical suspicion of PCa but inapparent tumour 
on multiparametric MRI could be spared of prostate biopsy. Of the 109 patients 
with normal MRI who underwent 18 core biopsies, cancer was identified in 19.2% 
with 47.6% classified as clinically significant and 38.1% having high grade tumours. 
In another series of 106 men who underwent transperineal biopsy of suspicious, 
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questionably suspicious or not suspicious lesions from 3 Tesla Multiparametric MRI; 
cancer was diagnosed in 13 of 37 (35%) men with non-suspicious MRI (Hadaschik et 
al, 2011).  Similarly, Kuru and colleagues (Kuru et al, 2013) found that 14 of 94 
(15%) men with non-suspicious MRI prior to targeted fusion biopsy had prostate 
cancer diagnosed by systematic biopsy and 11 of the cancers were intermediate risk 
disease. Hence, although the cancer detection rates of MRI is promising, our data 
and that of others described above suggest that cases with a negative MRI should 
continue to be investigated. 
When we compared tumour burden between accurate MRI and those that missed 
cancers, we found that MRI identified cancers with significant tumour load as 
shown by the significantly larger biopsy tumour volume parameters in true positive 
cases compared to the false negatives. It is therefore not surprising that majority of 
tumours identified in studies incorporating targeted biopsy of suspicious areas on 
MRI are clinically significant as our data show that when MRI is positive, the tumour 
is mostly of significant size. For example, Sonn et al (Sonn et al, 2013) performed 
multiparametric MRI on 105 men with prior negative biopsy followed by a fusion 
biopsy of suspicious areas to determine clinically significant cancer (Gleason ≥3 + 4 
or Gleason 6 with maximal cancer core length ≥4 mm) detection rate compared to 
systematic biopsy. Fusion biopsy detected cancer in 34%. Additionally, 21 of 23 men 
(91%) with PCa on targeted biopsy had significant cancer compared to 15 of 28 
(54%) for systematic biopsy. Furthermore, the proportion of significant cancer 
positively correlated with worsening MRI suspicion grade with highly suspicious 
areas (grade 5) having 75% clinically significant cancer in at least one of the 
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targeted biopsy core. Similarly, a recent prospective series of 347 men who 
underwent 3T Multiparametric MRI followed firstly by MRI-targeted TRUS biopsies 
in case of MRI abnormalities and then systematic sector biopsies reported that 74% 
of PCa identified were clinically significant (Kuru et al, 2013). Of the 104 with highly 
suspicious MRI, cancer was identified in 83% with 72% having Gleason score 7 and 
above. Nevertheless, our observation that MRI missed 24 tumours of which 66.7% 
were clinically significant in this series is of concern. Given this finding, it should be 
considered inappropriate and potentially dangerous to base the decision on 
whether or not to offer repeat biopsy to a patient with persistent clinical suspicion 
of prostate cancer on MRI report. 
In clinical practice, routine pre-biopsy MRI is not included as part of the diagnostic 
strategy for prostate cancer. The reasons for this are probably due to increased cost 
and potential staff burden. However, should MRI result in reduction of the number 
of biopsies needed to diagnose prostate cancer especially in this cohort who are 
prone to multiple repeat biopsies; its cost and staff burden could be overlooked. 
One recent study showed that mp-MRI performed prior to a 21 core systematic 
transperineal biopsy reduced the number of initial prostate biopsies when 
combined with prostate volume (Numao et al, 2013). Of the 151 men classed as low 
risk (PSA <10 and a normal DRE), the negative predictive value (NPV) of a 
combination of positive MRI and prostate volume <33mL for significant cancer 
diagnosis was up to 98% and at this NPV, 33% of biopsies could have been spared. 
However, in the same study, amongst men classed as high risk (PSA ≥10 and 
abnormal DRE) with normal MRI report, a high cancer detection rate of 47 - 51% 
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was identified depending on the definition of significant cancer utilised; prompting 
the authors to conclude that the role of pre-biopsy MRI in reducing biopsy in high 
risk men might be limited.    
Another critical question is whether MRI would be accurate enough to allow TTSB 
with less number of cores. An accurate localisation of tumour and subsequent 
targeted biopsy could enhance feasibility of focal therapy for prostate cancer. To 
evaluate this potential for MRI, we divided abnormity location on MRI into 4 
anatomical quadrants and correlated this with the eventual cancer location on 
TTSB. Our data showed that when MRI is abnormal in a quadrant, 92% would 
harbour cancer on TTSB. Furthermore, as previously noted, MRI also identified 
quadrants harbouring larger volume tumours more accurately that smaller volume 
tumours. However, MRI missed cancer from 62 quadrants with median Gleason 
score of 7 indicating that MRI is limited in its ability to spot abnormality within a 
quadrant. As it is important in the selection process for focal therapy that those 
patients with clinically significant, unsuspected cancer outside the target area for 
focal ablative therapy are not inadvertently excluded from treatment, an ideal MRI 
sequence should spot most if not all abnormality.  A recent review of image-guided 
biopsies using MRI-derived target reported that MR-directed prostate biopsies 
using 4 cores show detection of clinically significant cancer equivalent to standard 
12-core biopsy (Moore et al, 2013).  The authors suggested that MR imaging could 
allow 1 in 3 men to avoid biopsy and 1 in 10 to avoid a diagnosis of clinically 
insignificant prostate cancer. However, this report was based on conclusions drawn 
from comparisons between MRI targeted biopsies and conventional transrectal 
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biopsy strategy which has been shown to lack accuracy with regards to cancer 
diagnosis. Transperineal template saturation biopsy strategy has a high precision 
(Crawford et al, 2005) and allows representative sampling of entire prostate making 
it a good reference test for validation of prostate MRI. Using TTSB as a reference 
test would remove the positive selection bias from studies comparing MRI to 
prostatectomy specimens as all men with suspicious MRI can be included as it 
allows for complete sampling of the entire prostate with good correlation to final 
prostatectomy outcome. 
Unfortunately, there is paucity of studies comparing MRI-targeted biopsy and 
complete prostate mapping using TTSB. In a series of 64 men using TTSB as the 
reference standard to determine the potential utility of mp-MRI for identification of 
clinically significant PCa and evaluate its diagnostic performance in cancer 
detection; the negative predictive value of mp-MRI for clinically significant cancer 
was 89 to 95% depending on the definition used for clinical significance 
(Arumainayagam et al, 2013).  Kasivisvanathan et al (Kasivisvanathan et al, 2013) 
reported on 182 men who had transperineal MR-targeted biopsy followed 
immediately by systematic TTSB. In their study, MRI-targeted biopsy detected 5% 
fewer clinically significant cancers compared to systematic TTSB (57% vs. 62%). 
However, MR-targeted biopsy required less number of cores per patient (median 5 
vs. 30); but missed more clinically significant cancer compared to TTSB (21% vs. 
13%).             
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Perhaps not surprisingly, we found that multiparametric MRI was superior to the 
other sequences for cancer detection. Our data shows a higher sensitivity and 
negative predictive value for mp-MRI (83.3% and 91%) compared to 44.4% and 
86.8% for dwi-MRI and 63.8% and 48.5% for T1/T2 sequence. In a standard T2WI a 
focus of cancer is identified as low signal intensity relative to surrounding tissues. 
Consequently, T2WI has low specificity as benign conditions such BPH, prostatitis 
and post biopsy haemorrhage can mimic cancer. Furthermore, tumours of 
transition zone (TZ) origin are difficult to detect on T2WI due to overlap between 
signal intensity characteristics of TZ and cancer. On the contrary, mp-MRI which 
combines high resolution T2WI with at least two functional MRI sequences 
demonstrate increased accuracy in the detection of transition zone (TZ) and 
anterior tumours. In a small retrospective series of 23 patients to evaluate the value 
of dwi-MRI and DCE-MRI in combination with T2-MRI for the diagnosis of prostate 
TZ cancer, the addition of DCE-MRI and dwi-MRI to T2-MRI improved accuracy for 
TZ cancer detection from 64.3% to 78.6% (Yoshizako et al, 2008). In 28 patients with 
similar characteristics, Wang et al analysed 31 TZ cancers and demonstrated an 
improved accuracy from 63% to 73% from addition of dwi-MRI and diffusion-
weighted magnetic resonance imaging to conventional MRI (Wang et al, 2011). The 
area under the ROC curve (AUC) of combined modality was increased from 0.659 to 
0.712. Furthermore, in the cohort studied in this series with significant proportion 
having predominantly anterior tumours; mp-MRI has been shown to have increased 
ability to detect these awkwardly located tumours. In a limited population of 31 
men who underwent prostate biopsy for PSA ≥10ng/mL, Lawrentschuk et al 
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(Lawrentschuk et al, 2010) reported that mp-MRI had a positive predictive value of 
87% for detection of anterior prostate tumours. 
Similar to our findings, data from other series confirm that mp-MRI provides better 
characterisation of prostate abnormality than either T2WI alone or in combination 
with either one of the functional sequences (Amsellem-Ouazana et al, 2005; 
Kirkham et al, 2006; Tanimoto et al, 2007). Franiel et al (Franiel et al, 2011) 
investigated the incremental value of mp-MRI compared to T2WI for detection of 
cancer areas in 55 men after 2 previous negative biopsies. Addition of dwi-MRI and 
DCE-MRI to standard T2WI identified 94% of abnormal areas and subsequent 
targeted biopsy detected prostate cancer in 100% of cases compared to 86% for 
T2WI/DCE-MRI or T2WI alone. In another study, analysis of functional MRI 
parameters of 20 men with histologically proven PCa prior to prostatectomy 
showed that combination of two functional parameters significantly improved 
cancer detection over use of any parameter alone (Riches et al, 2009). The area 
under the ROC curves for a combination of ADC and choline/citrate ratio was 0.94 
compared to 0.71 and 0.73 for either parameter alone. 
One of the main drawbacks of MRI is its reduced sensitivity and specificity for 
detecting small tumours. This study found that mp-MRI was more accurate than 
other MRI sequences at localising cancers with small tumour load. Multiparametric 
MRI missed 2 of 24 (8.4%) tumours compared to 70.8% and 20.8% for T1/T2-MRI 
and dwi-MRI in this series.  Similar finding was reported in a prospective study of 
347 patients in which mp-MRI prior to biopsy missed 11 of 94 small tumours (Kuru 
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et al, 2013). The authors hypothesised that poor image resolution and slice 
thickness or nearby adenoma with similar appearance are likely causes of MRI 
missing small tumours in their cohort.  
 
4.6 Study Limitations 
There are a few limitations inherent to this technique including the definition of 
insignificant cancer utilised in this study, use of a non-validated morbidity 
questionnaire and MRI abnormality reporting predating recently proposed 
guideline.  
This was not a randomised study. Consequently there was no direct comparison of 
cancer detection and urinary retention rates with other biopsy approaches. 
Additionally, analysis of whole mount radical prostatectomy specimen will be 
needed in order to validate cancer locations, tumour volume and Gleason score 
from this technique. Furthermore, 16.2% clinically insignificant cancer rate reported 
in this study was based on a widely recognised definition proposed by Epstein for 
saturation biopsy. This is the first study to apply these criteria in such a setting. The 
optimum system for classification of clinically insignificant cancer remains a debate 
amongst investigators. In a recent series, one group from London analysed data 
from 500 simulated transperineal mapping biopsies from 107 whole mount 
prostatectomy specimens to define characteristics of clinically significant disease 
(Ahmed et al, 2011).  The presence of Gleason ≥7, maximum cancer core length 
 165 
 
(MCCL) ≥ 6mm and  total cancer core length (TCCL) ≥10mm provided 95%  or 
greater sensitivity for prediction of tumour ≥0.5mL whilst MCCL and TCCL values ≥ 
4mm and 6mm predicted tumours 0.2mL or greater. However, this data is yet to be 
validated. 
Additionally, the cohort of men studied in this series is a unique group hence our 
findings should be interpreted with caution and not be generalised to the entire 
PCa population. Nonetheless, for men persistently suspected of harbouring PCa 
despite multiple negative transrectal biopsies who represent applicable study 
population, it provides a useful adjunct to aid clinicians in decision making and 
patient counselling prior to offering TTSB.  A further limitation is that we utilised a 
single (Roche Elecsys) free PSA assay to determine %fPSA values, as is standard 
clinical practice. However, despite calibrations against WHO standard, one study 
demonstrated highly significant differences amongst five different commonly used 
commercial assays especially when fixed threshold are utilised (Stephan et al, 
2007).  
Our patient reported outcome questionnaire used for morbidity data acquisition is 
yet to be validated. However, similar in-house designed questionnaires have been 
utilised by others (Kuru et al, 2013). Furthermore, an element of recall bias cannot 
be completely eliminated, but the possible confounding effect of receiving the 
disturbing news of prostate cancer and reporting complications after biopsy at the 
same time was eliminated by conducting the questionnaire before the biopsy 
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outcome was revealed. Further prospective series in large cohort would be required 
to validate it.  
Additionally, at the time of initiation of this study, the recently proposed Magnetic 
Resonance Prostate Imaging Reporting and Data System (MR PI-RADS) by the 
European Society of Urogenital Radiology (ESUR) for prostate MRI was not in 
existence (Barentsz et al, 2012). The PI-RADS score informs the probability of cancer 
risk and its aggressiveness plotted on a scheme. The use of such guideline might 
lead to an improved cancer risk stratification and prognostication. However, it is 
noteworthy that data from a recent series of 351 men using 5-point MR reporting 
system prior to biopsy showed results comparable to ours (Numao et al, 2013). 
4.7 Concluding Remarks 
The optimum diagnostic pathway for men with persistent clinical suspicion of 
prostate cancer despite repeated negative biopsy remains enigmatic. This 
unfortunate group of men with a diagnostic conundrum suffer from severe 
psychological stress which has been under-reported in literature. Experience from 
clinical practice suggests that for this cohort, an improved diagnostic strategy with 
limited morbidity is desirable.  
This thesis describes a modified TTSB technique with equivalent, if not superior 
cancer detection rate compared to rates reported in the literature. The procedure is 
well tolerated with lower retention rates when compared with similar series. In the 
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current climate of limited resources, modified TTSB provides an acceptable number 
of biopsy cores and workload for the pathologist.  
An important observation from this study is that rising PSA in the context of failed 
histological confirmation of cancer should not be disregarded. Hence TTSB should 
be offered to all patients with reasonable life expectancy in the presence of 
persistent clinical suspicion of cancer. However, the challenge remains how to 
predict outcome of saturation biopsy in this cohort in order to identify those who 
are harbouring potentially life threatening disease whilst sparing unnecessary 
biopsy in low risk men. The thesis identified preoperative predictors of positive 
cancer and aggressive disease diagnosis, thus laying foundation for the 
development of a predictive model specific for this cohort in the future. The impact 
of an accurate predictive model in this group will be huge given the large number of 
biopsies performed worldwide.  
The potential of MRI as a screening tool and subsequent targeted biopsy were 
explored in this thesis. As MRI technology continues to evolve, its impact is likely to 
progress geometrically. In the words of Dr Patrick Walsh at the lecture in honour of 
Willet Whitmore who is considered to be the father of modern urologic oncology, 
“by far the most important discovery that would have the greatest impact in our 
field would be the development of accurate imaging of tumour within the prostate” 
(Walsh, 2009).  A more accurate MRI could potentially result in less number of 
biopsy cores and morbidity without compromising detection of significant cancer. 
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Currently, our data support a complete prostate mapping in this group regardless of 
MRI finding. 
Although currently there are wide ranging data which have become available in this 
field of science since initiation and compilation of studies reported in this thesis. 
Nevertheless, the impact from presentation of various aspects of the studies in the 
thesis at key regional, national and international urology meetings have generated 
lots of interests which have impacted on clinical practice far beyond the Mersey 
region. As a consequence of this research, a dedicated prostate cancer diagnostic 
service for this cohort of men has been developed on the Wirral. Other questions 
raised herein are timely as we continue to explore the optimum diagnostic strategy 
for prostate cancer detection in this population.     
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Appendix A Morbidity Questionnaire 
 
 
0151 334 4000 ext. 4367 
Dear  
You are having a template biopsy of the prostate under the care of Mr Parr.  This is a technique 
that we have only introduced over the past year.  As a department we are seeking information 
from patients who undergo this to evaluate their experience. This ensures that we are able to 
give future patients accurate information regarding what to expect after the procedure.   
 
Your thoughts and input would be much appreciated should you wish to take part and your 
involvement in this service evaluation is entirely voluntary and confidential.   
If you choose not to take part, at any point, this will not affect your care. 
Please return forms completed or otherwise using the stamped addressed envelope enclosed.  
If you have any questions about this form, please do not hesitate to contact me on the above 
number. 
Wishing you a speedy recovery, 
 
Clare Hanson 
Advanced Nurse Practitioner in Urology 
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Please tick relevant boxes for all questions. 
Please ask for the nursing staff to help you if required. 
 1 hour after the procedure: 
 
Any Bleeding? 
 
1. Bleeding from your back passage yes    no     
 
Please state colour of bleeding from back passage 
1.1. Fresh bright red blood  
1.2. Pale (pink)                              
1.3. Dark (pink-red)                
1.4. Dark red, old blood                  
Other, please 
state______________________________________________________________________ 
 
2. Bleeding in your urine  yes    no     
 
Please state colour of bleeding in urine 
2.1. Fresh bright red blood  
2.2. Pale (pink) diluted in the urine  
2.3. Dark (pink-red) diluted in the urine  
2.4. Dark red, old blood    
Other, please 
state______________________________________________________________________ 
 
3. Not passed urine   Comments  ________________________________________ 
 
 Pain:  
 
4. Is there any pain?   Yes    No  
4.1. If yes, please state where it is; 
4.2. Pain in your perineum (the bit of skin between your scrotum and back passage)  
 
4.3. Pain in or around your back passage/rectum   
 
Other, please state__________________________________________________________ 
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5 Please rate your pain on a scale of 0-100, 0= no pain 100= the worst pain ever 
 
Use the scale below to mark your response 
 
Perineum 
0_____________________________________________________100 
 
 
Back passage/rectum 
0_____________________________________________________100 
 
Other, please state_______________________________ 
 
0_____________________________________________________100 
 
6. Have you needed any painkillers? Yes   No  
 
If so, please state which you used or which you were 
given_____________________________ 
(Please ask the nursing staff if you are not sure) 
 
This completes this Questionnaire, Thank you 
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Please tick relevant boxes for all questions. 
 
 1 day after the procedure:  date ___/___/___ 
 
Any Bleeding? 
 
1. Bleeding from your back passage yes    no     
 
Please state colour of bleeding from back passage 
1.1. Fresh bright red blood  
1.2. Pale (pink)           
1.3. Dark (pink-red)     
1.4. Dark red, old blood  
Other, please 
state______________________________________________________________________ 
 
2. Bleeding in your urine  yes    no     
 
Please state colour of bleeding in urine 
2.1. Fresh bright red blood  
2.2. Pale (pink) diluted in the urine  
2.3. Dark (pink-red) diluted in the urine  
2.4. Dark red, old blood    
Other, please 
state______________________________________________________________________ 
 
3. Not passed urine  Comments  ________________________________________ 
 
4. Bleeding in your semen  yes    no     
 
4.1. Fresh bright red blood  
4.2. Pale (pink) diluted in the urine  
4.3. Dark (pink-red) diluted in the urine  
4.4. Dark red, old blood    
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Other, please 
state______________________________________________________________________ 
 
 Pain:  
 
5. Is there any pain?   Yes    No  
5.1. If yes, please state where it is; 
5.2. Pain in your perineum (the bit of skin between your scrotum and back passage)  
 
5.3. Pain in or around your back passage/rectum   
 
Other, please state__________________________________________________________ 
 
6. Please rate you pain on a scale of 0-100, 0= no pain 100= the worst pain ever 
 
Use the scale below to mark your response 
 
Perineum 
0_____________________________________________________100 
 
Back passage/rectum 
0_____________________________________________________100 
 
Other, please state______________________________ 
 
0_____________________________________________________100 
 
7. Have you needed any painkillers? Yes   No  
If so, please state which you 
used__________________________________________________ 
 
This completes this Questionnaire, Thank you 
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Please tick relevant boxes for all questions. 
 
 3 days after the procedure:   date ___/___/___ 
 
Any Bleeding? 
 
1. Bleeding from your back passage yes    no     
 
Please state colour of bleeding from back passage 
1.1. Fresh bright red blood  
1.2. Pale (pink)           
1.3. Dark (pink-red)    
1.4. Dark red, old blood          
Other, please 
state______________________________________________________________________ 
 
2. Bleeding in your urine  yes    no     
 
Please state colour of bleeding in urine 
2.1. Fresh bright red blood  
2.2. Pale (pink) diluted in the urine  
2.3. Dark (pink-red) diluted in the urine  
2.4. Dark red, old blood    
Other, please 
state______________________________________________________________________ 
 
3. Not passed urine  Comments  ________________________________________ 
 
4. Bleeding in your semen   yes    no     
 
4.1. Fresh bright red blood  
4.2. Pale (pink) diluted in the urine  
4.3. Dark (pink-red) diluted in the urine  
4.4. Dark red, old blood    
Other, please 
state______________________________________________________________________  
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Pain:  
 
5. Is there any pain?   Yes    No  
5.4. If yes, please state where it is; 
5.5. Pain in your perineum (the bit of skin between your scrotum and back passage)  
 
5.6. Pain in or around your back passage/rectum   
 
Other, please state__________________________________________________________ 
Please rate you pain on a scale of 0-100, 0= no pain 100= the worst pain ever 
 
Use the scale below to mark your response 
Perineum 
0_____________________________________________________100 
 
Back passage/rectum 
0_____________________________________________________100 
 
Other, please state______________________________ 
 
0_____________________________________________________100 
 
 
7. Have you needed any painkillers? Yes   No  
If so, please state which you 
used__________________________________________________ 
 
 
 
This completes this Questionnaire, Thank you 
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Please circle your responses for all questions 
 
 7 days after the procedure:  date ___/___/___ 
 
Any Bleeding? 
 
1. Bleeding from your back passage yes    no     
 
Please state colour of bleeding from back passage 
1.1. Fresh bright red blood  
1.2. Pale (pink) diluted   
1.3. Dark (pink-red)    
1.4. Dark red, old blood          
Other, please 
state______________________________________________________________________ 
 
2. Bleeding in your urine  yes    no     
 
Please state colour of bleeding in urine 
2.1. Fresh bright red blood  
2.2. Pale (pink) diluted in the urine  
2.3. Dark (pink-red) diluted in the urine  
2.4. Dark red, old blood    
Other, please 
state______________________________________________________________________ 
 
3. Not passed urine  Comments  ________________________________________ 
 
4. Bleeding in your semen  yes    no     
 
4.1. Fresh bright red blood  
4.2. Pale (pink) diluted in the urine  
4.3. Dark (pink-red) diluted in the urine  
4.4. Dark red, old blood    
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Other, please 
state______________________________________________________________________   
 
Pain:  
5. Is there any pain?   Yes    No  
5.1. If yes, please state where it is; 
5.2. Pain in your perineum (the bit of skin between your scrotum and back passage)  
 
5.3. Pain in or around your back passage/rectum   
 
Other, please state__________________________________________________________ 
 
6. Please rate you pain on a scale of 0-100, 0= no pain 100= the worst pain ever 
 
Use the scale below to mark your response 
Perineum 
0_____________________________________________________100 
 
Back passage/rectum 
0_____________________________________________________100 
 
Other, please state______________________________ 
 
0_____________________________________________________100 
 
7. Have you needed any painkillers? Yes   No  
If so, please state which you 
used__________________________________________________ 
 
 
Any further comments about any stage of your recovery or experience: 
 
 
This completes this Questionnaire 
Please return in the pre-paid envelope provided 
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Appendix B Peer reviewed Publication 
 
This appendix contains a publication in a peer reviewed journal of aspects of this 
thesis (Ekwueme K, Simpson H, Zakhour H, Parr NJ. Transperineal template-guided 
saturation biopsy using a modified technique: outcome of 270 cases requiring 
repeat prostate biopsy. BJU Int. 2013 Jun;111(8):E365-73. doi: 10.1111/bju.12134).  
 
It covers the technical aspects of modified TTSB and outcomes in 270 patients.  
Please see overleaf. 
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Appendix C Crude data 
 
This is an appendix of crude data that I generated over the course of this study 
Please see attached CD 
 
